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1 INTRODUCTION 1 
 
1 INTRODUCTION 
1.1 Role of lipid mediators in inflammation 
 
Inflammation is a complex physiological mechanism in response to tissue 
injury and/or infection and contemporaneously the initiation of the healing 
process. The cardinal signs of inflammation are swelling, pain, heat, 
redness and loss of function (tumor, dolor, calor, rubor and functio laesa) 
[1]. 
Bioactive lipids play important roles as signalling and regulatory mediators 
in the body, see Fig. 1.1 for overview. Various lipid mediators derived 
from polyunsaturated fatty acids (PUFAs), arachidonic acid (AA) or 
lysophospholipids (LPC) and can be structurally classified into three 
groups, see Table 1.1 [2]. 
 
Fig. 1.1: Overview on lipid mediator pathways [2] 
Phospholipases, mainly cPLA2 but also iPLA2 and sPLA2, release polyunsaturated fatty 
acids (AA, DHA and EPA) or lysophospholipids (LPC) from the membrane. AA is 
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converted through the COX or 5-LO pathway to prostanoids or leukotrienes. AA, DHA 
and EPA are converted by 5-LO and 12/15-LO to the anti-inflammatory mediators 
lipoxin A4 (LXA4), resolvin E1 (RevE1) and protectin D1 (PD1). LPC is converted to 
PAF or LPA. Incurred lipid mediators act via their corresponding G protein-coupled 
receptors (GPCR). Abbreviations: iPLA2, inhibitory phospholipase A2; sPLA2, secretory 
phospholipase A2; cPLA2, cytosolic phospholipase A2; DHA, docosahexaenoic acid; 
EPA, eicosapentaenoic acid; LPC, lysophosphatidylcholine; LO, lipoxygenase; COX, 
cyclooxygenase; FLAP, 5-lipoxygenase-activating protein; LPCAT2, 
lysophosphatidylcholine acetyltransferase 2; ATX, autotoxin; LTC4S, LTC4 synthase; 
LTA4H, LTA4 hydrolase; H-/L-PGDS, hematopoetic or lipocalin-type prostaglandin D2 
synthase; mPGES-1/-2, microsomal prostaglandin E2 synthase 1/2; cPGES, cytosolic 
prostaglandin E2 synthase; PAF, platelet activating factor; LPA, lysophosphatidic acid 
 
Table 1.1: classification of lipid mediators [2] 
1 
arachidonic acid-derived 
eicosanoids 
e.g. prostaglandins (PGs), 
leukotrienes (LTs) 
2 
lysophospholipids and 
endocannabinoids 
e.g. platelet-activating factor 
(PAF), lysophosphatidic acid 
(LPA), sphingosine-1-
phosphate (S1P) 
3 
ω-3-polyunsaturated fatty acids 
derived anti-inflammatory 
mediators 
e.g. resolvins, protectins 
 
1.1.1 Acute inflammation 
 
Tissue damage provokes three types of acute signals. Hyperalgesia is 
mediated by PGE2 and in response to pain. Cytokine production is induced 
as a consequence of broken cells that release their intracellular proteins to 
the vicinity, and pathogens are sensed by the complement system and cell-
surface receptors, such as toll like receptors (TLR). Responding to these 
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signals, leukocytes are recruited from the blood. Histamine and eicosanoids 
released from perivascular mast cells cause vasodilatation (heat and 
redness) and extravasation of fluid (swelling). In addition, platelet-
activating factor (PAF) is released to amplify leukocyte emigration. 
Neutrophils, activated by tumor necrosis factor (TNF) and leukotrienes 
degranulate and gear the inflammatory process. Monocytes and tissue 
macrophages are chemotactically attracted and lymphocytes as well as 
dendritic cells are recruited by prostaglandins, leukotrienes, chemokines 
and defensins to mature and activate macrophages. The acute inflammatory 
process requires ongoing signals in a positive feedback-loop from every 
newly recruited cell after contact to pathogens or broken cells. If the 
initiating factor is removed, the inflammatory reaction will resolve. During 
resolution of inflammation PGE2 turns to anti-inflammatory properties, as 
rising PGE2 levels inhibit the pro-inflammatory enzymes cyclooxygenase-2 
(COX-2) and 5-lipoxygenase (5-LO) and additionally induce 15-
lipoxygenase (15-LO) expression in neutrophils. Neutrophil-derived 
arachidonic acid (AA) is then metabolized to anti-inflammatory lipoxins 
via 12- and 15-LOs leading to resolution of inflammation. Macrophages 
and lymphocytes return to pre-inflammatory numbers and phentotypes and 
tissue repair is accomplished [1, 3]. 
 
1.1.2 Chronic inflammation and cancer 
 
If the initiating factors persist or inflammatory responses are dysregulated, 
inflammation becomes chronic and leads to inflammatory disorders, such 
as Alzheimer disease, asthma, atherosclerosis, chronic obstructive 
pulmonary disease (COPD), multiple sclerosis (MS) or rheumatoid arthritis 
(RA). 
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Moreover, a connection between chronic inflammation and cancer is 
evident [4, 5]. For example, several studies have shown that inflammatory 
cells and mediators are present in the tumour microenvironment [6-8]. 
Triggers of chronic inflammation, such as microbial or viral infections, 
autoimmune diseases or other inflammatory conditions of unknown origin, 
are associated with different types of cancer development [4]. In line, 
treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or coxibes 
was shown to decrease the risk of cancer development [9-11]. However, 
inflammatory processes in tumours do not have to be causally related to a 
classical inflammation [12]. 
 
1.1.3 Eicosanoids  
 
In 1982, the Nobel Prize in Physiology or Medicine was awarded to 
Samuelsson, Bergstrom (Sweden) and Vane (UK) "for their discoveries 
concerning prostaglandins and related biologically active substances" 
[13]. Eicosanoids, including PGs, LTs and derivatives, act as autocrine or 
paracrine lipid mediators. They are derived from 20-carbon unsaturated 
fatty acids such as AA via the COX or LO pathway and are involved in 
various physiological and pathological actions in the body (see Table 1.2 
for overview) [2, 3, 14-16]. 
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Table 1.2: overview of biological actions of eicosanoids [17] 
Organ function eicosanoids  
Vasodilatation PGE2, PGD2, PGI2 
Vasoconstriction 
PGE2, PGD2, PGF2α, 
TXA2, LTC4, LTD4, 
LTE4 
vessels and 
sphincter 
Permeability ↑ 
LTB4, LTC4, LTD4, 
LTE4 
Relaxation of smooth muscle PGE2 
Contraction of smooth muscle 
PGE2, PGF2α, PGI2, 
TXA2, LTC4, LTD4, 
LTE4 
secretory volume, acidity and 
pepsin ↓ 
PGE2, PGI2 
Stomach and 
gastrointestinal 
tract 
mucus secretion ↑ PGE2, PGI2 
blood flow ↑ PGE2 
Cardiac output ↑ PGE2, PGF2α, PGI2 
Cardiac contractility ↑ PGF2α 
heart 
Modulation of cardiac rhythm PGF2α 
Diuresis, natriuresis and 
kaliuresis ↑ 
PGE2, PGI2 
Renin secretion ↑ PGE2, PGD2, PGI2 
kidney 
Glomerular filtration ↓ TXA2 
Relaxation of smooth muscle PGE2, PGI2 
Contraction of smooth muscle 
PGD2, PGF2α, LTC4, 
LTD4, LTE4 
Mucosal edema LTC4, LTD4, LTE4 
lung and 
bronchia 
Secretion of mucus and 
glycoproteins 
LTC4, LTD4, LTE4 
1 INTRODUCTION 6 
chemotaxis LTB4 
Aggregation of neutrophils LTB4 
Recruitment, migration, 
adhesion of leukocytes 
LTB4 
Degranulation of leukocytes LTB4 
Cytokine production ↑ LTB4 
immune system 
Proliferation, activation and 
immunoglobulin production of 
B lymphocytes 
LTB4 
Hyperalgesia PGE2, PGI2, LTB4 
nervous system 
Nociceptive modulation PGD2 
Relaxation of smooth muscle PGE2 
uterus 
Contraction of smooth muscle PGF2α, TXA2 
Endocrine system 
ACTH, growth hormone, 
prolactin, gonadotropin ↑ 
PGE2 
 
1.2 PGE2 as prominent bioactive lipid mediator 
1.2.1 Prostanoids 
 
Five endogenously produced bioactive prostanoids are known to date: 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), prostaglandin F2a 
(PGF2a), prostacyclin (PGI2) and thromboxane A2 (TXA2). They are 
generated via the COX pathway, see Fig. 1.2. As prostanoids cannot be 
stored, they are synthesized de novo in most cells of the body either 
constitutively or after certain stimuli. Here, phospholipases, mainly 
cytosolic phospholipase A2 (cPLA2), release arachidonic acid (AA) from 
membrane glycerophospholipids. AA is further oxygenated via the activity 
of either COX-1 or -2 to PGG2 and subsequently reduced to the instable 
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intermediate PGH2. Terminal synthases isomerize PGH2 into different 
prostanoids, depending on the cellular constitution of the respective cell. 
Then, prostanoids are released from the cell and act via their corresponding 
G protein-coupled receptors (GPCR). These receptors are highly selective 
for the individual prostanoids [2, 14]. 
 
Fig. 1.2: Biosynthesis of PGI2, PGF2α, PGE2, PGD2 and TXA2 via the cyclooxygenase 
pathway [18], modified. 
 
Inhibition of PGE2 biosynthesis has been an effective pharmacological 
strategy in the therapy of inflammation for more than 100 years [19]. Due 
to the fact that inhibition of COX-1 and -2 by NSAIDs or selective COX-2 
inhibition by coxibs is associated with severe side-effects such as 
gastrointestinal toxicity and cardiovascular complications, there is still a 
strongly need for further development of anti-inflammatory drugs. 
Gastrointestinal toxicity is predominantly attributed to the suppression of 
constitutively COX-1-derived prostanoid
 
formation. Based on the fact that 
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constitutive COX-2 expression is essentially restricted to the brain and 
kidney and pathogenic PGE2 levels are generated via the inducible COX-2 
isoform, selective COX-2 inhibitors (coxibs) have been developed. COX-2 
is inducible and expressed in response to pro-inflammatory stimuli, 
whereas COX-1 is constitutively active and rather responsible for 
physiological housekeeping functions. Coxibs possess an improved 
gastrointestinal tolerance, but studies reveal an increased risk for 
cardiovascular complications due to an imbalance of COX-1 derived pro-
thrombotic TXA2 and COX-2 derived anti-thrombotic PGI2. Therefore, 
several coxibs have been withdrawn from the market [2, 14]. 
Since long-term application is required for therapy of chronic 
inflammation, there is still a strong need for the development of anti-
inflammatory drugs with an improved safety profile. Thus, suppression of 
selective microsomal prostaglandin E2 synthase-1 (mPGES-1)-derived 
PGE2 has been considered as an alternative strategy for the treatment of 
inflammation [20]. 
 
1.2.2 PGE2 
 
PGE2 is among the most powerful lipid mediators and exerts various 
physiological and pathological effects depending (I) on the amount of 
PGE2 and (II) the subtype of receptor (EP1-4) available within the 
respective tissue [15]. Several basic homeostatic functions are known for 
PGE2 like gastrointestinal mucosa protection and motility [21], blood 
pressure control, airway homeostasis, female reproduction and kidney 
function [22]. On the other hand, PGE2 is also involved in pathological 
actions, basically inflammation, fever and pain. 
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Fig. 1.3: PGE2 biosynthesis (from [15], modified) 
Abbreviations: cPLA2, cytosolic phospholiase A2; COX, cyclooxygenase; mPGES-1/-2, 
microsomal prostaglandin E2 synthase-1/-2; cPGES, cytosolic prostaglandin E2 
synthase; MRP4, multidrug resistance protein 4 
 
Three terminal synthases that catalyze PGE2 formation from COX-derived 
PGH2 are known, namely the cytosolic PGE2 synthase (cPGES) and the two 
membrane-bound PGE2 synthases mPGES-1 and mPGES-2 (Fig. 1.3) [23-
25]. 
cPGES and mPGES-2 are structurally and biologically distinct from 
mPGES-1. They are constitutively expressed and therefore more likely 
involved in homeostatic processes in the body [26-28]. mPGES-2 can use 
PGH2 as a substrate from both COX-1 and -2, whereas cPGES is mainly 
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coupled to COX-1. However, mPGES-1 is inducible and functionally 
coupled to COX-2 [25]. 
 
mPGES-1 (16kDa) was discovered by Jakobsson et al. in 1999 and belongs 
to the MAPEG (membrane-associated proteins involved in eicosanoid and 
glutathione metabolism) family. This superfamily also contains leukotriene 
C4 (LTC4) synthase, 5-lipoxygenase-activating protein (FLAP) and three 
different glutathione-transferases 1-3 (MGST1-3). The structure forms a 
homotrimer consisting of twelve transmembrane helices (four for each 
monomer) with a large cone-shaped cavity in the center of the trimer [29], 
which is similar to other MAPEG members. Glutathione (GSH) is required 
as cofactor for the activity [30]. It is coordinated by hydrogen bonds 
involving the side chains of helices I, II and IV and π-stacking interactions 
of Tyr130 in a horseshoe conformation. The catalysis of PGH2 to PGE2 has 
not yet been fully determined, but it is likely that glutathione, Asp49 and 
Ser127 are involved to initiate the catalytic cycle [31]. Its regulation is still 
under investigation. 
 
The human gene for mPGES-1 (18.3 kb) contains three exons and is 
localized to chromosome 9q34.3 [32]. Although there is no obvious 
similarity of the mPGES-1 and COX-2 promoters, their expression is 
generally co-regulated [25, 33]. Constitutive expression levels of mPGES-1 
are low and as mPGES-1 is primarily linked to COX-2 it can be strongly 
upregulated by pro-inflammatory stimuli, such as interleukin-1β (IL-1ß), 
tumor necrosis factor-α (TNFα), or LPS. Studies reveal the concomitant 
induction of COX-2 and mPGES-1 in various cultured cells, i.e. human 
lung carcinoma A549 cells [30], macrophages [34] or endothelial cells [35] 
in response to pro-inflammatory stimuli and its prevention by 
glucocorticoids [32-34, 36, 37]. PGE2 formation was significantly 
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increased in HEK293 cells, cotransfected with mPGES-1 and COX-2, in 
response to A23187 (induces acute inflammatory response) or IL-1ß 
(mediator of the delayed response) [34]. These observations could not be 
shown for HEK293 cells cotransfected with COX-1 and mPGES-1. 
Increased mPGES-1 expression was found in various diseases related to 
inflammation, i.e. synovial tissue of patients with rheumatoid arthritis [38], 
in the cartilage and chondrocytes of osteoarthritic patients [39-42] in 
inflamed intestinal mucosa from patients with inflammatory bowel disease 
[43], in atherosclerotic carotid plaques [44-46], in Alzheimer disease 
tissues [47], in muscle tissue of patients with idiopathic inflammatory 
mypathies [48], in endothelial cells, smooth muscle cells and immune cells 
from patients with periodontitis [49], in chronic active lesions localized to 
microglia/macrophages from patients with multiple sclerosis [50], and 
various cancer types including gastrointestinal, lung, stomach, brain, breast, 
pancreas, prostate, cervix, papillary thyroid, head and neck squamous 
carcinoma [51].  
In vivo experiments with wild-type rats and mice support the role of 
mPGES-1 in inflammation in vivo [52]. Constitutive expression of 
mPGES-1 resulted in small amounts of PGE2 levels, whereas addition of 
LPS could significantly increase the PGE2 production [36, 53, 54]. 
Moreover, mPGES-1 RNA and protein was observed in carrageenan-
induced and adjuvant-induced paw edema in rats [55, 56]. 
mPGES-1 knockout mice exhibit normal phenotype, life period and fertility 
compared to their littermates. They show significantly reduced PGE2 levels 
in response to pro-inflammatory stimuli, such as LPS, TNFα or interleukin-
6/-12 compared to wild type mice in different models of inflammation [57, 
58]. Several studies demonstrate a pathogenic role of mPGES-1 in 
collagen-induced arthritis [57], atherosclerosis [59], LPS–induced pyresis 
[60], pain hypersensitivity [54], experimental autoimmune 
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encephalomyelitis [50], infection-induced neonatal hypoxia [61], 
Alzheimer´s disease [62] and several types of cancer [63, 64]. 
 
PGE2 is secreted by the ATP-dependent multidrug resistance protein-4 
(MRP4) or by diffusion and acts nearby through binding to one or more of 
the PGE2 receptor (EP) subtypes EP1 to EP4 [23, 65]. EP receptors are 
GPCR receptors and for signal transduction cAMP, Ca2+ and inositol 
phosphates act as second messenger, depending on the subtype of EP 
receptor. EP1 regulates Ca2+ influx without relevant levels of a 
phosphatidylinositide response, suggesting that it is coupled to an 
unidentified G protein. The EP2 and EP4 receptor subtypes are coupled to 
Gs and mediate increase in cAMP concentrations. In contrast, EP3 is Gi 
coupled and reduces cAMP concentrations [65]. 
EP1 has been reported to be involved in mediating hyperalgesia on 
peripheral sensory neurones [66] and acute pain response in acetic acid-
induced writhing test [67]. EP2 and EP3 are described to participate in 
inflammatory exudation [68]. In addition development of paw swelling 
associated with collagen induced arthritis [69] is also contributed to EP2. 
EP4 is known to have a pro-inflammatory role in pathogenesis of 
rheumatoid arthritis [70] and in the development of paw swelling 
associated with collagen induced arthritis [69]. 
Besides its pro-inflammatory properties, EP2-4 receptors can also 
contribute to the resolution of inflammation [71-75]. 
 
1.2.3 Drug discovery of mPGES-1 inhibitors 
 
The story of coxibs has taught us what might happen if the sensitive 
balance of prostanoids (here PGI2 and TXA2) is affected by drugs. 
Concerns about cardiotoxicity of potential mPGES-1 inhibitors could not 
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be confirmed, since deletion of mPGES-1 did not result in any impact on 
blood pressure when mice were crossed with low-density lipoprotein 
receptor (LDLR) knockout mice [59]. Moreover, reduced levels of 
myocardial damage after coronary occlusion and no alteration of PGI2 and 
TXA2 after myocardial infarct were observed in mPGES-1 knockout mice 
[76, 77]. 
By now, multiple diverse structures of mPGES-1 inhibitors are described in 
literature, but no selective mPGES-1 inhibitor is available for clinical use. 
Chang and Meuillet [78] characterized them into four groups: (I) 
endogenous lipids, fatty acids and PGH2 analogues (II) known anti-
inflammatory drugs and/or inhibitors of LT biosynthesis (III) natural 
compounds and (IV) further development.  
 
Endogenous lipids, fatty acids and PGH2 analogues 
LTC4 (IC50 = 5 µM) [33], identified as inhibitor of mPGES-1, was first 
shown to inhibit MGST-1 [79]. Since MGST- 1 and mPGES-1 are 
structural homologues that both belong to the MAPEG superfamily, the 
mode of inhibition might be similar by competing with GSH. Also other 
lipids could be identified as mPGES-1 inhibitors, i.e. 15-deoxy-∆12,14-
PGJ2 (IC50 = 0.3 µM) and a number of fatty acids, including AA, DHA, 
EPA (IC50 = 0.3 µM each) and palmitic acid (IC50 = 2 µM) [80]. As 15-
deoxy-∆12,14-PGJ2, DHA and EPA have anti-inflammatory properties, 
mPGES-1 inhibition might contribute to their anti-inflammatory effects. 
Among stable PGH2 analogues, U-51605 was shown to inhibit mPGES-1 
activity [33, 80]. 
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Table 1.3: structures of endogenous lipids, fatty acids and PGH2 analogues identified as 
mPGES-1 inhibitors 
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COOH
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LTC4 15-deoxy-∆12,14-PGJ2 
COOH
 
COOH
 
DHA EPA 
CH3
COOH
 
 
AA  
COOH
 
N
N
COOH
 
palmitic acid U-51605 
 
Known anti-inflammatory drugs and/or inhibitors of LT biosynthesis 
Several NSAIDs and coxibs were identified as mPGES-1 inhibitors, 
including sulindac sulfide (IC50 = 80 µM), NS-398 (IC50 = 20 µM) [33], 
celecoxib (IC50 = 22 µM), dimethylcelecoxib (IC50 = 16 µM), lumiracoxib 
(IC50 = 33 µM) and valdecoxib (IC50 = 75 µM) [81]. The well-known 
FLAP inhibitor MK-886 also inhibits mPGES-1 (IC50 = 2.4 µM) [56]. As 
FLAP also belongs to the MAPEG superfamily, inhibition might be due to 
similarities in the structure. Furthermore, licofelone, a proposed dual 
COX/5-LO inhibitor, was identified as inhibitor of mPGES-1 (IC50 = 6 
µM) [82]. 
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Table 1.4: structures of anti-inflammatory drugs identified and/or inhibitors of LT 
biosynthesis identified as mPGES-1 inhibitors 
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   lumiracoxib    valdecoxib        MK-886       licofelone 
 
Natural compounds 
A series of anti-inflammatory natural mPGES-1/5-LO inhibitors from our 
group have been described in literature, such as curcumin from turmeric 
(IC50 = 0.3 µM) [83], epi-gallocatechin gallate (EGCG) from green tea 
(IC50 = 1.8 µM) [84], garcinol from the fruit rind of Guttiferae species (IC50 
= 0.3 µM) [85], myrtucommulone from myrtle (IC50 = 1 µM) [86], several 
boswellic acids from frankincense (IC50 = 3–10 µM) [87], and the 
acylphloroglucinol hyperforin from St. John’s wort (IC50 = 1 µM) [88]. 
 
Table 1.5: structures of natural compounds identified as mPGES-1 inhibitors 
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            curcumin           EGCG           garcinol 
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     myrtucommulone      boswellic acids           hyperforin 
 
Further development of mPGES-1 inhibitors [89] 
Based on the structure and cellular activities some compounds were further 
improved, resulting in a heterologue field of synthetic mPGES-1 inhibitors. 
These scaffolds include carboxylic acids from MK-886 [90], phenanthrene 
imidazoles from the JAK inhibitor azaphenanthrenone [91], 
biarylimidazoles from MF63 [92], pirinixic acid derivatives [93], 2-
mercaptohexanoic acids from 2-mercaptohexanoic [94], arylpyrrolizines 
from licofelone [95], benzo[g]indol-3-carboxylates [96], oxicames from a 
screening series of benzo-thiopyran S-dioxides [97, 98], trisubstituted ureas 
from high-throughput screening campaign [99] and carbazole benzamide 
from a series of carbazole benzamides [100]. 
1.3 The dual inhibition concept 
 
In 1996, the group of Nickerson-Nutter demonstrated the effects of 5-LO 
and/or COX inhibitor administration in a mouse model of collagen-induced 
arthitis (CIA) [101]. Surprisingly, a significant reduction of CIA was only 
observed in the dual approach of 5-LO and COX inhibitors and no effect 
could be observed when administered alone. 
COX inhibition might redirect available AA towards 5-LO, leading to an 
increased formation of pro-inflammatory leukotrienes [14] and therefore 
increase the risk of gastric damage. Comedication of NSAIDs with 5-LO 
inhibitors or leukotriene receptor antagonists was shown to be superior 
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over single NSAID administration not only in the treatment of 
inflammation and pain as they have an improved side-effect profile [102]. 
COX-1 is constitutively expressed in nearly all tissues and considered to 
mediate physiological responses, such as cytoprotection of the stomach, 
platelet aggregation and renal function. COX-2 on the other hand is known 
to be inducible and highly upregulated in inflammatory cells during 
pathological processes [103]. Classical NSAIDs have no selectivity for 
COX-1 or -2 and mostly inhibit both enzymes with a similar potency. As 
the anti-inflammatory action results from COX-2 inhibition, unwanted 
side-effects, mainly gastrointestinal and renal toxicity, are ascribed to 
COX-1 inhibition [104]. Consequently, selective COX-2 inhibitors, known 
as coxibs, were developed in order to improve the safety profile and 
potency. To this knowledge dual COX-2/5-LO inhibition seems to be 
favored in the development of safer anti-inflammatory drugs. Several 
studies demonstrate that selective COX-2 inhibition indeed causes 
significantly less ulceration, but renal and cardiovascular toxicity were 
observed [105]. Since synthesis or end actions of LTs are unaffected by 
NSAIDs, “targeting of these enzyme systems suggested a promising 
pharmacological approach in the post-COX-2 era to reduce the 
cardiovascular events of selective COX-2 inhibition without gastric side 
effects of non-specific inhibition of COX” [103]. 
Because mainly PGE2 among the COX products is responsible for 
inflammatory events, current research outcomes propose the dual inhibition 
of mPGES-1/5-LO as a promising strategy to avoid ordinary side effects of 
NSAIDs or coxibs and to improve the safety of anti-inflammatory drugs 
[93]. 
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1.4 5-LO products and their role in inflammation 
1.4.1 Leukotrienes  
 
Besides the COX pathway, released AA can be converted via the LO 
pathway into leukotrienes and other hydroxylated derivatives, see Fig. 1.4. 
Five human LOs are known by now, i.e., 5-(S)-LO, platelet-type 12-(S)-
LO, epidermis-type 12(R)-LO, reticulocyte type 15-(S)-LO (15-LO-1) and 
epidermis-type 15(R)-LO (15-LO-2) [106]. Of these LOs, 5-LO seems to 
play a critical role in inflammatory events. 
5-LO is the key enzyme in the LO pathway and catalyzes the incorporation 
of molecular oxygen into AA yielding LTA4. LTA4 can be either 
hydrolysed to LTB4 by LTA4-hydrolase (LTA4H) or conjugated with 
glutathione to LTC4 by LTC4 synthase (LTC4S), depending on the cellular 
facilities. LTB4 and LTC4 are secreted from the cell. Extracellular 
metabolism can form the cysteinyl leukotrienes (CysLTs) LTD4 and LTE4 
out of LTC4 [107], see Fig. 1.4. Leukotrienes exert their biological actions 
via their corresponding GPCR receptors. They have multiple biologic 
actions and are involved in several pathologies, including allergic and 
inflammatory diseases [108]. At least, combined action of 5-LO and 12-LO 
or 15-LO can form anti-inflammatory bioactive lipoxins, which act through 
the ALX receptor and are involved in resolution of inflammation [107]. 
The CysLT1 receptor antagonist montelukast is used as drug for the 
therapy of asthma. No other “leukotriene pharmaceuticals” are available on 
the European market by now [14]. Zafirlukast, Pranlukast as leukotriene 
receptor antagonists and Zileuton, a FLAP inhibitor, are available on the 
Japanese and/or US market. 
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Fig. 1.4: Biosynthesis of leukotrienes via the LO pathway (from [18], modified) 
Abbreviations: AA, arachidonic acid; 5-HpETE, 5(S)-hydroperoxy-6-trans-8,11,14-cis-
eicosatetraenoic acid; 5-HETE, 5(S)-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic 
acid; LO, lipoxygenase 
 
1.4.2 5-LO 
 
5-LO (78 kDa) is a nonheme iron dioxygenase and is located in the soluble 
compartment of the cell. It is expressed primarily in leukocytes. The 5-LO 
enzyme possesses a large catalytic domain, which binds the iron and a 
regulatory C2-like domain, which binds Ca2+ [14]. 
 
cPLA2 and 5-LO are activated by immune complexes, bacterial peptides 
and other certain stimuli, whereupon they translocate to the nuclear 
envelope. There, AA is released from phospholipids and metabolized by 5-
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LO aided by FLAP, which facilitates the transfer of AA to 5-LO. Cellular 
activation of 5-LO is known to be predominantly mediated by Ca2+, ATP 
and phosphorylation. Ca2+ either stimulates 5-LO activation and the 
association to the nuclear membrane [109]. The catalytic activity of 5-LO 
is stimulated by ATP, which binds to 5-LO and seems to have a stabilizing 
effect [110]. Phosphorylation by p38 mitogen-activated protein kinase 
(MAPK)-regulated MAPK-activated protein kinase (MK)-2/3 [111] or 
extracellular signal-regulated kinase (ERK) 1/2 at Ser271 and Ser663 [112] 
activates 5-LO, promoted by unsaturated fatty acids [113]. In contrast, 
phosphorylation of Ser523 by protein kinase A (PKA) results in inhibition 
of 5-LO activity. Essential for activation is the degree of oxidation of the 
nonheme iron in the catalytic centre of 5-LO. The ferrous state (Fe2+) is the 
inactive iron conformation. Oxidation by lipid hydroperoxides forms the 
active ferric state (Fe3+) [114].  
 
Activated 5-LO catalyzes the oxygenation of AA to 5(S)-hydroperoxy-6-
trans-8,11,14-cis-eicosatetraenoic acid (5-HpETE) and further dehydration 
to the epoxide LTA4. Besides the formation of LTA4, 5-HpETE can be 
reduced to its corresponding alcohol 5-HETE and further oxidized to 5-
oxo-ETE by 5-HEDH in eosinophils. After synthesis, 5-LO products are 
released from the cell. LTB4 efflux is facilitated through a LTB4 transporter 
and LTC4 is secreted by MRP1 [107]. 
 
LTB4 acts through its specific BLT1 or non-specific BLT2 receptor and is 
involved in the regulation of the immune response, as it is known to be a 
chemotactic mediator and enhances phagocyctic activity and secretion of 
immunoglobulins [14, 107]. CysLTs that act through the receptors CysLT1 
or CysLT2, are involved in asthma as they induce smooth muscle 
contraction, mucus secretion and vasoconstriction [14, 107]. Also 5-
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H(p)ETE and 5-oxo-ETE exert pharmacological effects through their 
GPCR receptors, termed OXE, which may be involved in asthma and 
allergic diseases [115].  
 
Studies with 5-LO knockout mice confirmed the participation of 5-LO in 
inflammatory events, including AA-induced ear inflammation, zymosan- or 
immune-complex-induced peritonitis, allergic airway inflammation and 
PAF-induced shock [116]. 
 
1.4.3 5-LO inhibitors 
 
Suppression of 5-LO product biosynthesis can be implemented by direct 
inhibition of 5-LO or antagonism of FLAP or cPLA2 [107]. Different 
categories of inhibitors according to the mode of action are classified. 
FLAP inhibitors interfere with the transfer of the substrate AA and thus 
reduce AA availability for 5-LO. Redox-active inhibitors keep the active 
site iron in the ferrous state and thereby uncouple the catalytic cycle of 5-
LO. Many of this inhibitor class comprise lipophilic antioxidants from 
plant origin, such as flavonoids or polyphenols. As redox type 5-LO 
inhibitors often interfere with other redox systems, leading to severe side 
effects such as methemoglobin formation and possess mostly poor 
selectivity; no substance has entered the market yet. Iron ligand inhibitors 
chelate the active site iron with hydroxamic acid or N-hydroxyurea 
derivative structures. Zileuton (Zyflo®) is approved in the US for the 
prophylaxis and chronic treatment of asthma. Nonredox type inhibitors 
compete with AA or hydroperoxides for binding to 5-LO. Note that 
phosphorylation of 5-LO and/or elevated hydroperoxide levels (present in 
inflammatory reactions) were shown to strongly reduce the efficacy of 
nonredox type inhibitors [107]. 
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1.5 Compounds from plant origin with historical use in the 
treatment of inflammatory diseases  
1.5.1 Helichrysum italicum 
 
Helichrysum italicum is a widespread Mediterranean plant that has been 
traditionally used in folk medicine to treat inflammatory diseases [117, 
118]. It is a member of the Asteracaeae family and is domestic along the 
east coast and on the islands of the Adriatic Sea [119]. Extracts of H. 
italicum are known to exhibit anti-inflammatory, antioxidant [117], 
antibacterial [120], antifungal [121] and antiviral [122] properties.  
Several constituents of H. italicum have been reported by now, including α-
amyrin, uvaol [123], ß-diketones [124], kaempferol-3-glucoside, 
naringenin-glycoside [125], gnaphaliin, pinocembrin, tiliroside [126], 
eudesm-5-en-11-ol [127], iso-italicene epoxide, ß-costol, (Z)-α-trans-
bergamotol [128], and the phloroglucinol α-pyrone arzanol [118]. Among 
these, the acylphloroglucinol arzanol (Fig. 1.5), which was first identified 
in 2007, was recently suggested as the active constituent responsible for the 
anti-inflammatory effects of H. italicum [118]. 
 
1 INTRODUCTION 23 
 
Fig. 1.5: chemical structure of arzanol from the plant Helichrysum italicum 
 
Arzanol was already shown to inhibit the release of pro-inflammatory 
mediators, such as interleukin (IL)-1ß, IL-6, IL-8, TNFα and PGE2 in LPS-
stimulated monocytes [118]. In addition, activation of NFκB and HIV-1 
replication in T-cells could be blocked by arzanol [118]. Antioxidant and 
cytotoxic effects of arzanol were studied in various systems of lipid 
peroxidation in vitro and protected VERO cells against tert-butyl 
hydroperoxide (TBH)-induced oxidative stress [129].  
This study describes structure activity relationship (SAR) of arzanol and 24 
synthetic derivatives thereof on mPGES-1 and 5-LO [130]. Furthermore, 
mPGES-1, 5-LO and TXAS were addressed as molecular targets of 
arzanol. In a rat model of carrageenan-induced pleurisy arzanol confirmed 
the anti-inflammatory potential with a significantly reduced inflammatory 
response and reduced PGE2 levels in the pleural exudate [131]. 
 
1.5.2 Cannabis sativa 
 
Cannabis sativa, a member of the Cannabaceae family, has been cultivated 
as a source of industrial fibre, seed oil, food, recreation and medicine for 
millennia. Depending on the purpose of its use, different parts of the plant 
are used. Cannabis sativa L. (hemp) preparations have traditionally been 
used in folk medicine [132]. Concerns over addiction and abuse led to the 
banning of the medicinal use in most countries in the 1930s [133]. 
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Many inflammatory disorders, such as inflammation, pain, MS, 
Alzheimer´s disease, osteoporosis, cancer, cardiovascular disorders and 
metabolic syndrome-related disorders have been treated by Cannabis sativa 
preparations [133]. 
Several hundred secondary metabolites were identified by now with 
widespread biological actions. Cannabis sativa is the exclusive natural 
source of its cannabinoid constituents, except cannabigerol, which was 
shown to occur also in a Helichrysum species [134]. In addition to the well-
known psychotropic properties of THC, cannabinoids and non-
cannabinoids have been reported to possess anti-inflammatory properties 
[135]. THC was shown to reduce inter alia airway inflammation in mice 
[136] and the development of experimental atherosclerosis [137]. 
cannabidiol (CBD), which is the most abundant non-psychoactive 
cannabinoid in the plant, reduces joint inflammation in collagen-induced 
arthritis (CIA) in mice [138] and carrageenan induced paw edema in rats 
[139]. cannflavin (CF), a non-cannabinoid, was shown to be 30-fold more 
potent than aspirin in TPA-induced PGE2 release from cultured synovial 
cells [140]. However, only few molecular targets of phytocannabinoids or 
non-cannabinoids within the AA cascade have been described in literature 
so far, namely COX-1 at rather high concentrations (>10 µM) [141], COX-
2 [142] and 15-LO [143]. This thesis addresses mPGES-1 and/or 5-LO as 
potent molecular targets of several phytocannabinoids and non-
cannabinoids. The molecular pharmacology of CFA was intensively 
studied. 
 
1.5.3 Lichen spec. 
 
Lichens are symbiotic organisms of fungi and algae and extracts of certain 
lichen species have been traditionally used as remedies in folk medicine 
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[144]. Due to various algalfungal combinations and the variable ecological 
and climatic growth conditions, lichens differ widely in appearance and 
produce a vast diversity of secondary metabolites, such as mono- and 
diaromatics, terpenoids, steroids, anthraquinones, naphthoquinones, 
xanthones, and furans [145]. These secondary metabolites were proposed to 
exhibit anti-inflammatory, antipyretic, and analgesic properties [144]. 
Among the secondary metabolites, the exclusively occurring depsides and 
depsidones in lichens, seem to have interesting properties. Only one study 
has reported that lichen depsides and depsidones interfere with COX 
activity in a cell-free assay using rabbit renal microsomes [146]. 
Furthermore, little is known about the bioactivities of lichen compounds on 
the PG biosynthetic pathway.  
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Fig. 1.6: chemical core structures of depsides and depsidones from Lichen spec.  
 
Some molecular targets of depsides and depsidones have been identified. 
For example, several depsides were shown to act as nonredox-type 
inhibitors of LTB4 formation in Ca2+-ionophore-activated bovine 
polymorphonuclear leukocytes (PMNL) [147, 148], and blocked acetic-
acid-induced writhing and hypothermia after oral administration in mice 
[149]. Similarly, depsidones were shown to inhibit 5-LO from porcine 
leukocytes and the formation of cys-LTs in human smooth muscle cells 
[150]. Moreover, for depsides, a selective inhibition of MAO-B [151, 152], 
inhibition of rat brain homogenate auto-oxidation [153], and suppression of 
the growth of human keratinocytes could be demonstrated [154]. This study 
adresses new molecular targets of depsides and depsidones within the AA-
cascade. 
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1.5.4 Ginkgo biloba 
 
Ginkgo biloba is called a “living fossil”, as it is a member of the 
gymnosperms that has flourished 150 million years ago. Ginkgo seeds and 
leafs have been used in traditional Chinese medicine to treat pulmonary 
disorders, bladder inflammation, heart dysfunctions and skin infections 
[155-159]. Nowadays, several Ginkgo biloba preparations are available on 
the market. Among these the standard extract formulation Ginkgo biloba 
extract (GBE) or EGb 761 (Tebonin®) of Dr. Wilmar Schwabe GmbH & 
Co has shown to be beneficial in the treatment of Alzheimer´s disease, 
cardiovascular disease, cancer, stress, memory loss and psychiatric 
disorders [158, 160, 161]. The standardized extract contains 24% flavonoid 
glycosides (e.g. ginketin, isoginkgetin, bilobetin), 6% terpene lactones 
(mainly ginkgolides and bilobalides) and less than 5 ppm ginkgolic acids, 
since ginkgolic acids are considered to be toxic and cause gastrointestinal 
and allergic reactions [156, 162]. Administration of EGb 761 resulted in a 
decrease of platelet aggregation, allergic reaction, general inflammatory 
response, oxygen radical discharge and other pro-inflammatory functions 
of macrophages [163, 164] these anti-inflammatory effects are ascribed to 
mainly ginkgolides and flavonoids. PAF, COX and LO could be addressed 
as molecular targets of flavonoids [165, 166]. Besides, flavonoids exert 
antioxidant activity [167], whereas ginkgolides and bilobalides have 
antioxidant [168] and antimicrobial activities [169]. 
Another interesting class are the ginkgolic acids. Ginkgolic acids are 2-
hydroxy-6-alkylbenzoic acids with a varying alkyl side chain from 13 to 17 
carbons with zero to two double bonds [170]. They are considered to be 
toxic and cause gastrointestinal and allergic reactions, but have low 
cytotoxicity [171]. Ginkgolic acid, which is the main component of the 
nutshells and leaves of Ginkgo biloba [172], has been reported to show 
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antioxidant, radical-captivated, anti-inflammatory and antiallergic 
properties and is not allergenic as long as the carboxylic acid group is 
intact, either in free or conjugated form [173, 174].  
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Fig. 1.7: chemical structure of ginkgolic acid from the plant Ginkgo biloba 
 
This thesis will address several enzymes, i.e. mPGES-1, 5-LO and TXAS 
within the AA-cascade as molecular targets of ginkgolic acid. 
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1.6 Aim of this work 
 
Nonsteroidal anti-inflammatory drugs (NSAID) and selective COX-2 
inhibitors (coxibs) suppress the biosynthesis of prostanoids via inhibition of 
COX activity. Because not only pathogenic formed prostanoids, mainly 
PGE2, but also physiologically important prostanoids are suppressed, long-
term application can lead to severe side effects. Targeting COX-1 primarily 
leads to gastrointestinal and renal complications while COX-2 inhibition 
has been linked to cardiovascular incidents due to an imbalance of 
prothrombotic TXA2 and antithrombotic PGI2. Therefore, selective 
targeting of terminal PG synthases to inhibit individual prostanoids has 
been considered as an improved alternative in the treatment of 
inflammation and pain. The discovery of mPGES-1, a terminal synthase of 
PGE2 biosynthesis that is believed to regulate pathogenic PGE2 formation 
is of great interest. As mPGES-1 is known to be upregulated in pathogenic 
events and only low constitutive levels are present, mPGES-1 inhibitors 
may achieve anti-inflammatory efficacy of NSAIDs, while avoiding 
adverse side effects. 
 
Discovery of mPGES-1 inhibitors started in 1999 and to date no selective 
inhibitors are available for clinical use. This discrepancy might be 
explained by the lack of suitable cell-based models for analysis of mPGES-
1 inhibition [175]. Another reason was the lack of lead structures and 
structural models of mPGES-1, making it difficult to discover mPGES-1 
inhibitors. Furthermore, problems and challenges in the development of 
mPGES-1 inhibitors occurred, leading to only few inhibitors that exhibit 
also in vivo activity.  
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The aim of this study was to discover natural and synthetic mPGES-1 
inhibitors and to characterize the pharmacological profile of promising 
candidates towards their potency in vitro and in vivo, their selectivity 
within several enzymes (cPLA2, 5-LO, COX, TXAS) of the eicosanoid 
pathway and their mechanistic properties. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Compounds 
 
Arzanol was isolated from H. italicum [118] and arzanol derivatives were 
prepared as described [130]. Phytocannabinoids and non-cannabinoids 
were synthesized by Prof. G. Appendino, Italy, unpublished data. Lignan 
derivatives from the dichloromethane extract of K. lappacea roots were 
isolated as described [176]. Depsides and depsidones were obtained from 
plant material as described [177]. Ginkgolic acid was kindly provided by 
Prof. H. Stuppner, Innsbruck, unpublished data. NSAID derivatives were 
synthesized by Prof. S. Laufer, Tübingen [178]. 
All compounds were dissolved in dimethyl sulfoxide (DMSO) and kept in 
the dark at −20°C and freezing/thawing cycles were kept to a minimum. 
 
2.1.2 Materials  
 
The TXAS inhibitor CV4151 and celecoxib were generous gift by Prof. S. 
Laufer (University of Tuebingen, Germany). BWA4C was a generous gift 
by Dr. L. G. Garland (Wellcome Res. Laboratories, Kent, UK). COX-2 
antibody was obtained from Enzo Life Sciences (Loerrach, Germany). 
DMEM/HighGlucose (4.5 g/l) medium, penicillin, streptomycin, 
trypsin/EDTA solution, PAA Laboratories (Linz, Austria); λ-Carrageenan 
type IV isolated from Gigartina aciculaire and Gigartina pistillata and 
indomethacin were purchased from Sigma–Aldrich (Milan, Italy); PGH2, 
Larodan (Malmo, Sweden); 11b-PGE2, PGB1, MK-886 (3-[1-(4-
chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-
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dimethylpropanoicacid), human recombinant COX-2, ovine isolated COX-
1, Cayman Chemical (AnnArbor, MI); UltimaGoldTM XR, PerkinElmer 
(Boston, MA); [3H]-PGE2 was from Perkin Elmer Life Sciences (Milan, 
Italy) and PGE2 antibody from Sigma–Aldrich (Milan, Italy). All other 
chemicals were obtained from Sigma–Aldrich (Deisenhofen, Germany) 
unless stated otherwise.  
2.2 Methods 
2.2.1 Cells and cell viability assay 
 
A549 cells were cultured in DMEM/High Glucose (4.5 g/l) medium 
supplemented with heat-inactivated fetal calf serum (10%, v/v), penicillin 
(100 U/ml), and streptomycin (100 µg/ml) at 37 °C in a 5% CO2 incubator. 
After 3 days, confluent cells were detached using 1 × trypsin/EDTA 
solution and reseeded at 2 x 106 cells in 20 ml medium in 175 cm2 flasks.  
Blood cells were freshly isolated from leukocyte concentrates obtained at 
the Blood Center of the University Hospital Tuebingen (Germany) as 
described [179]. In brief, venous blood was taken from healthy adult 
donors that did not take any medication for at least 7 days, and leukocyte 
concentrates were prepared by centrifugation (4000 x g, 20 min, 20 °C). 
Cells were immediately isolated by dextran sedimentation and 
centrifugation on Nycoprep cushions (PAA Laboratories, Linz, Austria). 
Platelet-rich-plasma was obtained from the supernatants, mixed with 
phosphate-buffered saline (PBS) pH 5.9 (3:2 v/v), centrifuged (2100 x g, 
15 min, room temperature), and the pelleted platelets were resuspended in 
PBS pH 5.9/0.9% NaCl (1:1, v/v). Washed platelets were finally 
resuspended in PBS pH 7.4 and 1 mM CaCl2. Neutrophils were 
immediately isolated from the pellet after centrifugation on Nycoprep 
cushions, and hypotonic lysis of erythrocytes was performed as described 
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[179]. Cells were finally resuspended in PBS pH 7.4 containing 1 mg/ml 
glucose and 1 mM CaCl2 (PGC buffer) (purity > 96-97%). For isolation of 
human monocytes, peripheral blood mononuclear cells (PBMC) were 
promptly isolated from leukocyte concentrates by dextran sedimentation 
and centrifugation on Nycoprep cushions. PBMC were washed three times 
with cold PBS and then monocytes were separated by adherence for 1 h at 
37 °C to culture flasks (Greiner, Nuertingen, Germany; cell density was 2 x 
107 cells/ml of RPMI 1640 medium containing 2 mM L-glutamine and 50 
µg/ml penicillin/streptomycin), which finally gave a purity of > 85%, 
defined by forward- and side-light scatter properties and detection of the 
CD14 surface molecule by flow cytometry (BD FACS Calibur). Monocytes 
were finally resuspended in ice-cold PBS plus 1 mg/ml glucose (PG buffer) 
or in PG buffer supplemented with 1 mM CaCl2 (PGC buffer).  
For analysis of acute cytotoxicity during pre-incubation periods, viability 
was analyzed by light microscopy and trypan blue exclusion. For analysis 
of cytotoxicity of A549 cells, the MTT assay was used. In brief, cells (100 
µl cell suspension corresponding to 3 x 105 A549 cells) were incubated for 
24 h and 48 h at 37 °C with vehicle (0.3% DMSO) or the indicated 
compounds. After 24 h or 48 h, 20 µl of a sterile filtered solution of 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) in PBS 
(5 mg/ml) was added and samples were incubated for 4 h at 37 °C. Then, 
100 µl of 10% SDS in 20 mM HCl (pH 4.5; SDS lysis buffer) was added 
and samples were shaken for 15 h at RT in the dark and the absorption was 
measured at 570 nm. Results are reported as percentage of viable cells as 
compared to vehicle control. A statistically significant impairment of MTT 
reduction to formazan was considered cytotoxic. 
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2.2.2 Animals  
 
Male adult Wistar Han rats (200 – 220 g, Harlan, Milan, Italy) were housed 
in a controlled environment and provided with standard rodent chow and 
water. Animal care complied with Italian regulations on protection of 
animals used for experimental and other scientific purpose (Ministerial 
Decree 116192) as well as with the European Economic Community 
regulations (Official Journal of E.C. L 358/1 12/18/1986).  
 
2.2.3 DPPH assay 
 
The radical scavenger capability was assessed by measuring the reduction 
of the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH). Briefly, an 
ethanol solution of a sample at various concentrations (100 µl) was mixed 
with an acetate-buffered (pH 5 - 6.5) DPPH solution (final concentration 50 
µM). After incubation for 30 min in the dark the absorbance of the mixture 
was measured at 520 nm. Ascorbic acid and L-cysteine were used as 
reference compounds. All analyses were performed in triplicates. 
 
2.2.4 Preparation of crude mPGES-1 in microsomes of A549 cells and 
determination of PGE2 synthase activity 
 
Preparations of A549 cells and determination of mPGES-1 activity was 
performed as described previously [82]. In brief, cells were treated with 1 
ng/ml Il-1β for 48 h at 37 °C, 5% CO2. Cells were harvested, sonicated and 
the homogenate was subjected to differential centrifugation at 10,000 x g 
for 10 min and 174,000 x g for 1 h at 4 °C. The pellet (microsomal 
fraction) was resuspended in 1 ml homogenization buffer (0.1 M potassium 
phosphate buffer, pH 7.4, 1 mM phenylmethanesulfonyl fluoride, 60 µg/ml 
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soybean trypsin inhibitor, 1 µg/ml leupeptin, 2.5 mM glutathione, and 250 
mM sucrose), and the total protein concentration was determined. 
Microsomal membranes were diluted in potassium phosphate buffer (0.1 
M, pH 7.4) containing 2.5 mM glutathione. Test compounds or vehicle 
were added, and after 15 min at 4 °C reaction (100 µl total volume) was 
initiated by addition of PGH2 at the indicated concentration. After 1 min at 
4 °C, the reaction was terminated using stop solution (100 µl; 40 mM 
FeCl2, 80 mM citric acid, and 10 µM 11β-PGE2 as internal standard. PGE2 
formation was analyzed using PGE2-ELISA according to the manufactures 
protocol (1 and 5 µM PGH2) or separated by solid-phase extraction and 
analyzed by RP-HPLC (20 and 50 µM PGH2) as described previously [82]. 
 
2.2.5 COX-2 and mPGES-1 expression in LPS stimulated human 
monocytes 
 
Freshly isolated monocytes (106/ml) were cultured in RPMI medium 
supplemented with heat-inactivated fetal calf serum (0.5%, v/v) stimulated 
with 1 µg/ml LPS and the indicated compounds at 37 °C in a 5% CO2 
incubator. After 20 or 24 h monocytes were harvested, lysed and 
expression of COX-2 or mPGES-1 was detected by SDS-PAGE and 
Western blot. 
 
2.2.6 Expression and purification of human recombinant 5-LO  
 
E.coli MV1190 was transformed with pT3-5-LO plasmid and recombinant 
5-LO protein was expressed at 27 °C as described [180]. Cells were lysed 
in 50 mM triethanolamine/HCl pH 8.0, 5 mM EDTA, soybean trypsin 
inhibitor (60 µg/ml), 1 mM phenylmethanesulphonyl fluoride, and 
lysozyme (500 µg/ml), homogenized by sonication (3 x 15 sec), and 
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centrifuged at 40,000 x g for 20 min at 4 °C. The 40,000 x g supernatant 
(S40) was applied to an ATP-agarose column to partially purify 5-LO as 
described previously [180]. Semi-purified 5-LO was immediately used for 
activity assays. 
 
2.2.7 Determination of 5-LO activity in cell-free assay 
 
Aliquots of semi-purified 5-LO were diluted with ice-cold PBS containing 
1 mM EDTA, and 1 mM ATP was added. Samples were pre-incubated 
with the test compounds as indicated. After 10 min at 4 °C, samples were 
pre-warmed for 30 sec at 37 °C, and 2 mM CaCl2 plus 20 µM AA was 
added to start 5-LO product formation. The reaction was stopped after 10 
min at 37 °C by addition of 1 ml ice-cold methanol, and the formed 
metabolites were analyzed by RP-HPLC as described [181]. 5-LO products 
include the all-trans isomers of LTB4 and 5(S)-hydro(pero)xy-6-trans-
8,11,14-cis-eicosatetraenoic acid (5-HETE). 
 
2.2.8 Determination of 5-LO product formation in intact cells  
 
For determination of LO products in intact PMNL, 5 x 106 cells were 
resuspended in 1 ml PG-buffer containing 1 mM CaCl2, pre-incubated for 
15 min at 37 °C with test compounds or vehicle (0.3% DMSO), and 
incubated for 10 min at 37 °C with the indicated stimuli. Thus, the Ca2+-
ionophore A23187 (2.5 µM) was added with or without 20 µM AA and 10 
min later the reaction was stopped on ice by addition of 1 ml of methanol. 
30 µl 1 N HCL and 500 µl PBS, and 200 ng prostaglandin B1 were added 
and the samples were subjected to solid phase extraction on RP18-columns 
(100 mg, UCT, Bristol, PA, USA). 5-LO products (LTB4, trans-isomeres, 
5-HETE) were analyzed by HPLC and quantities calculated on the basis of 
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the internal standard PGB1. Alternatively, cells were first primed at 37 °C 
with lipopolysaccharide (LPS, 1 µg/ml) plus adenosine deaminase (Ada, 
0.3 U/ml) for 30 min. Formation of 5-LO products was started by addition 
of 1 µM formyl-methionyl-leucyl-phenylalanine (fMLP) and after 5 min 
the reaction was stopped on ice. Supernatants were collected after 
centrifugation at 600 x g for 10 min at 4 °C. LTB4 levels were measured by 
ELISA according to the manufacturer´s (Assay Designs, Ann Arbor, MI) 
protocol.) 
For determination of 5-LO products in cell homogenates, cell suspensions 
were resuspended in PBS containing 1 mM EDTA for 5 min at 4 °C and 
sonicated (4 x 10 sec, 4 °C). After addition of 1 mM ATP, homogenates 
corresponding to 5 x 106 cells/ml were incubated with the test compounds 
or vehicle (0.3% DMSO) for 15 min at 4 °C, pre-warmed for 30 sec at 37 
°C and the reaction was started by the addition of 2 mM CaCl2 and 20 µM 
AA. The reaction was stopped after 10 min at 37 °C and the samples were 
analyzed as described for intact cells above. 
 
2.2.9 Activity assays of isolated COX-1, COX-2 and TXAS  
 
Inhibition of the activities of isolated ovine COX-1 and human COX-2 was 
performed as described [82]. In brief, purified COX-1 (ovine, 50 units) or 
COX-2 (human recombinant, 20 units) were diluted in 1 ml reaction 
mixture containing 100 mM Tris buffer pH 8, 5 mM glutathione, 5 µM 
haemoglobin, and 100 µM EDTA at 4 °C and pre-incubated with the test 
compound for 5 min. Samples were pre-warmed for 60 sec at 37 °C, and 
AA (5 µM for COX-1, 2 µM for COX-2) was added to start the reaction. 
After 5 min at 37 °C, the reaction was stopped on ice by addition of 1 ml of 
methanol. 30 µl 1 N HCL and 500 µl PBS, and 200 ng prostaglandin B1 
were added and the samples were subjected to solid phase extraction on 
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RP18-columns (100 mg, UCT, Bristol, PA, USA). 12-HHT was analyzed 
by HPLC and quantities calculated on the basis of the internal standard 
PGB1. Indomethacin (10 µM) was used as well-recognized reference 
inhibitor of COX-1 and celecoxib (5 µM) for COX-2 to control the assays. 
For analysis of the activity of TXAS in platelet homogenates (108/ml), cells 
were resuspended in PBS/EDTA for 5 min at 4 °C and sonicated (4 x 10 
sec, 4 °C). Freshly prepared platelet homogenates were pre-incubated with 
test compounds or vehicle. After 15 min at 4 °C the reaction (100 µl total 
volume) was initiated by addition of 20 µM PGH2 for 1 min at 4 °C and 
reaction was terminated using stop solution (100 µl; 40 mM FeCl2, 80 mM 
citric acid). The formation of TXB2 was measured via TXB2-ELISA 
according to the manufactures protocol.  
 
2.2.10 Determination of COX-1 product formation in human washed 
platelets  
 
Freshly isolated human platelets (108/ml PGC buffer) were pre-incubated 
with the indicated compounds for 4 min at room temperature. Samples 
were pre-warmed for 60 sec at 37 °C and AA (5 µM) was added to start the 
reaction. After 10 min at 37 °C the reaction was stopped on ice or by the 
addition of 1 ml ice-cold methanol. The formation of TXB2 was measured 
via TXB2-ELISA according to the manufactures protocol and 12-HHT was 
analyzed by HPLC as described [182]. 
 
2.2.11 Determination of MAPK activation  
 
Neutrophils (107/100 µl of PGC buffer) were pre-warmed for 3 min at 37 
°C and pre-incubated with the indicated compounds at 37 °C for 15 min. 
The reaction was started by the addition of 0.1 µM fMLP and stopped after 
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1.5 min with 100 µl of ice-cold SDS-loading buffer and heated for 6 min at 
95 °C. Total cell lysates were analyzed for ERK1/2, phosphorylated 
ERK1/2 (Thr-202/Tyr-204), phosphorylated p38 MAPK (Thr-180/Tyr-
182), by SDS/PAGE and western blotting.  
 
2.2.12 SDS–PAGE and Western blotting  
 
Monocytes (5 x 106 cells) or neutrophils (107 cells) were resuspended in 50 
µl PBS buffer pH 7.2, mixed with the same volume of 2 x SDS/PAGE 
sample loading buffer (20 mM Tris–HCl, pH 8, 2 mM EDTA, 5% (m/v) 
SDS, and 10% (v/v) β-mercaptoethanol), 20 µl glycerol/0,1% bromophenol 
blue (1:1, v/v) and boiled for 5 min at 95 °C. Proteins were separated by 
SDS-PAGE. Correct loading of the gel and transfer of proteins to the 
nitrocellulose membrane was confirmed by Ponceau staining. After 
electroblotting to nitrocellulose membrane (GE Healthcare, Munich, 
Germany) and blocking with 5% BSA for 1 h at room temperature, 
membranes were washed and incubated with primary antibodies overnight 
at 4 °C. The membranes were washed and incubated with a 1:1000 dilution 
of alkaline phosphatase-conjugated immunoglobulin G for 1 h at room 
temperature. After washing, proteins were visualized with nitro blue 
tetrazolium and 5-bromo-4-chloro-3-indolylphosphate. 
 
2.2.13 Determination of activity of isolated human recombinant 
cPLA2α in a cell-free assay 
 
The cPLA2α coding sequence was cloned from pVL1393 plasmid (kindly 
provided by Dr. Wonhwa Cho, University of Illinois at Chicago) into 
pFastBacTM HT A containing a 6 x his-tag coding sequence. The 
recombinant plasmid was transformed into DH10BacTM E. coli. Sf9 cells 
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were transfected with recombinant bacmid DNA using Cellfectin® Reagent 
and the generated baculovirus was amplified. Overexpression of His-tagged 
cPLA2 in baculovirus-infected Sf9 cells and isolation using Ni-NTA 
agarose beads was performed as described [183].  
Multilamelar vesicles (MLVs) were prepared by drying 1-palmitoyl-2-
arachidonyl-sn-glycero-3-phosphocholine (PAPC) and 1-palmitoyl-2-
oleoyl-sn-glycerol (POG) in a ratio of 2:1 (nn-1, in chloroform) under 
nitrogen in glass vials. After addition of 20 mM Tris buffer (pH 7.4) 
containing 134 mM NaCl and 1 mg/mL fatty acid free BSA, the MLV 
suspension was disrupted by several freeze-thaw cycles (liquid nitrogen) 
and then extruded 11 times with a mini-extruder (Avanti Polar Lipids, Inc.) 
through a polycarbonate membrane (100 nm pore diameter) at room 
temperature (above transition temperature of the lipids) to produce LUV 
(large unilamelar vesicles). Final total concentration of lipids was 250 µM 
in 200 µL. Test compounds and 1 mM CaCl2 were added to the vesicles, 
and the reaction was started by addition of 500 ng his-tagged cPLA2 (in 10 
µL buffer). After 1 h at 37 °C, 1.6 mL CH3OH was added, and AA was 
extracted by RP-18 solid phase extraction. Following derivatisation with p-
anisidinium chloride, the resulting derivate was analyzed by RP-HPLC at 
249 nm as described [183]. 
 
2.2.14 5-LO activity in human whole blood 
 
Peripheral blood from healthy adult volunteers, who had not received any 
medication for at least 2 weeks under informed consent, was obtained by 
venipuncture and collected in syringes containing heparin (20 U/ml). 2 mL 
aliquots were pre-incubated with the indicated compounds and stimulated 
with A23187 (30 µM) for 10 min at 37 °C. After stimulation, the reaction 
was stopped on ice and the samples were centrifuged at 600 x g, 10 min, 4 
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°C. Aliquots of plasma (500 µL) were mixed with 2 mL of methanol and 
200 ng PGB1 were added as internal standard. The samples were put at -20 
°C for 2 h and centrifuged (600 x g, 15 min, 4 °C). The supernatants were 
collected and diluted with 2.5 mL PBS + 75 µL HCl 1N. Formed 5-LO 
metabolites were extracted and analyzed by HPLC as described before. 
 
2.2.15 Prostanoid formation in human whole blood  
 
Peripheral blood from healthy adult volunteers, who had not received any 
medication for at least 2 weeks under informed consent, was obtained by 
venipuncture and collected in syringes containing heparin (20 U/ml) or 
citrate (0.106 mol/l trisodium citrate solution). 
 
Stimulation for 5 h with LPS (10 µg/ml) 
 
Aliquots of whole blood (for PGE2: 0.8 ml, for 6-ketoPGF1a: 0.4 ml) were 
mixed with CV4151 (1 µM) and with aspirin (50 µM) for determination of 
PGE2 and with CV4151 (1 µM) for analysis of 6-ketoPGF1a, respectively. 
For determination of TXB2, aliquots of whole blood (0.4 ml) were used 
without additives. A total volume of 1 ml or 0.5 ml was adjusted with 
sample buffer (10 mM potassium phosphate buffer pH 7.4, 3 mM KCl, 140 
mM NaCl and 6 mM D-glucose). After pre-incubation with the indicated 
compounds for 5 min at room temperature, the samples were stimulated 
with LPS (10 µg/ml) for 5 h at 37 °C. Prostanoid formation was stopped on 
ice, the samples were centrifuged (2300 x g, 10 min, 4 °C) and 6-ketoPGF1a 
and TXB2 were quantified in the supernatant using High Sensitivity EIA 
Kits (Assay Designs, Ann Arbor, MI), respectively, according to the 
manufacturer’s protocols. PGE2 was determined as described. In brief, the 
supernatant was acidified with citric acid (30 µl, 2 M), and after 
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centrifugation (2300 x g, 10 min, 4 °C), solid phase extraction and 
separation by RP-HPLC was performed to isolate PGE2. The PGE2 peak (3 
ml), identified by co-elution with the authentic standard, was collected and 
acetonitrile was removed under a nitrogen stream. The pH was adjusted to 
7.2 by addition of 10 x PBS buffer pH 7.2 (230 µl) before PGE2 contents 
were quantified using a PGE2 High Sensitivity EIA Kit (Assay Designs, 
Ann Arbor, MI) according to the manufacturer’s protocol. 
 
Stimulation for 24 h with LPS (10 µg/ml) 
 
Aliquots of heparinized whole blood (1 ml) were pre-incubated with the 
indicated compounds for 5 min at room temperature and the samples were 
stimulated with LPS (10 µg/ml) for 24 h at 37 °C. Prostanoid formation 
was stopped on ice and the samples were centrifuged (2300 x g, 10 min, 4 
°C). 6-ketoPGF1a was quantified in the supernatant using High Sensitivity 
EIA Kits (Assay Designs, Ann Arbor, MI) according to the manufacturer’s 
protocols.  
 
Stimulation with thrombin (2 U/ml) 
 
For determination of TXB2 levels citrated human whole blood was pre-
incubated with the indicated compounds for 15 min at 37 °C and the 
reaction was initiated with thrombin (2 U/ml). After 10 min the reaction 
was stopped on ice and TXB2 levels were detected in the supernatant using 
a TXB2 High Sensitivity EIA Kit according to the manufacturer's protocol. 
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2.2.16 Carrageenan-induced pleurisy in rats  
 
Test compounds at the indicated concentration or indomethacin (5 mg/kg) 
were given i.p. 30 min before carrageenan. A group of male rats received 
the vehicle (DMSO, 4%, i.p.) 30 min before carrageenan. Rats were 
anaesthetized with enflurane 4% mixed with O2, 0.5 l/min, N2O 0.5 l/min 
and submitted to a skin incision at the level of the left sixth intercostal 
space. The underlying muscle was dissected, and saline (0.2 ml) or λ-
carrageenan type IV 1% (w/v, 0.2 ml) was injected into the pleural cavity. 
The skin incision was closed with a suture, and the animals were allowed to 
recover. At 4 h after the injection of carrageenan, the animals were killed 
by inhalation of CO2. The chest was carefully opened, and the pleural 
cavity was rinsed with 2 ml saline solution containing heparin (5 U/ml). 
The exudates and washing solution were removed by aspiration, and the 
total volume was measured. Any exudate that was contaminated with blood 
was discarded. The amount of exudates was calculated by subtracting the 
volume injected (2 ml) from the total volume recovered. Leukocytes in the 
exudates were resuspended in PBS and counted with an optical light 
microscope in a Burker’s chamber after vital trypanblue staining. The 
amounts of PGE2, LTB4 and 6-ketoPGF1a in the supernatant of centrifuged 
exudates (800 x g for 10 min) were assayed by radioimmunoassay (PGE2) 
and enzyme immunoassay (LTB4, 6-ketoPGF1a), respectively (Cayman 
Chemical, Ann Arbor, MI) according to manufacturer’s protocol. The 
results are expressed as ng per rat and represent the mean ± S.E. of 10 rats.  
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2.2.17 Statistics 
 
Data are expressed as mean ± S.E. IC50 values were graphically calculated 
from averaged measurements at 3 - 5 different concentrations of the 
compounds using SigmaPlot 9.0 (Systat Software Inc., San Jose, USA). 
Statistical evaluation of the data was performed by one-way ANOVA 
followed by Tukey-Kramer post-hoc test for multiple comparisons 
respectively. A p value < 0.05 (*) was considered significant.
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3 RESULTS 
 
The design of novel mPGES-1 inhibitors is of great interest, since mPGES-
1 inhibitors are considered as a promising alternative to NSAIDs in the 
therapeutic strategy of inflammatory diseases. 
To enhance the benefit in pharmacotherapy, a dual inhibition concept of 
mPGES-1 and 5-LO might have synergistic effects and a reduced side 
effect profile compared to classical NSAIDs. 
 
3.1 Discovery of mPGES-1 or dual mPGES-1/ 5-LO 
inhibitors from plant-origin that are traditionally used in folk 
medicine 
3.1.1 Arzanol (1) from Helichrysum italicum as lead structure for 
structure activity relationship (SAR) 
 
Arzanol (1), a constituent of Helichrysum italicum, was suggested to highly 
contribute to the anti-inflammatory potential of the plant. Arzanol (1) 
significantly inhibited (I) PGE2 formation in microsomal preparations of 
IL-1ß-stimulated A549 cells as a source of mPGES-1¶ (IC50= 0.4 µM) and 
(II) 5-LO product formation in the semi-purified 5-LO¶ assay (IC50= 3.1 
µM). SAR studies were performed to enhance the anti-inflammatory 
potential [131]. The basic structure consists of a prenylated heterodimeric 
acylphloroglucinol with an α-pyrone and a phloroglucinol core. As arzanol 
(1) is instable to acids and bases and exhibit high functionalization, the 
possibilities of chemical modification are restricted. Therefore, focus for 
the improvement of the pharmacophore of arzanol (1) was placed on the 
alkylidene linker and/or the pyrone moiety (1a-g), as well as on 
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homodimeric analogues from both structural moieties (Helipyron, 2a-i and 
4a-d). To check whether the basic structure elements itself influence the 
enzymatic activity of mPGES-1, a prenylated acylphloroglucinol core (5) 
and alkyl-substituted pyrones (6, 7) were tested for their ability to block 
mPGES-1 derived PGE2 and 5-LO derived LT formation under cell-free 
conditions (Table 3.6). 
 
Table 3.6: Biological evaluation of arzanol (1) and its derivatives on product formation 
of cell-free mPGES-1 and semi-purified 5-LO. Mean values (n = 3-5) (IC50 [µM] or % 
remaining activity at 10 µM) 
# structure 
Cell-free 
mPGES-1 
Semipurified 
5-LO 
 
O
OH
OH
O
OH
R1
OH
O
R2
R3
 
R1              R2            R3 
  
arzanol (1) H CH3 CH3 0.4 µM 3.1 µM 
1a H H H 1.0 µM 9.5 µM 
1b CH3 CH3 CH3 2.1 µM 5.9 µM 
1c CH3 H H 2.4 µM 7.9 µM 
1d nC6H13 CH3 CH3 0.3 µM 1.6 µM 
1e nC6H13 H H 0.2 µM 1.2 µM 
1f Phenyl CH3 CH3 0.8 µM 4.9 µM 
1g Phenyl H H 1.1 µM 8.4 µM 
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O
O
OR2
OH
R1
OH
O
R2
R3
R3
 
R1              R2            R3 
  
helipyron (2) H CH3 CH3 6 µM n.i. 
2a H H H 99.8±1.3 93.0±9.3 
2b CH3 CH3 CH3 102.7±15.8 83.5±5.7 
2c CH3 H H 98.9±8.1 88.5±1.8 
2d nC6H13 CH3 CH3 0.84 µM 56.1±7.2 
2e nC6H13 H H 79.2±11.8 7.8 µM 
2f Phenyl CH3 CH3 66.6±4.6 86.1±12.8 
2g Phenyl H H 92.8±16.7 81.8±2.3 
2h 2-furyl CH3 CH3 80.3±6.6 71.2±16.8 
2i 2-furyl H H 102.3±7.9 93.1±20.1 
3 
O
OH
OH
OH
O
MeO
O
 
99.3±15.9 5 µM 
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OH
OH
OH
OH
OHOH
O
R
O
R 
  
4a H 0.5 µM 1.4 µM 
4b CH3 0.7 µM 1.2 µM 
4c nC6H13 0.6 µM 0.6 µM 
4d Phenyl 1.5 µM 0.7 µM 
5 
OH
OH
O
OH
 
62.4±5.8 5.1 µM 
6 
O
OH
O
 
107.7±3.5 111.7±10.8 
7 
O
OH
O
 
107.1±11.1 129.8±25.7 
 
The reference drugs MK886 (standard mPGES-1 inhibitor [56]) and 
BWA4C (standard 5-LO inhibitor [184]) suppressed product formation as 
expected (not shown). 
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First, the pyrone substitution pattern was simplified which resulted in the 
bis-nor derivative 1a. Compound 1a basically retained activity towards 
mPGES-1 and 5-LO with IC50 values of 1 and 9.5 µM, respectively, 
suggesting that substitution of the pyrone pattern is not essential for the 
inhibitory potential. Introduction of a methyl on the alkylidene linker (1b 
and 1c) slightly decreased the inhibitory potency of mPGES-1 and 5-LO 
with IC50 values of 2.1 and 5.9 µM as well as 2.4 and 7.9 µM, respectively. 
Interestingly, the derivatives 1d and 1e, which both possess n-hexyl 
residues on the alkylidene linker, increased the inhibitory potential of 
mPGES-1 and 5-LO product formation with IC50 values of 0.3 and 1.6 µM 
as well as 0.2 and 1.2 µM, respectively, suggesting that lipophilic 
substituents on the alkylidene linker enhance the efficacy towards mPGES-
1 and 5-LO. However, introduction of a phenyl residue on the alkylidene 
linker (1f and 1g) resulted in IC50 values of 0.8 and 4.9 µM as well as 1.1 
and 8.4 µM, respectively. Moreover, 1f and 1g increased the inhibitory 
potential towards both enzymes compared to derivatives with the methyl 
residue 1b and 1c, but were less efficient compared to 1d and 1e which 
possess the lipophilic n-hexyl residue. 
Next, the basic structure elements were investigated for their ability to 
suppress cell-free mPGES-1 and 5-LO product formation. The alkyl-
substituted pyrones 6 and 7 did not inhibit mPGES-1 and 5-LO activity, 
whereas the prenylated acylphloroglucinol core 5 slightly inhibited 
mPGES-1 derived PGE2 formation (62.4% remaining activity at 10 µM) 
and potently inhibited 5-LO product formation in the semi-purified 5-LO 
assay (IC50= 5.1 µM). These findings suggest that 5 might be essential for 
the inhibitory potential whereas 6 and 7 (and 1a) might have no influence 
on the inhibitory potential of the natural product arzanol (1). 
Surprisingly, the enolether derivative 3 did not suppress mPGES-1 derived 
PGE2 formation (99.3% remaining activity at 10 µM) but mainly sustained 
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5-LO inhibition (IC50= 5 µM). These unexpected findings imply that the 
existence of an acidic group might be crucial for mPGES-1 inhibition. 
To further investigate the significance of the heterodimeric structure of the 
natural compound arzanol (1), homodimeric pyrone- (Helipyron and 2a–2i) 
and phloroacetophenon-derivatives (4a-4d) were tested for their ability to 
block the formation of mPGES-1-derived PGE2 and 5-LO-derived LT 
formation. 
The homodimeric pyrone helipyron (2) is known to occur in Helichrysum 
italicum [118]. Helipyron (2) is much less potent on mPGES-1 inhibition 
(IC50= 6 µM) compared to arzanol (1) and even inactive towards 5-LO 
inhibition. Consistent with the results of the heterodimeric derivatives 
(arzanol (1) and 1a-1g) introduction of n-hexyl residue to the methylene 
linker (2d and 2e) increased the potency towards mPGES-1 and 5-LO 
inhibition whereas helipyron and the corresponding bis-nor derivatives (2a 
and 2e) were less efficient. Methyl, phenyl or 2-furyl residues on the 
methylene linker resulted in completely inactive compounds (2b, c, f, g, h, 
i) towards mPGES-1 and 5-LO inhibition. 
As the prenylated acylphloroglucinol core 5 already implied, homodimeric 
phloroacetophenon derivatives (4a-4d) potently suppressed the formation 
of mPGES-1 derived PGE2 and 5-LO derived LTs. In line with other 
results, introduction of n-hexyl residue (4c) resulted in the most potent 
derivative of group 4 with IC50 values of 0.6 µM, each. 
Taken together, arzanol (1) could be identified as a dual inhibitor of 
mPGES-1/5-LO and the performed SAR studies yield that introduction of 
lipophilic elements (especially n-hexyl residues) to the alkylidene linker 
enhance the potency towards mPGES-1 and 5-LO inhibition compared to 
the natural compound arzanol (1). Furthermore, the α-pyrone core is 
apparently not crucial for the inhibition potential which could be verified 
by the corresponding bis-nor derivatives and the homodimeric pyrone- and 
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phloroacetophenon-derivatives. 1e, as the most promising derivative, with 
potent properties will be further investigated on its molecular 
pharmacology within the eicosanoid pathway (see chapter 3.4.1) 
 
3.1.2 Phytocannabinoids and non-cannabinoids from Cannabis sativa 
 
Phytocannabinoids as well as non-cannabinoids from Cannabis sativa have 
been shown to interfere with the AA cascade [140-143]. Thus, little is 
known about the molecular targets. To screen for inhibition of mPGES-1, 
seven phytocannabinoids and eight non-cannabinoids were tested in 
microsomal preparations of interleukin-1β-stimulated A549 cells for their 
ability to block the formation of PGE2 (see Table 3.7 and Table 3.8). 
 
Table 3.7: Biological evaluation of phytocannabinoids on cell-free mPGES-1 product 
formation. Mean values (n = 3-4) (IC50 [µM] or % remaining activity at 10 µM) 
# Structure 
Cell-free 
mPGES-1 
cannabidiol 
(CBD) (8) 
OH
OH
 
65.0±3.5 
cannabidiol-
viridine  
(CBD vir) (9) 
OH
OH
 
62.5±4.1 
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cannabigerol 
(CBG) (10) 
OH
OH
 
0.9 µM 
cannabi-
chromene 
(CBCr) (11) 
O
OH
 
84.0±5.6 
tetrahydro-
cannabinol  
(THC) (12) O
OH
H
H
 
70 µM 
tetrahydro-
cannabinol-
viridine 
(THCvir) (13) 
O
OH
H
H
 
77.7±1.6 
cannabinol 
(CBN) (14) 
O
OH
 
70.3±5.9 
 
The standard reference inhibitor MK-886 blocked PGE2 formation as 
expected (IC50 = 2.1 µM, data not shown). CBG (10) could be identified as 
a potent inhibitor of mPGES-1 with an IC50 value of 0.9 µM. Furthermore, 
THC (12) (IC50 = 70 µM) could be identified as weak inhibitor of mPGES-
1 derived PGE2 formation. All other cannabinoids (8, 9, 11, 13, 14) did not 
inhibit mPGES-1 activity up to 10 µM. 
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Table 3.8: Biological evaluation of non-cannabinoids on cell-free mPGES-1 and semi-
purified 5-LO product formation. Mean values (n = 2-3) (IC50 [µM], % remaining 
activity at 10 µM, n.i. no inhibition) 
# Structure 
Cell-free 
mPGES-1 
Semipurified 
5-LO 
feruloyl-
tyramine 
(15) 
OH
N
H
OH
O
O
 
81.4±3.4 85.5±7.1 
cumaroyl-
tyramine 
(16) 
OH
N
H
OH
O
 
89.3±5.0 114.9±4.8 
cannabis-
pyrenone 
(17) 
O
OH
O
 
n.i. 8.6 µM 
cannabis-
pyranol 
(18) 
OH
OH
O
 
88.2±6.9 118.1±3.8 
cann-
flavin A 
(19) 
O
OH
OH
O
OH
O
 
1.8 µM 0.95 µM 
cann-
flavin B 
(20) 
O
OH
OH
O
OH
O
 
3.7 µM 0.9 µM 
oxylipin 
(21) 
OH
O
OH
57.5±5.6 6.0 µM 
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canni-
prene (22) 
O
OH
O
OH
 
10 µM 0.4 µM 
 
The references MK886 (standard mPGES-1 inhibitor [56]) and BWA4C 
(standard 5-LO inhibitor [184]) suppressed product formation as expected 
(not shown). Of all tested non-cannabinoids, the prenylated flavonoids 
cannflavin (CF) A (19) and B (20) and the dihydrostilbene canniprene (22) 
potently inhibited cell-free mPGES-1 and semi-purified 5-LO product 
formation with IC50 values of 1.8 and 0.95 µM for CFA (19), 3.7 and 0.9 
µM for CFB (20) and 10 and 0.4 µM for canniprene (22), respectively. The 
endocannabinoid-related oxylipin (21) and the “spiro compound” cannabis-
pyrenone (17) selectively blocked 5-LO products with IC50 values of 8.6 
and 6.0 µM, respectively. The tyramine derivatives (15, 16) as well as the 
“spiro compound” cannabispyranol (18) did not influence PGE2 formation 
or 5-LO product formation in semi-purified 5-LO up to 10 µM. 
As CFA (19) could be identified as a potent dual inhibitor of mPGES-1/5-
LO, further experiments were performed to disclose the pharmacological 
profile within the AA cascade (see chapter 3.4.2). 
 
3.1.3 Lignan derivatives from Krameria lappacea 
 
Lignan derivatives rank among the phenolic constituents of the South 
American plant Krameria lappacea (Dombey) Burdet et Simpson. The 
dried roots (syn. rhatany) are traditionally used in folk medicine to treat 
inflammation-related diseases predominantly of the mouth [185-188]. 
As lignans are already known to act as anti-inflammatory agents [189, 
190], eleven lignan derivatives comprising neolignans, norneolignans, and 
3 RESULTS 54 
7,70-epoxy lignans were investigated for their ability to block mPGES-1 
derived PGE2 formation in a cell-free system (Table 3.9). 
 
Table 3.9: Biological evaluation of lignan derivatives on cell-free mPGES-1 product 
formation. Mean values (n = 3) (IC50 [µM] or % remaining activity at 50 µM) 
# structure 
Cell-free 
mPGES-1 
 
O
OH
R1
R2
 
R1                                R2 
 
23a OH OCH3 56.5±3.0 
23b OCH3 OH 42 µM 
 
O
R2
R3 R1
 
R1                  R2                         R3 
 
24a H OH OH 7.4 µM 
24b H OH H 5.3 µM 
24c H OH OCH3 13.5 µM 
24d H OCH3 OH 13 µM 
24e CH3 OH H 11 µM 
25 O
OH
OH
 
77.6±3.1 
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26 O
OH
OH
 
75.7±2.9 
27 
O
OH
OH
 
39.5 µM 
28 
O
OH
 
19.5 µM 
 
The standard reference inhibitor MK-886 blocked PGE2 formation as 
expected (IC50 = 2.1 µM, data not shown). Compound 24a and 24b could 
be identified as potent inhibitors of mPGES-1 with IC50 values of 7.4 and 
5.3 µM, respectively. The 7,7´-epoxy lignans (25, 26) as well as compound 
23a did not show any inhibition up to 50 µM. All other compounds (23b, 
24c-e, 27, 28) moderately inhibited mPGES-1 with IC50 values between 11 
and 42 µM [176]. 
 
3.2 Discovery of novel mPGES-1/5-LO inhibitors by 
pharmacophore model and virtual screening 
 
Pharmacophore model and virtual screening 
 
The pharmacophore model was developed by the group of Prof. Hermann 
Stuppner (Univ. Innsbruck) for acidic mPGES-1 inhibitors and was based 
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on highly potent indole derivatives as mPGES-1 inhibitors with IC50 values 
in the nanomolar range. 
The pharmacophore model M1 consists of four hydrophobic features, one 
aromatic ring, one negatively ionizable feature and a shape restriction to 
limit the size of fitting compounds. 
The second pharmacophore model M2 is a partial query of M1, in which 
the aromatic feature or one of the hydrophobic features is allowed to be 
omitted during the screening. While M1 achieved a more favorable 
enrichment of active compounds in a virtual screening, M2 correctly 
recognized chemically diverse mPGES-1 inhibitors for which M1 was too 
restrictive [191]. 
 
3.2.1 Depsides and depsidones from lichen spec. 
 
The Chinese herbal medicine (CHM) database consists of 10,216 
compounds that are common in the traditional Chinese medicine [192]. 
Therefore, it was used for in silico screening with the pharmacophore 
models M1 and M2. More than 10% of the virtual hits could be identified 
as constituents of lichen spec. A set of ten different depsides and the related 
group of depsidones was composed and a virtual screening with the 
pharmacophore models M1 and M2 was disposed. Physodic acid (29b), 
perlatolic acid (30c), evernic acid (30b) and olivetoric acid (30d) were 
identified as virtual hits, whereas all other compounds in Table 3.10 did 
not map the features of M1 or M2. [177] 
Multifaceted biological activities are known for depsides and depsidones, 
e.g. antioxidant, antibiotic, antiviral, antitumor properties [152]. As 
physodic acid (29b) is known to inhibit PG biosynthesis in rabbit renal 
microsomes [146] the selected depsides and depsidones (Table 3.10) were 
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tested for their ability to interfere with mPGES-1 derived PGE2 formation 
and semi-purified 5-LO product formation. 
 
Table 3.10: biological evaluation of depsides and depsidones on cell-free mPGES-1 and 
semi- purified 5-LO product formation. Mean values (n = 3-4) (IC50 [µM] or % 
remaining activity at 10 µM) 
# structure 
Cell-free 
mPGES-1 
Semi-
purified 
5-LO 
Depsidone (29) 
basic structure 
O
O
O
 
  
fumarproto-cetraric 
acid 
(29a) 
O
O
O
OH
O
OH
OH
O
O
O
O OH
 
74.6±10.7 82.6±9.4 
physodic acid 
(29b) 
O
O
O
OH
OH
OH
O
O
 
0.43 µM 2.4 µM 
3 RESULTS 58 
salazinic acid 
(29c) 
O
O
O
OH
OH
OO OH
O
OH
 
60.8±10.7 85.0±5.1 
variolaric acid 
(29d) 
O
O
O
OH
O
OH O
 
75.5±12.9 96.2±7.3 
scensidin 
(29e) 
O
O
O
O
Cl
Cl
O
 
73.3±9.7 7.3 µM 
Depside (30) 
basic structure O
O
 
  
methylbeta-
orcinolcarboxylate 
(30a) 
O
O
OH
OH
 
89.1±12.5 92.1±8.2 
evernic acid 
(30b) O
O
O
OH
OH
OH
O
 
53.9±2.7 9.9 µM 
perlatolic acid 
(30c) O
O
O
OH
OH
OH
O
 
0.4 µM 0.4 µM 
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olivetoric acid 
(30d) 
O
O
OH
OH
OH
OH
O
O
 
1.15 µM 2.4 µM 
atranorin 
(30e) O
O
OH
OH O
O
OHO
 
87.5±13.2 66.3±4.4 
 
The reference inhibitors MK886 (mPGES-1 inhibitor [56]) and BWA4C 
(5-LO inhibitor [184]) worked as expected. The virtual hits physodic acid 
(29b), evernic acid, perlatolic acid and olivetoric acid (30b-d) from model 
M1 and M2 could be identified as inhibitors of mPGES-1 and 5-LO, in 
which physodic acid (29b), perlatolic acid (30c) and olivetoric acid (30d) 
strongly suppressed mPGES-1 and 5-LO product formation with IC50 
values in the low micromolar range of 0.4 to 2.4 µM. Evernic acid (30b) 
moderately inhibited mPGES-1 and 5-LO product formation with IC50 
values of >10 and 9.9 µM, respectively. Salazinic acid (29c) acts as a weak 
mPGES-1 inhibitor and scensidin (29e) and atranorin (30e) could be 
identified as moderate inhibitors of 5-LO (IC50 = 7.3 µM and >10 µM, 
respectively). All other compounds (fumarproto-cetraric acid (29a), 
variolaric acid (29d) and methylbeta-orcinolcarboxylate (30a)) were 
completely inactive towards mPGES-1 and 5-LO inhibition. 
Interestingly, lipophilic residues seem to be crucial for the strong 
suppression of mPGES-1 and 5-LO derived product formation as the potent 
dual inhibitors 29b, 30c and 30d all possess a long lipophilic alkyl chain at 
position 6 and 6’. 30b, consisting of small alkyl residues at these positions, 
could be identified as a weak dual inhibitor of mPGES-1 and 5-LO. 
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In addition, also a free acidic group seems to be essential as all inactive 
compounds except 29a lack a carboxylic group in position 1’. 
Taken together, (I) an acidic moiety in position 1’ and (II) lipophilic chains 
in position 6 and 6’ seem to be essential for the inhibition potential of 
depsides and depsidones on mPGES-1 and 5-LO product formation. Fitting 
studies with the potent compounds 29b, 30c and 30d into pharmacophore 
model M2 pointed out that two of the hydrophobic features are mapped by 
the lipophilic alkyl chains. Moreover, the data of pharmacophore model 
M1 indicate that the aromatic ring feature is not essential for the inhibition 
potential towards mPGES-1 and 5-LO as 29b and 30d do not map this 
feature and 29b is considered equally potent compared to 30c which maps 
all features of M1 [177]. 
So far, only few natural compounds could be identified as equally potent 
dual inhibitors compared to 29b and 30c. For this reason their molecular 
pharmacology on the eicosanoid biosynthesis will be further investigated 
(see chapter 3.4.3). 
 
3.2.2 Ginkgolic acid from Ginkgo biloba 
 
Another virtual hit of the Chinese herbal medicine (CHM) database using 
the pharmacophore models M1 and M2 was ginkgolic acid from ginkgo 
biloba. As ginkgolic acid has been reported to show antioxidant, radical-
captivating, anti-inflammatory properties [173], it has been tested in a cell-
free model for its ability to block the product formation of microsomal 
preparations of IL-1ß stimulated A549 cells as a source of mPGES-1 as 
well as semi-purified 5-LO product formation (Table 3.11). 
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Table 3.11: biological evaluation of ginkgolic acid (31) on cell-free mPGES-1 and 
semipurified 5-LO product formation. Mean values (n = 3) (IC50 [µM]) 
# structure 
Cell-free 
mPGES-1 
Semi-
purified 
5-LO 
ginkgolic acid 
(31) 
OH
OH
O
 
0.7 µM 0.2 µM 
 
Ginkgolic acid (31) could be identified as a potent dual mPGES-1 and 5-
LO inhibitor with IC50 values of 0.7 and 0.2 µM, respectively, compared to 
the standard reference inhibitors MK886 (mPGES-1 inhibitor IC50= 2.1 
µM) and BWA4C (5-LO inhibitor IC50=0.16 µM). 
Since only few natural compounds are known to potently block the product 
formation of both enzymes (mPGES-1 and 5-LO), the molecular 
pharmacology of ginkgolic acid on the arachidonic acid pathway was 
further analysed (see chapter 3.4.4). 
 
3.3 Synthetic-derivatives of acid-modified NSAIDs as new 
leads of mPGES-1 inhibitors  
 
Modification of the acidic carboxylic group from the anti-inflammatory 
drug licofelone to sulfonamides was recently shown to impair COX activity 
and increase the potency of mPGES-1 inhibition [82]. 
Studies on the classical NSAIDs ibuprofen, ketoprofen, naproxen, 
indomethacin and lonazolac were performed in the same line of action. 
Preparations of IL-1ß stimulated A549 cells were used as source for 
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mPGES-1. Synthesized NSAID derivatives (by Prof. Stefan Laufer, Univ. 
Tuebingen) were tested for their ability to block the formation of PGE2 
using PGH2 as substrate [178]. 
 
Table 3.12: biological evaluation of NSAID derivatives on cell-free mPGES-1 product 
formation. Mean values (n = 3) (IC50 [µM] or % remaining activity at 10 µM) 
(Experiments were partially conducted by Giulia Ambrosi, University of Tuebingen) 
# structure 
Cell-free 
mPGES-1 
 
R
O
 
R 
 
ibuprofen 
(32) 
OH 81.2±2.7 
32a S
O
O
N
H
 
78.6±6.4 
32b SNH
O
O
 
67.9±15.8 
 
R
O
O
 
R 
 
keto-
profen 
(33) 
OH n.i. 
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33a S
O
O
N
H
 
76.3±10.0 
33b SNH
O
O
 
78.6±2.1 
 
R
O
O
 
R 
 
naproxen 
(34) 
OH n.i. 
34a S
O
O
N
H
 
72.8±6.9 
34b SNH
O
O
 
92.5±4.8 
 
N
Cl
O
R1
R2
O
 
R1                                        R2 
 
indo-
methacin 
(35) 
O
 
OH 40.6 µM 
35a O
 
S
O
O
N
H
 
6.4 µM 
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35b O
 
SN
H
O
O
 
73.6±14.5 
35c O
 
S
O
O
C
H2
N
H
 
68.7±3.5 
35d Br S
O
O
N
H
 
1.75 µM 
35e 
 
O
 
86.1±3.1 
35f 
 
OH 2.5 µM 
35g 
 
ClS
O
O
N
H
 
1.8 µM 
35h 
 
S
O
O
N
H
 
2.8 µM 
lonazolac 
(36) 
 
N N
O
Cl
OH
 
45 µM 
 
 
N
N
O R1
R2
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R1                                  R2 
36a S
O
O
N
H
 
Cl 3.4 µM 
36b SNH
O
O
 
Cl 98.0±26.9 
36c NH S
O
O
 
Cl 5.9 µM 
36d ClS
O
O
N
H
 
Cl 2.3 µM 
36e S
O
O
N
H
 
 
1.7 µM 
 N N
R3
O
R1
R2
 
R1                    R2                          R3 
 
36f H H OH 0.4 µM 
36g H Cl OH 0.16 µM 
36h Cl H OH 0.18 µM 
36i H H ClSNH
O
O
 
0.2 µM 
36j H Cl ClSNH
O
O
 
0.35 µM 
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36k Cl H ClSNH
O
O
 
0.8 µM 
 
The mPGES-1 inhibitor MK886 was used a reference [56] and inhibited 
mPGES-1 derived PGE2 formation as expected (data not shown). 
Comparable to the classical NSAIDs ibuprofen (32), ketoprofen (33) and 
naproxen (34) also the corresponding sulfonamides (32a-b, 33a-b, 34a-b) 
did not inhibit mPGES-1 up to 10 µM. 
Introduction of a p-tolylsulfonamide residue to indomethacin (IC50 = 40.6 
µM) resulting in compound 35a highly increased the potency towards 
mPGES-1 (IC50 = 6.4 µM), whereas the methansulfonamide residue (35b) 
was less active, suggesting that a lipophilic residue is required at this 
position. The phenylacetylene-substituted derivatives 35e–h further 
enhanced the efficacy towards mPGES-1 inhibition. Introduction of a 
bromide led to the most potent indomethacin derivative 35d (IC50 = 1.75 
µM). Furthermore, derivatives of lonazolac (36a-k) were prepared and 
tested for their ability to block mPGES-1 derived PGE2 formation. 
Consistent with the results of the indomethacin derivatives (35a-h), 
introduction of phenylsulfonamide residues (36a, 36c-e, 36i-k) increased 
the inhibitory potential of mPGES-1 activity whereas the 
methansulfonamide analogue (36b) decreased the potency of mPGES-1 
inhibition. Replacing the methyl group from toluensulfonamide with 
chlorine (36d, 36i-k) and/or introduction of substituted phenylacetylene 
moieties (36f-k) further enhanced the inhibitory potential towards mPGES-
1 resulting in the most potent lonazolac derivative 36g (IC50 = 0.16 µM), 
that inhibited mPGES-1 with IC50 value in the nanomolar range [178]. 
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3.4 Molecular pharmacology of promising dual mPGES-
1/5-LO inhibitors 
3.4.1 Pharmacological profile of arzanol (1) and its promising 
derivative 1e on eicosanoid biosynthesis 
3.4.1.1 Arzanol (1) and 1e inhibit 5-LO product formation 
 
Arzanol (1) and its derivative 1e potently suppressed the activity of semi-
purified 5-LO in a cell-free assay with IC50 values of 3.1 and 1.2 µM, 
respectively (Fig. 3.8A). In addition, the IC50 value shifted to 5.7 µM when 
5-LO inhibition of 1e was analyzed in crude neutrophil homogenates under 
the same experimental conditions, suggesting that cellular components 
present in the homogenates may hamper 5-LO inhibition. Washout 
experiments demonstrated that this effect was reversible, as incubation of 
5- LO with 10 µM arzanol (1) or 3 µM 1e and a subsequent dilution to 1 or 
0.3 µM (final concentration, respectively) fully abolished 5-LO inhibition 
(Fig. 3.8B). BWA4C was used as reference inhibitor and blocked the 
formation of 5-LO products as expected (not shown). 
A
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Fig. 3.8: Effects of arzanol¶ (1) 
and 1e on isolated 5-LO 
(A) Inhibition of isolated 5-LO. 
Semi purified, human 
recombinant 5-LO or PMNL 
homogenates (5 x 106 
cells/exp.) were pre-incubated 
with 1e, arzanol¶, BWA4C (0.3 
µM) or vehicle (DMSO) in the 
presence of 1 mM ATP for 10 
min. 5-LO product formation 
was initiated by addition of 
2mM Ca2+ and 20 µM AA for 
10 min at 37 °C. Reaction was stopped with methanol on ice and 5-LO products were 
analyzed by RP-HPLC. Data are given as mean + S.E., n = 3, *p < 0.05, **p < 0.01 
and ***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) 
Reversibility of 5-LO inhibition. Semi purified, human recombinant 5-LO was pre-
incubated in the presence of 1 mM ATP for 10 min and an aliquot was diluted 10-fold to 
obtain an inhibitor concentration of 0.3 or 1 µM. 5-LO product formation was initiated 
by addition of 2mM Ca2+ and 20 µM AA for 10 min at 37 °C. Reaction was stopped with 
methanol on ice and 5-LO products were analyzed by RP-HPLC. Data are given as 
mean + S.E., n = 3-6, ***p < 0.001; 3 or 10 µM vs. diluted sample, ANOVA + Tukey 
HSD post-hoc tests. 
 
Many plant-derived 5-LO inhibitors are lipophilic reducing agents that act 
by uncoupling the redox cycle of the active-site iron of 5-LO or by radical 
scavenging activity [193]. Previous studies already revealed antioxidant 
properties of arzanol (1) [129] that could be confirmed for arzanol (1) and 
1e in the DPPH assay. Arzanol (1) and 1e caused a concentration 
dependent reduction of DPPH with similar efficiency as the well 
recognized antioxidants cysteine or ascorbic acid (Fig. 3.9). 
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Fig. 3.9: radical scavenger 
properties of arzanol (1) and 1e. 
Arzanol, 1e, vehicle and 
controls were mixed with DPPH 
solution and incubated for 30 
min in the dark. The absorbance 
was measured at 520 nm. Data 
are given as mean + S.E. n=3. 
 
 
 
 
Next, investigation of arzanol (1) and 1e on 5-LO activity in intact human 
neutrophils was performed. A concentration-dependent inhibition of 5-LO 
product synthesis for both compounds was evident in intact neutrophils 
stimulated with A23187 in the absence (IC50 = 2.4 and 2.6 µM, 
respectively) and presence (IC50 = 2.9 and 0.9 µM, respectively) of 
exogenous AA (20 µM) as well as for neutrophils primed with LPS (1 
µg/ml) and stimulated with fMLP (IC50 = 8.1 and 2.8 µM, respectively, 
Fig. 3.10). The product formation of 12- and 15-LO was not inhibited by 
arzanol (not shown). The 5-LO inhibitor BWA4C (0.3 µM), used as 
reference compound, blocked 5-LO activity in all assays as expected 
(inhibition >90%, not shown). 
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Fig. 3.10: Effects arzanol¶ (1) and 1e on 
5-LO in intact neutrophils. 
Intact neutrophils (5 x 106/ml) were pre-
incubated with arzanol¶, 1e or vehicle 
(DMSO) for 10 min at 37 °C and cells 
were stimulated with 2.5 µM A23187 or 
2.5 µM A23187 plus 20 µM AA. 5-LO 
products were determined by RP-HPLC. 
Alternatively, cells were primed with 
LPS (1 µg/ml) for 30 min and the 
formation of 5-LO products was 
initiated by addition of 1 µM fMLP. 
LTB4 levels were detected using a TXB2 High Sensitivity EIA Kit according to the 
manufacturer's protocol. Data are given as mean + S.E. n=3-7, *p < 0.05, **p< 0.01 
and ***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. 
 
An interference at the level of AA supply, e.g. by inhibition of cPLA2 can 
be excluded, as arzanol (1) and 1e failed to significantly inhibit isolated 
recombinant human cPLA2 up to 10 µM, whereas the pyrrolidine inhibitor 
(5 µM) blocked AA release as expected (Fig. 3.11). 
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Fig. 3.11: arzanol (1) and 1e do 
not inhibit cPLA2. 
Freshly prepared large unilamelar 
vesicles were incubated with 
cPLA2 enzyme, 1 mM Ca2+ and the 
indicated compounds for 1 h at 37 
°C. Reaction was stopped using 
methanol. Following deri-
vatisation with p-anisidinium 
chloride, the resulting derivate 
was analyzed by RP-HPLC. Data 
are given as mean + S.E., n = 3. 
Performed by Marius Melzer in 
the lab of Prof. Dr. O. Werz (University of Jena, Germany). 
 
5-LO activity is tightly regulated in the cell [111], i.e. phosphorylation via 
the ERK-1/2 or p38 MAPK pathway leads to a strong upregulation of 5-LO 
activity. Therefore, 1e was analyzed for its ability to interfere with the 
ERK-1/2 or p38 MAPK pathway. As can be seen in Fig. 3.12, 1e did not 
influence the phosphorylation state compared to the reference inhibitor 
U0126. Thus, an influence on 5-LO regulation by phosphorylation can be 
excluded for 1e. 
Fig. 3.12: Effects on ERK and 
p38 MAPK pathway of 1e. 
Neutrophils (107) were pre-
warmed for 3 min at 37 °C and 
pre-incubated with 1e or 
vehicle (DMSO) at 37 °C for 
15 min. The reaction was 
started by the addition of 0.1 
µM fMLP, stopped after 1.5 
min with SDS-b and heated for 
6 min at 95 °C. Total cell lysates were analyzed for ERK1/2, phosphorylated ERK1/2 
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(Thr-202/Tyr-204) and phosphorylated p38 MAPK (Thr-180/Tyr-182) by SDS/PAGE 
and western blotting. Results are representative of 2-3 independent experiments. 
 
Experiments performed in human whole blood focussing on 5-LO 
inhibition revealed a loss of efficacy for arzanol (1) and 1e. Both failed to 
block 5-LO product formation up to 10 µM (Fig. 3.13) in whole blood 
stimulated with A23187 for 10 min, whereas the standard inhibitor 
BWA4C suppressed 5-LO product formation as expected. 
Fig. 3.13: Effects of arzanol (1) and 1e 
on 5-LO inhibition in human whole 
blood. 
Heparinized whole blood was pre-
incubated with arzanol, 1e or vehicle 
(DMSO) for 15 min at 37 °C and 
stimulated with A23187 (30 µM) for 10 
min. Reaction was stopped on ice and 
5-LO product formation was detected 
using RP-HPLC. Data are given as 
mean + S.E. n=2-3. 
 
 
 
Together, arzanol (1) and its synthetic derivative 1e are direct inhibitors of 
5-LO. Both could be identified as redox active inhibitors with a reversible 
mechanism of action largely independent of the substrate supply. 
Interference with 5-LO regulation can be excluded. 5-LO inhibition in cell-
based assay was comparable to the results from semi-purified 5-LO assay. 
In crude neutrophil homogenates and human whole blood inhibition of 5-
LO product formation seem to be hampered by components present in the 
assays medium. 
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3.4.1.2 Arzanol (1) and 1e block mPGES-1 derived PGE2 
formation 
 
As reported in Table 3.6, arzanol (1) and 1e potently inhibited PGE2 
formation in microsomal preparations of IL-1ß stimulated A549 cells with 
IC50 values of 3.1 and 1.2 µM, respectively. Alteration of PGH2 to lower (1, 
5 µM) or higher (50 µM) concentration caused only slight changes in the 
potency of 1e (Fig. 3.14A), suggesting that mPGES-1 inhibition is largely 
independent of the substrate supply. Alteration to lower PGH2 
concentration (1 µM) shifted IC50 value to 0.25 µM, whereas higher PGH2 
concentration (50 µM) did not change the inhibitory potential of arzanol 
(1), indicating a competitive mode of action. Washout experiments were 
carried out, to investigate whether inhibition of PGE2 synthesis is reversible 
(Fig. 3.14B). A 10-fold dilution of the samples containing 1 µM arzanol (1) 
or 1e restored mPGES-1 activity, implying a reversible mode of inhibition. 
Adding 10% FCS to the sample of 1e reduced the potency (60% remaining 
activity at 10 µM), suggesting that plasma protein binding due to the 
lipophilic acid structure might occur. MK886 was used as standard 
inhibitor and blocked PGE2 formation as expected (not shown). 
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A 
 
B 
Fig. 3.14: Effects of arzanol¶ 
(1) and 1e on mPGES-1 in cell-
free assay. 
(A) Concentration-response 
analysis of arzanol¶ and 1e. 
Microsomal preparations of IL-
1β-stimulated A549 cells were 
pre-incubated with arzanol, 1e 
or vehicle (DMSO) for 15 min 
at 4 °C and PGE2 formation 
was induced by addition of 
variable PGH2 concentrations 
(1, 5, 20 and 50 µM). The amount of PGE2 was quantified for 1 and 5 µM PGH2 by the 
use of a PGE2 High Sensitivity EIA Kit according to the manufacturer's protocol and 
PGE2 formation of samples with or w/o 10% FCS stimulated with 20 and 50 µM PGH2 
was analyzed by RP-HPLC. Data are given as mean + S.E., n=3, *p < 0.05, **p < 0.01 
***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) 
Reversibility of mPGES-1 inhibition. Microsomal preparations were pre-incubated for 
15 min with 1 µM arzanol, 1e or vehicle (DMSO), and an aliquot was diluted 10-fold to 
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obtain an inhibitor concentration of 0.1 µM. Then, 20 µM PGH2 was added and all 
samples were incubated for 1 min on ice, and PGE2 formation was analyzed as 
described by RP-HPLC. Data are given as mean + S.E., n=3, *p < 0.05 or ***p < 
0.001 vs. diluted sample, ANOVA + Tukey HSD post-hoc tests. 
 
In summary, arzanol (1) and 1e potently inhibit mPGES-1 derived PGE2 
formation under cell-free conditions. Both act in a reversible mode of 
action largely independent of the substrate supply. Lower concentrations of 
PGH2 (1 µM) enhanced the inhibitory potential of arzanol (1) by 10-fold 
(IC50= 0.25 µM), indicating a competitive mode of action. 
 
3.4.1.3 Arzanol (1) and 1e interfere with the prostanoid synthesis 
 
As mPGES-1 acts downstream of COX, arzanol (1) and 1e were 
investigated for their ability to interfere with either COX-1 or -2. 
Therefore, arzanol (1) and 1e were analyzed in test system of isolated ovine 
COX-1 and human recombinant COX-2. Indomethacin and celecoxib were 
used as reference inhibitors and blocked 12-HHT formation as expected 
(not shown). No inhibition of isolated COX-1 could be observed for 
arzanol (1) and 1e. In contrast, COX-2 derived 12-HHT formation was 
moderately affected by 1e (IC50 > 10 µM), but not by arzanol (1). 
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Fig. 3.15: Effects of arzanol¶ (1) and 
1e on isolated COX-1 and -2 
Purified ovine COX-1 (50 units) or 
human recombinant COX-2 (20 units) 
were pre-incubated 5 min prior 
stimulation with AA (5 µM or 2 µM, 
respectively). 12-HHT in the samples 
was analyzed using RP-HPLC. Data 
are given as mean + S.E., n=2-3, **p 
< 0.01 vs. vehicle (DMSO) control, 
ANOVA + Tukey HSD post-hoc tests. 
 
 
Using a cell-based test system for COX-1, intact human platelets were pre-
incubated with arzanol (1) or 1e and the formation of 12-HHT and TXB2 
was measured after addition of AA (5 µM). The formation of 12-HHT (IC50 
= 2.3 and 1.6 µM, respectively) and TXB2 (IC50 = 2.9 and 2.2 µM, 
respectively) was concentration-dependently blocked by arzanol (1) and 1e 
(Fig. 3.16). The reference inhibitor indomethacin blocked COX-1 product 
formation as expected (not shown). 
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A                                       B 
 
Fig. 3.16: Effects of arzanol¶ (1) and 1e on human platelets 
Platelets (108/ml PBS containing 1 mM CaCl2) were pre-incubated for 5 min prior to 
stimulation with AA (5 µM). After another 5 min at 37 °C, the formation of (A) 12-HHT 
was determined by RP-HPLC (B) and formation of TXB2 was determined using a TXB2 
High Sensitivity EIA Kit according to the manufacturer's protocol. Data are given as 
mean + S.E., n=3-5, *p < 0.05, **p < 0.01 ***p < 0.001 vs. vehicle (DMSO) control, 
ANOVA + Tukey HSD post-hoc tests. 
 
Because direct inhibition of COX-1 can be excluded, the inhibitory effects 
observed in platelets may be due to thromboxane synthase (TXAS) 
inhibition. To check if TXAS is directly affected by arzanol (1) and 1e, 
freshly prepared platelet homogenates were pre-incubated with the 
compounds and stimulated with PGH2 (20 µM) as substrate of TXAS. 
Both, arzanol (1) and 1e concentration-dependently blocked the formation 
of TXB2 (as a biomarker for TXA2) from PGH2 with IC50 values of 2.7 and 
2.5 µM, respectively, suggesting a direct inhibition of TXAS (Fig. 3.17). 
CV4151, used as selective inhibitor of TXAS suppressed TXB2 formation 
as expected (not shown). 
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Fig. 3.17: Effects of arzanol (1) and 1e on 
TXAS 
Thromboxane A2 synthase (TXAS) activity 
was determined in platelet homogenates 
(108/ml PBS containing 1 mM CaCl2, 
sonified 3 x 15 sec) pre-incubated for 15 
min on ice and stimulated with 20 µM 
PGH2 for 1 min. TXB2 levels were 
detected in the supernatant using a TXB2 
High Sensitivity EIA Kit according to the 
manufacturer's protocol. Data are given 
as mean + S.E., n=3-4, ***p < 0.001 vs. 
vehicle (DMSO) control, ANOVA + Tukey 
HSD post-hoc tests. 
 
In addition, intact human monocytes stimulated with LPS and arzanol (1) 
or 1e for 24 h were used as cell-based system for COX-2. As can be seen in 
Fig. 3.18B/D the reference inhibitor dexamethason completely blocked 
COX-2 and mPGES-1 expression comparable to the unstimulated sample. 
Arzanol (1) and 1e did not affect COX-2 expression. In addition, influence 
on mPGES-1 expression can be excluded for arzanol (1). 1e suppressed 
TXB2 formation comparable to the levels detected in unstimulated 
monocytes. Also PGE2 formation was affected by 1e, suggesting a 
synergistic effect of COX-2 and mPGES-1 inhibition. Arzanol (1) potently 
suppressed the formation PGE2 and TXB2 detected in the supernatant of 
intact human monoycte cultures after 24 h (Fig. 3.18A). Cytotoxic effects 
can be excluded as arzanol (1) suppressed prostanoid formation below the 
levels detected in the unstimulated cells. Therefore, a concentration-
response analysis of arzanol (1) on cellular COX-2-derived PGE2 formation 
in intact human monocytes primed with LPS for 20 h was conducted (Fig. 
3.18C). Arzanol (1) significantly inhibited PGE2 formation already at 3 µM 
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(IC50 = 9 µM). Indomethacin and MD-52, a selective mPGES-1 inhibitor, 
were used as controls. 
A                                          B 
 
 
 
C                                          D 
 
Fig. 3.18: Effects of arzanol¶ (1) and 1e (10 µM) on intact human monocytes and A549 
cells stimulated with LPS. 
(A) PGE2 and TXB2 levels of LPS stimulated monocytes. Intact human monocytes (5 x 
106/exp. in RPMI 1640 medium containing 0.5% FCS, P/S and 2 mM glutamine) were 
stimulated with 1 µg/ml LPS and arzanol, 1e (10 µM), dexamethason (1 µM) or vehicle 
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(DMSO) was added for 24 h at 37 °C. PGE2 and TXB2 levels were detected in the 
supernatant using a PGE2 and TXB2 High Sensitivity EIA Kit according to the 
manufacturer's protocol. Data are given as mean + S.E., n =2-4, *p < 0.05, **p < 0.01 
***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) 
COX-2 expression in LPS stimulated monocytes. Monocytes were stimulated as 
described above. After 24 h cells were detached and lysed (2 x SDS-b.). Samples were 
subjected to SDS-PAGE and WB using a specific antibody against COX-2. ßactin was 
used as loading control. Results are representative of 2-4 independent experiments. (C) 
PGE2 formation as parameter of COX-2 activity. Monocytes were pre-treated with LPS 
(1 µg/ml) for 20 h, cells were washed, and pre incubated with arzanol¶, indomethacin 
(Indo, 10 µM), MD52 (2 µM) or vehicle (veh, DMSO) for 15 min. PGE2 formation was 
initiated by addition of AA (1 µM), and after 30 min, PGE2 in the supernatant was 
analyzed by ELISA. Data are given as mean + S.E., n = 2-4, **p < 0.01 vs. vehicle 
(DMSO) control, ANOVA + Tukey HSD post-hoc tests. (D) Expression of COX-2 and 
mPGES-1. Monocytes (2 x 106 cells/ml, RPMI plus 0.5% FCS) were incubated in the 
presence or absence of 10 µg/ml LPS together with arzanol, dexamethasone (1 µM) or 
vehicle (DMSO) for 20 h at 37 °C. Cells were harvested, lysed by addition of 
SDS/PAGE sample loading buffer and proteins were separated by SDS–PAGE and 
analyzed for COX-2 (upper panel) and mPGES-1 (lower panel) by WB. Ponceau S 
staining confirms equal loading of protein and transfer of proteins to the membrane. 
Data are given as mean + S.E., n=3–4. 
 
Cytotoxic effects of arzanol (1) and 1e were analyzed in the MTT assay 
using HL60 or A549 cells for 24 h or 48 h. At 50 µM arzanol (1) 
significantly impaired cell viability within 24 h. Therefore, higher 
concentrations of more than 30 µM were not investigated in a cell-based 
assay. 1e slightly affected cell viability at 48 h but not 24 h (Fig. 3.19), 
implying that no unspecific cellular effects modulate prostanoid formation 
in cell-based assays up to 24 h. Staurosporin, used as positive control, 
significantly affected cell-viability as expected. 
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Fig. 3.19: cytotoxic 
properties of arzanol 
(1) and 1e. 
A549 or HL60 cells 
(3 x 105/exp.) were 
incubated for 24 h 
and 48 h at 37 °C 
with arzanol, 1e or 
vehicle (DMSO). 
After 24 h or 48 h, 
MTT was added and 
samples were 
incubated for 4 h at 
37 °C. Reaction was 
stopped and the absorption was measured at 570 nm. Data are given as mean + S.E. 
n=3. MTT in HL60 cells was performed by Dagmar Blaesius in the lab of Prof. Dr. O. 
Werz (University of Tübingen, Germany). 
 
Along these lines, arzanol (1) concentration-dependently inhibited PGE2 
formation in human whole blood primed with LPS for 5 h (Fig. 3.20). In 
parallel, the accompanied COX-2-mediated biosynthesis of TXB2 and 6-
ketoPGF1a were hardly affected by arzanol (1). 1e, in contrast, did not 
inhibit the formation of PGE2, TXB2 and 6-ketoPGF1a in human whole 
blood experiments primed with LPS for 24 h (not shown). The selective 
mPGES-1 inhibitor MD52 showed a comparable inhibitory profile as 
arzanol (1) by reducing PGE2 synthesis in LPS-treated whole blood for 5 h 
and hardly affected 6-ketoPGF1a in the respective assays. In contrast, 
indomethacin blocked the formation of the analyzed prostanoids in all 
assays as expected. 
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Fig. 3.20: Effects of 
arzanol¶ (1) on 
prostanoid formation 
in human whole blood.  
PGE2. Heparinized 
human blood, treated 
with 1 µM 
thromboxane synthase 
inhibitor and 50 µM 
aspirin, was pre-
incubated with 
arzanol, indomethacin 
(Indo, 50 µM), MD52 
(6 µM) or vehicle (DMSO) for 5 min at RT, and then, PGE2 formation was induced by 
addition of 10 µg/ml LPS. After 5 h at 37 °C, PGE2 was extracted from plasma and 
analyzed as described. TXB2 Heparinized blood was pre-incubated with arzanol, 
indomethacin (Indo, 50 µM) or vehicle (DMSO) for 5 min, then 10 µg/ml LPS were 
added and TXB2 was analyzed after 5 h at 37 °C in the plasma by ELISA. 6-keto PGF1a 
Heparinized human blood, treated with 1 µM thromboxane synthase inhibitor, was pre-
incubated with arzanol, indomethacin (Indo, 50 µM), MD52 (6 µM) or vehicle (DMSO) 
for 5 min at RT, prior to addition of 10 µg/ml LPS. After 5 h at 37 °C, 6-keto PGF1a 
was directly analyzed in plasma by ELISA. Data are given as mean ± S.E., n=3, **p < 
0.01 or ***p < 0.001 vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD post hoc 
tests. 
 
Taken together, arzanol (1) and 1e inhibit TXAS derived TXB2 formation 
in human platelets. No inhibition of COX enzymes for arzanol (1) and only 
moderate COX-2 inhibition (IC50 > 10 µM) by 1e was observed. 
Interference at the level of COX-2 and mPGES-1 expression can be 
excluded. For arzanol (1) effects on PGE2 biosynthesis were also evident in 
human whole blood stimulated with LPS for 5 h. 1e did not markedly 
inhibit prostanoid biosynthesis in human whole blood. Cytotoxic effects on 
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intact cells up to 30 µM can be excluded for both compounds, since cell-
viability was not affected within 24 h. 
 
3.4.1.4 Arzanol (1) suppresses carrageenan-induced pleurisy in 
rats and inhibits eicosanoid biosynthesis in vivo 
 
The anti-inflammatory effectiveness of arzanol (1) was also assessed in 
vivo using a model of carrageenan-induced pleurisy in rats. Injection of 
carrageenan into the pleural cavity of rats (DMSO 4% group) elicited an 
inflammatory response within 4 h, characterized by the accumulation of 
fluid that contained large numbers of inflammatory cells (Table 3.13). 
Arzanol (1) inhibited the inflammatory response as demonstrated by the 
significant attenuation of exudate formation (59%) and cell infiltration 
(48%). Indomethacin (5 mg/kg) reduced the exudate formation and cell 
infiltration by 75% and 65%, respectively (Table 3.13). In comparison with 
the corresponding exudates from DMSO treated rats, exudates of arzanol-
treated animals exhibited decreased PGE2 levels (47% inhibition), whereas 
indomethacin almost completely suppressed PGE2 (95%) as well as 6-
ketoPGF1a (94%) levels as expected. In agreement with the moderate 
inhibition of COX-2-derived 6-keto PGF1a formation in human whole 
blood (see above), arzanol (1) also slightly reduced the levels of 6-
ketoPGF1a (27% inhibition). On the other hand, indomethacin failed to 
significantly reduce LTB4 levels which were lowered by arzanol (1) (31% 
inhibition), seemingly due to direct inhibition of 5-LO. 
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Table 3.13: Effect of arzanol (1) on carrageenan-induced pleurisy in rats. 
Thirty min before intrapleural injection of carrageenan, rats (n = 10 for each 
experimental group) were treated i.p. with 3.6 mg/kg arzanol, 5 mg/kg indomethacin or 
vehicle (DMSO 4%). Exudate volume, eicosanoids and inflammatory cell accumulation 
in the pleural cavity were assessed 4 h after carrageenan injection. Data are expressed 
as mean ± SEM. n=10, * p<0.05. *** p<0.01 vs. vehicle. Experiments were performed 
by Dr. Rossi and Prof. Sautebin, Univ. Naples, Italy. 
Treatment 
Volume 
exudate [ml] 
Inflammatory 
cells x 106 
PGE2 
(ng/rat) 
LTB4 
(ng/rat) 
6-
ketoPGF1a 
(ng/rat) 
Vehicle 0.41±0.019 46.5±6.0 4.26±0.67 1.22±0.26 10.72±1.43 
arzanol 
(3.6 
mg/kg) 
0.17±0.05 
*** 
(59%) 
24.0±5.9 
* 
(48%) 
2.27±0.35 
* 
(47%) 
0.84±0.21 
(31%) 
7.79±0.72 
(27%) 
Indo-
methacin 
(5 mg/kg) 
0.10±0.03 
*** 
(76%) 
16.28±2.30 
*** 
(65%) 
0.21±0.024 
*** 
(95%) 
1.06±0.20 
(13%) 
0.64±0.09 
*** 
(94%) 
 
3.4.2 Pharmacological profile of CFA (19) within the AA-cascade 
3.4.2.1 CFA (19) interferes with the prostaglandin biosynthetic 
pathway 
 
CFA (19) was identified to potently inhibit the formation of PGE2 (IC50= 
1.8 µM) in microsomal preparations of IL-1ß stimulated A549 cells as 
source of mPGES-1. Variation of the substrate (PGH2) concentration for 
mPGES-1 did not markedly alter the potency of CFA (19) (IC50 = 1.8 - 3.7 
µM; Fig. 3.21A). The reference inhibitor MK886 blocked PGE2 formation 
as expected (data not shown). Wash out experiments demonstrate that the 
inhibitory effect on mPGES-1 is fully reversible (Fig. 3.21B). To check for 
plasma protein binding, 10% FCS was added to the sample. The inhibitory 
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potential shifted from 9.9% remaining activity at 10 µM to 61.6% 
remaining activity (Fig. 3.21A), indicating that CFA (19) binds to plasma 
proteins. 
A                                                  B 
 
Fig. 3.21: Effects of CFA (19) on mPGES-1 in cell-free assays. 
(A) Concentration-response analysis. Microsomal preparations of IL-1β-stimulated 
A549 cells were pre-incubated with CFA or vehicle (DMSO) for 15 min at 4 °C and 
PGE2 formation was induced by addition of variable PGH2 concentrations (1, 5, 20 and 
50 µM). The amount of PGE2 was quantified for 1 and 5 µM PGH2 by the use of a PGE2 
High Sensitivity EIA Kit according to the manufacturer's protocol and PGE2 formation 
of samples with or w/o 10% FCS stimulated with 20 and 50 µM PGH2 was analyzed by 
RP-HPLC. Data are given as mean + S.E., n = 3, *p < 0.05, **p < 0.01 ***p < 0.001 
vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) Reversibility of 
mPGES-1 inhibition. Microsomal preparations were pre-incubated for 15 min with 3 
µM CFA or vehicle (DMSO), and an aliquot was diluted 10-fold to obtain an inhibitor 
concentration of 0.3 µM. Then, 20 µM PGH2 was added and all samples were incubated 
for 1 min on ice, and PGE2 formation was analyzed as described by RP-HPLC. Data 
are given as mean + S.E., n = 3, *p < 0.05 vs. vehicle (DMSO) control, ANOVA + 
Tukey HSD post-hoc tests. 
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For the biosynthesis of PGE2 in the cell, AA must first be released by 
cPLA2 which is further converted by COX-2 to PGH2 that serves as 
substrate for mPGES-1 to form PGE2. Interference in the PGE2 
biosynthesis at the level of AA supply can be excluded as CFA (19) barely 
inhibited the activity of human recombinant cPLA2 at 10 µM (Fig. 3.22), 
whereas the cPLA2 control inhibitor pyrrolidine-1 (1 µM) effectively 
blocked AA release from phospholipids as expected. 
Fig. 3.22: CFA (19) barely inhibits 
cPLA2. 
Freshly prepared large unilamelar 
vesicles were incubated with cPLA2 
enzyme, 1 mM Ca2+ and the 
indicated compounds for 1 h at 37 
°C. Reaction was stopped using 
methanol. Following derivatisation 
with p-anisidinium chloride, the 
resulting derivate was analyzed by 
RP-HPLC. Data are given as mean + 
S.E., n = 3, *p < 0.05, ***p < 0.001 
vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. Performed by Marius 
Melzer in the lab of Prof. Dr. O. Werz (University of Jena, Germany). 
 
A potent suppressive effect of CFA (19) on PGE2 biosynthesis in intact 
human rheumatoid synovial cells was already demonstrated [140] but no 
concrete point of attack could be identified. Potent suppression of PGE2 
biosynthesis could be confirmed in intact cells using LPS-stimulated 
human monocytes, where PGE2 is essentially formed via the COX-
2/mPGES-1 pathway (Fig. 3.23A) [100]. TXB2 levels were completely 
blocked by CFA (19). Western blot experiments disclose that suppression 
of PGE2 biosynthesis is also provoked by reduced levels of COX-2 (Fig. 
3.23B), because CFA (19) blocked expression of COX-2 comparable to the 
control dexamethason. 
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A                                     B 
 
 
 
Fig. 3.23: Effects of CFA (19) (10 µM) on intact human monocytes stimulated with LPS. 
(A) PGE2 and TXB2 levels of LPS stimulated monocytes. Intact human monocytes (5 x 
106/exp. in RPMI 1640 medium containing 0.5% FCS, P/S and 2 mM glutamine) were 
stimulated with 1 µg/ml LPS and CFA (10 µM), dexamethasone (1 µM) or vehicle 
(DMSO) was added for 24 h at 37 °C. PGE2 and TXB2 levels were detected in the 
supernatant using a PGE2 and TXB2 High Sensitivity EIA Kit according to the 
manufacturer's protocol. Data are given as mean + S.E., n=2-4, *p < 0.05, **p < 0.01 
***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) 
COX-2 expression in LPS stimulated monocytes. Monocytes were stimulated as 
described above. After 24 h cells were detached and lysed (2 x SDS-b.). Samples were 
subjected to SDS-PAGE and WB using a specific antibody against COX-2. ßactin was 
used as loading control. Results are representative of 2-4 independent experiments. 
 
Experiments in intact human platelets, which solely express COX-1, reveal 
a moderate inhibition of 12-HHT (IC50 > 10 µM) and TXB2 (IC50= 6.8 µM) 
formation (Fig. 3.24A). The reference inhibitor indomethacin (10 µM) 
blocked the formation of 12-HHT and TXB2 as expected (data not shown). 
12-HHT (used as biomarker for COX activity) was hardly affected by CFA 
(19) with 30% inhibition at 10 µM (IC50 > 10 µM). Because CFA (19) 
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blocked TXB2 levels in intact human platelets as well as in human 
monocytes, platelet homogenates were stimulated with PGH2 to form TXB2 
via the thromboxane A2 synthase (TXAS). CFA (19) selectively blocked 
TXB2 formation in intact platelets stimulated with AA (IC50= 6.8 µM) and 
platelet homogenates stimulated with PGH2 (IC50= 2.3 µM), indicating 
TXAS as a direct target of CFA (19) (Fig. 3.24A). As 12-HHT in intact 
platelets was hardly affected, effects of CFA (19) on isolated COX 
enzymes were investigated, using ovine COX-1 and human recombinant 
COX-2. As shown in Fig. 3.24B, the activity of both enzymes is only 
moderately affected by CFA (19) comparable to the results in intact 
platelets with IC50 values > 10 µM, while the reference inhibitors 
indomethacin (10 µM) and celecoxib (5 µM) inhibited the enzyme 
activities efficiently (not shown). 
A                                           B 
 
Fig. 3.24: Effects of CFA (19) on human platelets and isolated COX-1 and -2 
(A) Effects in human platelets. Platelets (108/ml PBS containing 1 mM CaCl2) were pre-
incubated for 5 min prior to stimulation with AA (5 µM). After another 5 min at 37 °C, 
the formation of 12-HHT was determined by RP-HPLC as described and formation of 
TXB2 was determined using a TXB2 High Sensitivity EIA Kit according to the 
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manufacturer's protocol. TXAS activity was determined in platelet homogenates (108/ml 
PBS containing 1 mM CaCl2, sonified 3 x 15 sec) pre-incubated for 15 min on ice and 
stimulated with 20 µM PGH2 for 1 min. TXB2 levels were detected in the supernatant 
using a TXB2 High Sensitivity EIA Kit according to the manufacturer's protocol. Data 
are given as mean + S.E., n = 2-4, *p < 0.05, **p < 0.01 ***p < 0.001 vs. vehicle 
(DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) Isolated COX-1 and -2 
inhibition. Purified ovine COX-1 (50 units) or human recombinant COX-2 (20 units) 
were pre-incubated 5 min prior stimulation with AA (5 µM or 2 µM, respectively). 12-
HHT in the samples was analyzed using RP-HPLC. Data are given as mean + S.E., n = 
2-3, *p < 0.05 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. 
 
In studies using human whole blood CFA (19) failed to efficiently block 
the formation of the prostanoids 6-ketoPGF1a (the stable metabolite of 
PGI2) and TXB2. Indomethacin (50 µM), which was used as reference 
inhibitor of prostanoid biosynthesis blocked the formation of TXB2 and 6-
ketoPGF1a as expected (Fig. 3.25). Heparinized human whole blood was 
incubated with LPS (10 µg/ml) to induce COX-2/mPGES-1 expression and 
CFA (19), indomethacin (50 µM) or vehicle (DMSO) for 24h. After 24h 
reaction was stopped on ice and the formation of 6-ketoPGF1a was 
detected. For detection of TXB2, as a source of the COX-1/TXAS pathway, 
citrated human whole blood was pre-incubated with CFA (19), 
indomethacin (50 µM) or vehicle (DMSO) for 15 min and reaction was 
initiated using thrombin 2 U/ml. 
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Fig. 3.25: Effects of 
CFA (19) in whole blood 
experiments 
6-ketoPGF1a detection 
in human whole blood. 
Heparinized human 
whole blood was 
incubated with LPS (10 
µg/ml) and CFA, 
indomethacin (50 µM) 
or vehicle (DMSO) for 
24 h at 37 °C. After 24 h 
the reaction was 
stopped on ice and the formation of 6-ketoPGF1a was detected in the supernatant using 
a 6-ketoPGF1a High Sensitivity EIA Kit according to the manufacturer's protocol. TXB2 
detection in human whole blood. Citrated human whole blood was pre-incubated with 
CFA, indomethacin (50 µM) or vehicle (DMSO) for 15 min at 37 °C and the reaction 
was initiated with thrombin 2 U/ml. After 10 min the reaction was stopped on ice and 
TXB2 levels were detected in the supernatant using a TXB2 High Sensitivity EIA Kit 
according to the manufacturer's protocol. Data are given as mean + S.E, n=3. 
 
Together, these findings propose mPGES-1 and TXAS as direct and potent 
molecular targets of CFA (19). 12-HHT formation in intact platelets and 
isolated COX enzymes was hardly affected (IC50 > 10 µM). But plasma 
protein binding might impair effects in cell-based assay and human whole 
blood. 
 
3.4.2.2 CFA (19) inhibits the 5-LO pathway 
 
A concentration-response analysis of CFA (19) on 5-LO activity in cell-
free assays is shown in Fig. 3.26A. CFA (19) was more efficient for semi-
purified 5-LO (IC50 = 0.9 µM) as compared to 5-LO inhibition in crude 
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neutrophil homogenates (IC50 = 5.4 µM) under the same experimental 
conditions, suggesting that cellular components present in the homogenates 
may hamper 5-LO inhibition. The 5-LO inhibitor BWA4C (0.3 µM) 
blocked 5-LO activity as expected (data not shown). Note, that inhibition of 
semi-purified 5-LO was only partially reversible, as demonstrated by wash-
out experiments (Fig. 3.26B). 
A                                              B 
 
Fig. 3.26: effects of CFA (19) on isolated 5-LO 
(A) Inhibition of isolated 5-LO. Semi purified, human recombinant 5-LO or neutrophil 
homogenates (5 x 106 cells/exp.) were pre-incubated with CFA, BWA4C (0.3 µM) or 
vehicle (DMSO) in the presence of 1 mM ATP for 10 min. 5-LO product formation was 
initiated by addition of 2 mM Ca2+ and 20 µM AA for 10 min at 37 °C. Reaction was 
stopped with methanol on ice and 5-LO products were analyzed by RP-HPLC. Data are 
given as mean + S.E., n = 2-3, **p < 0.01 and ***p < 0.001 vs. vehicle (DMSO) 
control, ANOVA + Tukey HSD post-hoc tests. (B) Reversibility of 5-LO inhibition. Semi 
purified, human recombinant 5-LO was pre-incubated in the presence of 2 mM Ca2+ 
and 1 mM ATP for 10 min and an aliquot was diluted 10-fold to obtain an inhibitor 
concentration of 1 µM. 5-LO product formation was initiated by addition of 20 µM AA 
for 10 min at 37 °C. Reaction was stopped with methanol on ice and 5-LO products 
3 RESULTS 92 
were analyzed by RP-HPLC. Data are given as mean + S.E., n =2, **p < 0.01; 10 µM 
vs. diluted sample, ANOVA + Tukey HSD post-hoc tests. 
 
The effects of CFA (19) on 5-LO inhibition in intact neutrophils stimulated 
with A23187 was studied in the absence and presence of exogenous AA as 
substrate for 5-LO product biosynthesis. CFA (19) suppressed 5-LO 
product synthesis equally well, regardless of AA, with IC50 values of 1.6 
µM (A23187 plus AA) and 2.4 µM (A23187) (Fig. 3.27). This implies that 
(I) inhibition of 5-LO product synthesis is not related to block of substrate 
supply, and (II) high AA concentrations do not impede interference of CFA 
(19) with 5-LO. The reference inhibitor BWA4C suppressed 5-LO product 
formation as expected (data not shown). CFA (19) failed to suppress 5-LO 
product formation in intact PMNL stimulated with LPS/fMLP (Fig. 3.27). 
Fig. 3.27: Effects of CFA (19) on 5-
LO in intact PMNL. 
Isolated PMNL (5 x 106/ml) were 
pre-incubated with CFA or vehicle 
(DMSO) for 10 min at 37 °C and 
cells were stimulated with 2.5 µM 
A23187 or with 2.5 µM A23187 plus 
20 µM AA. 5-LO products were 
determined by RP-HPLC. 
Alternatively, cells were primed LPS 
(1 µg/ml) for 30 min and formation 
of 5-LO products was initiated by 
addition of 1 µM fMLP. LTB4 levels 
were detected using a TXB2 High Sensitivity EIA Kit according to the manufacturer's 
protocol. Data are given as mean + S.E. n=3, **p < 0.01 and ***p < 0.001 vs. vehicle 
(DMSO) control, ANOVA + Tukey HSD post-hoc tests. 
 
Studies of 5-LO inhibition in whole blood reveal that CFA (19) failed to 
block 5-LO product formation, maybe due to plasma protein binding, i.e. 
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albumin, present in the whole blood samples (Fig. 3.28). Heparinized 
whole blood was therefore pre-incubated and stimulated with A23187 for 
10 min. 5-LO product formation was detected in the supernatant. 
Fig. 3.28: Effects of CFA (19) on 
5-LO inhibition in human whole 
blood. 
Heparinized whole blood was 
pre-incubated with CFA or 
vehicle (DMSO) for 15 min at 37 
°C and stimulated with A23187 
(30 µM) for 10 min. Reaction was 
stopped on ice and 5-LO product 
formation was detected using RP-
HPLC. Data are given as mean + 
S.E. n=2-3. 
 
Mechanistic studies on 5-LO inhibition were performed to investigate the 
mechanism of action of CFA (19) on 5-LO. As 5-LO inhibitors often 
possess radical scavenger or antioxidant activities thereby uncoupling the 
redox cycle of the active site iron in 5-LO, CFA (19) was analyzed for its 
ability to reduce the stable DPPH radical. As shown in Fig. 3.29A, the 
antioxidants ascorbic acid and cysteine (used as positive controls) reduced 
the DPPH radical whereas CFA (19) failed in this respect, excluding 
radical scavenging features of CFA (19). Phosphorylation leads to strong 
upregulation of 5-LO and therefore CFA (19) was analyzed for its ability to 
interfere with ERK-1/2 and p38 MAPK phosphorylation. As can be seen in 
Fig. 3.29B, CFA (19) did not interfere with the ERK-1/2 or p38 MAPK 
signaling cascade, as it did not interrupt phosphorylation of ERK-1/2 and 
p38 MAPK. The reference inhibitor U0126 blocked phosphorylation of 
ERK-1/2 as expected. 
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A                                             B 
 
 
 
 
 
Fig. 3.29: radical scavenger properties and effects on ERK or p38 MAPK pathway of 
CFA (19). (A) Radical scavenger capability. CFA, vehicle and controls were mixed with 
DPPH solution and incubated for 30 min in the dark. The absorbance was measured at 
520 nm. Data are given as mean + S.E. n=3, ***p < 0.001 vs. vehicle, ANOVA + Tukey 
HSD post-hoc tests. (B) Neutrophils (107) were pre-warmed for 3 min at 37 °C and pre-
incubated with CFA or vehicle (DMSO) at 37 °C for 15 min. The reaction was started by 
the addition of 0.1 µM fMLP, stopped after 1.5 min with SDS-b and heated for 6 min at 
95 °C. Total cell lysates were analyzed for ERK1/2, phosphorylated ERK1/2 (Thr-
202/Tyr-204) and phosphorylated p38 MAPK (Thr-180/Tyr-182) by SDS/PAGE and 
Western blotting. Results are representative of 2-3 independent experiments. 
 
Finally, it was assessed if CFA (19) may affect cell viability using human 
lung carcinoma A549 cells that were treated with 10 µM CFA (19) for 24 h 
and 48 h. Analysis by MTT assay revealed no cytotoxicity or detrimental 
effects on cell viability (Fig. 3.30) excluding unspecific influences in the 
cell-based assay. Similarly, neutrophils treated with 10 µM CFA (19) for 1 
h still excluded the dye trypan blue, analyzed by light microscopy, 
implying cellular integrity (not shown). 
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Fig. 3.30: cytotoxic properties of 
CFA (19). 
Cells (3 x 105) were incubated for 
24 h and 48 h at 37 °C with CFA or 
vehicle (DMSO). After 24 h or 48 h, 
MTT was added and samples were 
incubated for 4 h at 37 °C. 
Reaction was stopped and the 
absorption was measured at 570 
nm. Results are reported as 
percentage of viable cells as 
compared to vehicle control. Data 
are given as mean + S.E. n=3. 
Performed by Dr. Anja Schaible in 
the lab of Prof. Dr. O. Werz 
(University of Jena, Germany). 
 
In summary, these findings indicate 5-LO as a direct target of CFA (19). 
The mechanism of action is apparently independent of redox actions, non 
competitive and only partially reversible. Inhibition of 5-LO in the cell-
based assay was comparable to the effects observed under cell-free 
conditions. Studies in neutrophil homogenates and human whole blood 
indicate high protein binding of CFA (19), due to a reduced inhibitory 
potential. 
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3.4.3 Pharmacological profile of on eicosanoid biosynthesis pathway 
 
3.4.3.1 Studies on the mode of action of perlatolic acid (30c) and 
physodic acid (29b) on mPGES-1 
 
Perlatolic (30c) and physodic acid (29b) are potent inhibitors of mPGES-1 
derived PGE2 formation in microsomal preparations of IL-1ß stimulated 
A549 cells (IC50= 0.4 and 0.43 µM, respectively). First it was investigated 
if alteration of the concentration of the substrate PGH2 of mPGES-1 may 
change the potency of perlatolic (30c) and physodic acid (29b). As shown 
in Fig. 3.31A, inhibition of mPGES-1 derived PGE2 formation by perlatolic 
acid (30c) and physodic acid (29b) at 1, 5, 20 and 50 µM PGH2 led to 
similar concentration-response curves with largely consistent IC50 values in 
the range of 0.43 – 1.8 µM for perlatolic acid (30c) and 0.4 – 1.6 µM for 
physodic acid (29b). Addition of 10% FCS to the samples abolished the 
effect, suggesting a strong plasma protein-binding for both compounds. 
Washout experiments imply a reversible mode of action, as both 
compounds fail to efficiently block mPGES-1 derived PGE2 formation after 
10-fold dilution of the samples at 1 µM inhibitor (Fig. 3.31B). The 
reference inhibitor MK-886 (used as positive control) blocked mPGES-1 
derived PGE2 formation in all assays as expected (not shown). 
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Fig. 3.31: Effects of perlatolic 
acid (30c) and physodic acid 
(29b) on mPGES-1. 
(A) Concentration-response 
analysis. Microsomal 
preparations of IL-1β-
stimulated A549 cells were pre-
incubated for 15 min at 4 °C 
and PGE2 formation was 
induced by addition of variable 
PGH2 concentrations (1, 5, 20 
and 50 µM). The amount of 
PGE2 was quantified for 1 and 
5 µM PGH2 by the use of a PGE2 High Sensitivity EIA Kit according to the 
manufacturer's protocol and PGE2 formation of samples with or w/o 10% FCS 
stimulated with 20 and 50 µM PGH2 was analyzed by RP-HPLC. Data are given as 
mean + S.E., n=2-3, *p < 0.05, **p < 0.01 ***p < 0.001 vs. vehicle (DMSO) control, 
ANOVA + Tukey HSD post-hoc tests (B) Reversibility of mPGES-1 inhibition. 
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Microsomal preparations were pre-incubated for 15 min with 1 µM perlatolic acid, 
physodic acid or vehicle (DMSO), and an aliquot was diluted 10-fold to obtain an 
inhibitor concentration of 0.1 µM. Then, 20 µM PGH2 was added and all samples were 
incubated for 1 min on ice, and PGE2 formation was analyzed as described by RP-
HPLC. Data are given as mean + S.E., n=2-3, **p < 0.01 1 µM vs. diluted sample, 
ANOVA + Tukey HSD post-hoc tests. 
 
3.4.3.2 Perlatolic acid (30c) and physodic acid (29b) affect 
prostanoid biosynthesis 
 
To exclude interference of perlatolic acid (30c) or physodic acid (29b) at 
the level of AA supply, the effects on the enzymatic activity of human 
recombinant cPLA2 were studied. The cPLA2 control inhibitor pyrrolidine-
1 (1 µM) effectively blocked AA release from phospholipids in a cell-free 
assay, whereas perlatolic (30c) and physodic acid (29b) did not influence 
AA release up to 10 µM (Fig. 3.32). 
Fig. 3.32: effects of perlatolic acid 
(30c) and physodic acid (29b) on 
cPLA2 activity. 
Freshly prepared large unilamelar 
vesicles were incubated with 
cPLA2 enzyme, 1 mM Ca2+ and the 
indicated compounds for 1 h at 37 
°C. Reaction was stopped using 
methanol. Following derivatisation 
with p-anisidinium chloride, the 
resulting derivate was analyzed by 
RP-HPLC. Data are given as mean 
+ S.E., n=3, ***p < 0.001 vs. 
vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. Performed by Marius 
Melzer in the lab of Prof. Dr. O. Werz (University of Jena, Germany). 
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Studies on the activity of isolated COX enzymes revealed that perlatolic 
acid (30c) only marginally inhibited isolated ovine COX-1 (IC50 > 10 µM) 
and did not affect COX-2 activity. In contrast, physodic acid (29b) did not 
interfere with the COX-1 or COX-2 derived 12-HHT formation up to 10 
µM (Fig. 3.33). Indomethacin (10 µM) and the selective COX-2 inhibitor 
celecoxib (5 µM) clearly blocked the activities of COX-1 and -2 as 
expected (data not shown). 
 
Fig. 3.33: effects of perlatolic acid 
(30c) and physodic acid (29b) on 
isolated COX enzymes. 
Purified ovine COX-1 (50 units) or 
human recombinant COX-2 (20 units) 
were pre-incubated 5 min prior 
stimulation with AA (5 µM or 2 µM, 
respectively). 12-HHT in the samples 
was analyzed using RP-HPLC. Data 
are given as mean + S.E., n = 3, ***p 
< 0.001 vs. vehicle (DMSO) control, 
ANOVA + Tukey HSD post-hoc tests. 
 
 
Next, the cell-based effects of perlatolic (30c) and physodic acid (29b) on 
the prostanoid synthesis were investigated. In line with previous findings 
by Bruno et al. [100], exposure of primary human monocytes to LPS for 24 
h caused elevated expression of COX-2 and mPGES-1, accompanied by a 
three-fold increased release of PGE2 but also by a two-fold increased 
release of TXB2 (Fig. 3.34). Perlatolic acid (30c) (10 µM) completely 
blocked expression of COX-2, repressed PGE2 biosynthesis to a minor 
extent and strongly blocked the formation of TXB2. In contrast, physodic 
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acid (29b) showed only slight effects on COX-2 expression and 
unexpectedly rather increased PGE2 formation but abolished TXB2 release. 
A                                              B 
 
 
 
Fig. 3.34: Effects of perlatolic (30c) and physodic acid (29b) on intact human 
monocytes stimulated with LPS. 
(A) PGE2 and TXB2 levels of LPS stimulated monocytes. Intact human monocytes (5 x 
106/exp. in RPMI 1640 medium containing 0.5% FCS, P/S and 2 mM glutamine) were 
stimulated with 1 µg/ml LPS and perlatolic acid and physodic acid (10 µM), 
dexathemason (dex 1 µM) or vehicle (DMSO) was added for 24 h at 37 °C. PGE2 and 
TXB2 levels were detected in the supernatant using a PGE2 and TXB2 High Sensitivity 
EIA Kit according to the manufacturer's protocol. Data are given as mean + S.E., n = 
2-4, *p < 0.05 ***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-
hoc tests. (B) COX-2 expression in LPS stimulated monocytes. Monocytes were 
stimulated as described above. After 24 h cells were detached and lysed (2 x SDS-b.). 
Samples were subjected to SDS-PAGE and WB using a specific antibody against COX-
2. ßactin was used as loading control. Results are representative of 2-4 independent 
experiments. 
 
Perlatolic acid (30c) and physodic acid (29b) did not or hardly inhibit 
COX-1/ -2 activity, but instead strongly blocked TXB2 in intact human 
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monocytes. Therefore, perlatolic (30c) and physodic acid (29b) were 
analyzed in human washed platelets, stimulated with exogenous AA, as a 
source of 12-HHT and TXB2 formed via the COX-1/TXAS pathway. 
Perlatolic acid (30c) potently inhibited the formation of 12-HHT and TXB2 
with IC50 values of 0.6 and 0.5 µM, respectively. Also physodic acid (29b) 
caused inhibition of 12-HHT and TXB2 biosynthesis even though with 
lower potency (IC50= 8.8 and 5.2 µM, respectively) as compared to 
perlatolic acid (30c) and the reference inhibitor indomethacin (20 µM) 
(Fig. 3.35A). To investigate whether perlatolic (30c) and physodic acid 
(29b) may act on TXAS, platelet homogenates were stimulated with 20 µM 
PGH2 and substantial amounts of TXB2 were detected in the supernatant. 
As reference inhibitor the selective TXAS inhibitor CV4151 (1 µM) was 
used, that blocked TXB2 formation as expected. Pre-incubation of the 
platelet homogenates with perlatolic (30c) or physodic acid (29b) 
concentration-dependently blocked TXB2 synthesis with IC50 values of 1.1 
and 0.7 µM, respectively Fig. 3.35B. 
A 
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Fig. 3.35: Effects of perlatolic 
acid (30c) and physodic acid 
(29b) on human platelets and 
the activity of TXAS in a cell-
free assay. 
(A) TXB2 and 12-HHT 
formation in human platelets. 
Platelets (108/ml PBS 
containing 1 mM CaCl2) were 
pre-incubated for 5 min prior 
to stimulation with 
arachidonic acid (5 µM). After 
another 5 min at 37 °C, the 
formation of 12-HHT was determined by RP-HPLC as described and formation of TXB2 
was determined using a TXB2 High Sensitivity EIA Kit according to the manufacturer's 
protocol. Data are given as mean + S.E., n=3-4, **p < 0.01, ***p < 0.001 vs. vehicle 
(DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) TXAS activity was 
determined in platelet homogenates (108/ml PBS containing 1 mM CaCl2, sonified 3 x 
15 sec) pre-incubated for 15 min on ice and stimulated with 20 µM PGH2 for 1 min. 
TXB2 levels were detected in the supernatant using a TXB2 High Sensitivity EIA Kit 
according to the manufacturer's protocol. Data are given as mean + S.E., n =3-4, **p 
< 0.01, ***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. 
 
Studies on prostanoid formation in human whole blood were performed in 
citrated and heparinized whole blood. For investigation of 6-ketoPGF1a 
biosynthesis, heparinized human whole blood was incubated with LPS (10 
µg/ml) to induce COX-2/mPGES-1 and perlatolic (30c) or physodic acid 
(29b) for 24 h at 37 °C and subsequent 6-ktoPGF1a level were detected as 
marker of COX-2. For detection of TXB2, as a source of the COX-1/TXAS 
pathway, citrated human whole blood was pre-incubated with perlatolic 
acid (30c), physodic acid (29b) or vehicle (DMSO) for 15 min and 
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stimulated with thrombin (Fig. 3.36). The standard inhibitor indomethacin 
(50 µM) blocked prostanoid formation as expected (data not shown). Both 
failed to inhibit prostanoid formation in human whole blood, indicating a 
strong plasma protein binding. 
 
Fig. 3.36: Effects of perlatolic acid (30c) and physodic acid (29b) in whole blood 
experiments. 
6-ketoPGF1a detection in human whole blood. Heparinized human whole blood was 
incubated with LPS (10 µg/ml) and perlatolic acid, physodic acid or vehicle (DMSO) 
for 24 h at 37 °C. After 24 h the reaction was stopped on ice and the formation of 6-
ketoPGF1a was detected in the supernatant using a 6-ketoPGF1a High Sensitivity EIA 
Kit according to the manufacturer's protocol. TXB2 detection in human whole blood. 
Citrated human whole blood was pre-incubated with perlatolic acid, physodic acid, 
indomethacin (50 µM) or vehicle (DMSO) for 15 min at 37 °C and the reaction was 
initiated with thrombin 2 U/ml. After 10 min the reaction was stopped on ice and TXB2 
levels were detected in the supernatant using a TXB2 High Sensitivity EIA Kit according 
to the manufacturer's protocol. Data are given as mean + S.E. n=3. 
 
Cytotoxic effects of perlatolic acid (30c) or physodic acid (29b) up to 30 
µM can be excluded as no reduced viability of A549 cells occurred in the 
MTT assay during 24 h or 48 h, implying that no unspecific cytotoxic 
effects affected the modulation of prostanoid formation in cell-based assays 
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(Fig. 3.37). The control inhibitor staurosporin decreased cell viability as 
expected. 
Fig. 3.37: cytotoxic 
properties of perlatolic 
acid (30c) and physodic 
acid (29b).  
A549 cells (3 x 105) 
were incubated for 24 h 
and 48 h at 37 °C with 
perlatolic (30c), 
physodic acid (29b) or 
vehicle (DMSO). After 
24 h or 48 h, MTT was 
added and samples were 
incubated for 4 h at 37 
°C. Reaction was 
stopped and the absorption was measured at 570 nm. Results are reported as 
percentage of viable cells as compared to vehicle control. Data are given as mean + 
S.E. n=3. 
 
Taken together, mPGES-1 and TXAS could be identified as direct 
molecular targets of perlatolic acid (30c) and physodic acid (29b). 
Interference of physodic acid (29b) on upstream enzymes can be excluded 
as physodic acid (29b) failed to inhibit the activity of cPLA2 and isolated 
COX-1 and -2. However, perlatolic acid (30c) moderately inhibited COX-1 
derived 12-HHT formation and did not interfere with COX-2 and cPLA2 
activity. Efficiency was also evident in vitro in human platelets and 
monocytes. Inhibition of COX-2 expression was observed for perlatolic 
(30c) and physodic acid (29b) which might contribute to the inhibitory 
potential on pathophysiological PGE2 synthesis. In vivo studies in human 
whole blood could however not confirm the results observed in cell-free 
and cell-based test systems. 
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3.4.3.3 Perlatolic acid (30c) and physodic acid (29b) interfere with 
the 5-LO pathway 
 
Perlatolic acid (30c) and physodic acid (29b) inhibit the activity of isolated 
5-LO in a concentration-dependent manner with IC50 values of 0.4 and 2.4 
µM, respectively (Fig. 3.38A). Perlatolic acid (30c) lost its potency (IC50 > 
10 µM) when a cell-free 5-LO activity assay based on PMNL homogenates 
as 5-LO source was used while physodic acid (29b) showed only a 
marginal reduced potency in homogenates (IC50= 5.5 µM) compared to 
isolated 5-LO, suggesting that cellular components present in the 
homogenates may hamper 5-LO inhibition by perlatolic acid (30c). 
BWA4C, used as reference 5-LO inhibitor, blocked the activity of 5-LO 
analogue in both test systems with same efficiency (data not shown). 
Washout experiments indicate a reversible inhibition of isolated 5-LO by 
perlatolic acid (30c) and physodic acid (29b) (Fig. 3.38B). 
A 
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Fig. 3.38: effects of perlatolic 
acid (30c) and physodic acid 
(29b) on isolated 5-LO 
(A) Inhibition of isolated 5-LO. 
Semi purified, human 
recombinant 5-LO or PMNL 
homogenates (5 x 106 
cells/exp.) were pre-incubated 
with perlatolic acid, physodic 
acid, BWA4C (0.3 µM) or 
vehicle (DMSO) in the presence 
of 1 mM ATP for 10 min. 5-LO 
product formation was initiated 
by addition of 2 mM Ca2+ and 20 µM AA for 10 min at 37 °C. Reaction was stopped 
with methanol on ice and 5-LO products were analyzed by RP-HPLC. Data are given as 
mean + S.E., n = 2-3, **p < 0.01 and ***p < 0.001 vs. vehicle (DMSO) control, 
ANOVA + Tukey HSD post-hoc tests. (B) Reversibility of 5-LO inhibition. Semi purified, 
human recombinant 5-LO was pre-incubated in the presence of 1 mM ATP for 10 min 
and an aliquot was diluted 10-fold to obtain an inhibitor concentration of 1 or 10 µM.  
5-LO product formation was initiated by addition of 2 mM Ca2+ and 20 µM AA for 10 
min at 37 °C. Reaction was stopped with methanol on ice and 5-LO products were 
analyzed by RP-HPLC. Data are given as mean + S.E., n = 3-4, *p < 0.05 and ***p < 
0.001; 1 or 10 µM vs. diluted sample, ANOVA + Tukey HSD post-hoc tests. 
 
Due to the fact that several 5-LO inhibitors interrupt the catalytic redox 
cycle of 5-LO by reducing the active-site iron, antioxidant properties of 
perlatolic (30c) and physodic acid (29b) were analyzed. Radical 
scavenging activities of perlatolic (30c) and physodic acid (29b) were not 
evident, as both failed to reduce the stable DPPH radical up to 100 µM. the 
reference inhibitors ascorbic acid and cysteine reduced DPPH as expected 
(Fig. 3.39). 
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Fig. 3.39: radical scavenger 
properties of perlatolic acid (30c) 
and physodic acid (29b). 
Perlatolic acid, physodic acid, 
vehicle and controls were mixed 
with DPPH solution and incubated 
for 30 min in the dark. The 
absorbance was measured at 520 
nm. Data are given as mean + S.E. 
n=3. 
 
 
 
Next, investigation on 5-LO inhibition in intact human neutrophils 
stimulated with A23187 in the presence and absence of exogenous AA 
were performed. Perlatolic acid (30c) blocked 5-LO product formation with 
IC50 = 1.8 µM (regardless of the presence of AA), and physodic acid (29b) 
inhibited 5-LO activity with IC50 values of 5.0 and 6.4 µM (without or with 
AA, respectively). Physodic acid (29b) was about 5-fold more potent in 
suppressing 5-LO product synthesis, when PMNL were primed with 1 
µg/ml LPS and stimulated with 1 µM fMLP (IC50 = 1.3 µM). The potency 
of perlatolic acid (30c) was not improved in PMNL activated by LPS/fMLP 
(IC50 = 8 µM) (Fig. 3.40A). These stimuli-dependent inhibitory effects of 
physodic acid suggest that physodic acid (29b) might interfere with the 5-
LO regulatory processes in the cell. Analysis on fMLP-induced ERK-1/2 
activation in PMNL showed an increased phosphorylation of ERK-1/2 that 
was concentration-dependently repressed by physodic acid (29b), whereas 
perlatolic acid (30c) did not affect phosphorylation of ERK-1/2 or p38 
MAPK (Fig. 3.40B). 
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Fig. 3.40: Effects of perlatolic acid (30c) and physodic acid (29b) on 5-LO in intact 
PMNL. 
(A) Isolated PMNL (5 x 106/ml) were pre-incubated with perlatolic acid, physodic acid 
or vehicle (DMSO) for 10 min at 37 °C and stimulated with 2.5 µM A23187 or 2.5 µM 
A23187 plus 20 µM AA. 5-LO products were determined by RP-HPLC. Alternatively, 
cells were primed with LPS (1 µg/ml) for 30 min and formation of 5-LO products was 
initiated by addition of 1 µM fMLP. LTB4 levels were detected using a LTB4 High 
Sensitivity EIA Kit according to the manufacturer's protocol. Data are given as mean + 
S.E. n=3-5, *p < 0.05, **p < 0.01 and ***p < 0.001 vs. vehicle (DMSO) control, 
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ANOVA + Tukey HSD post-hoc tests (B) Neutrophils (107) were pre-warmed for 3 min 
at 37 °C  and  pre-incubated with perlatolic acid (30c), phsysodic acid (29b) or vehicle 
(DMSO) at 37 °C for 15 min. The reaction was started by the addition of 0.1 µM fMLP, 
stopped after 1.5 min with SDS-b and heated for 6 min at 95 °C. Total cell lysates were 
analyzed for ERK1/2, phosphorylated ERK1/2 (Thr-202/Tyr-204), phosphorylated p38 
MAPK (Thr-180/Tyr-182), by SDS/PAGE and western blotting. Results are 
representative of 2-3 independent experiments. 
 
Whole blood experiments reveal that perlatolic (30c) and physodic acid 
(29b) completely loose their 5-LO inhibitory potential (Fig. 3.41). This fact 
may be explained by plasma protein binding as already observed in 
mPGES-1 experiments when 10% FCS is present in the samples. For 
determination of 5-LO product formation in whole blood, perlatolic (30c) 
and physodic acid (29b) were pre-incubated and heparinized whole blood 
was stimulated with A23187 for 10 min. 5-LO product formation was 
detected in the supernatant. BWA4C was used as control inhibitor and 
suppressed 5-LO product formation as expected. 
 
Fig. 3.41: Effects of 
perlatolic acid (30c) and 
physodic acid (29b) on 5-
LO inhibition in human 
whole blood. 
Heparinized whole blood 
was pre-incubated with 
perlatolic acid, physodic 
acid or vehicle (DMSO) 
for 15 min at 37 °C and 
stimulated with A23187 
(30 µM) for 10 min. 
Reaction was stopped on ice and 5-LO product formation was detected using RP-
HPLC. Data are given as mean + S.E. n=2-3. 
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Taken together, perlatolic (30c) and physodic acid (29b) inhibit 5-LO 
activity in a direct, non-redox and reversible manner. Physodic acid (29b) 
additionally prevents phosphorylation of ERK-1/2 which is responsible for 
upregulation of 5-LO activity, resulting in an increased potency of 5-LO 
inhibition. Both compounds failed to suppress 5-LO product formation in 
vivo in human whole blood. 
 
3.4.3.4 Carrageenan-induced pleurisy in rats is inhibited by 
perlatolic acid (30c) 
 
The activity of perlatolic acid (30c) was assessed in vivo using the 
carrageenan-induced pleurisy model in rats. These experiments were 
performed by Dr. Rossi and Prof. Sautebin, Univ. Naples, Italy. Injection of 
carrageenan into the pleural cavity of rats (DMSO 4% group) caused an 
inflammatory response within 4 h. Perlatolic acid (30c) (10 mg/kg, given 
i.p. 30 min prior the carrageenan injection) inhibited the inflammatory 
response by the decrease of PGE2 levels (35% inhibition) (Table 3.14) in 
the exudates of the rats, whereas indomethacin (5 mg/kg, i.p.) completely 
suppressed PGE2 levels as expected. Volume exudates and inflammatory 
cells in the pleural cavitiy were not affected by perlatolic acid (30c). 
 
 
Table 3.14: Effect of perlatolic acid (30c) on carrageenan-induced pleurisy in rats. 
Thirty min before intrapleural injection of carrageenan, rats (n=10 for each 
experimental group) were treated i.p. with 10 mg/kg perlatolic acid, 5 mg/kg 
indomethacin or vehicle (DMSO 4%). Exudate volume, PGE2 and LTB4 levels as well as 
inflammatory cell accumulation in pleural cavity were assessed 4 h after carrageenan 
injection. Data are expressed as mean ± S.E., n = 10. ANOVA + Tukey HSD post-hoc 
tests were performed, ***P < 0.01 vs vehicle (DMSO 4%). Experiments were 
performed by Dr. Rossi and Prof. Sautebin, Univ. Naples, Italy. 
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Treatment 
Volume 
exudate [ml] 
Inflammatory 
cells x 106 
LTB4 
(ng/rat) 
PGE2 
(ng/rat) 
Vehicle 0.32 ± 0.06 99.63 ± 11.55 0.65 ± 0.19 0.93 ± 0.18 
Perlatolic acid 
(10 mg/kg) 
0.43 ± 0.09 158.86 ± 20.61 0.83 ± 0.24 
0.61 ± 0.08  
(35%) 
Indomethacin 
(5 mg/kg) 
0.08 ± 0.02 
*** 
(75%) 
35.67 ± 5.08 
*** 
(64%) 
0.56 ± 0.11 
(14%) 
0.05 ± 0.005 
*** 
(95%) 
 
3.4.4 Pharmacological profile of gingkolic acid (31) within the AA 
cascade 
 
3.4.4.1 Mode of action on mPGES-1 derived PGE2 inhibition 
 
Ginkgolic acid (31) was identified to suppress mPGES-1 derived PGE2 
formation (IC50= 0.7 µM) under cell-free conditions (see chapter 3.2.2). 
Studies demonstrate that alteration of the substrate concentration PGH2 to 
lower (1 and 5 µM) or higher (50 µM) values lead to only slight changes in 
the potency (0.7 – 2.1 µM), suggesting that the mode of mPGES-1 
inhibition is substrate independent (Fig. 3.42A). In addition, a reversible 
mechanism of action can be assumed, as ginkgolic acid (31) ailed to 
efficiently block mPGES-1 derived PGE2 formation in washout 
experiments of a 10-fold dilution (Fig. 3.42B). Adding 10% FCS to the 
sample completely impaired the potency, indicating that ginkgolic acid (31) 
might bind to plasma proteins. MK-886 was used as control inhibitor and 
suppressed PGE2 formation in all test systems as expected (not shown). 
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A                                         B 
 
 
Fig. 3.42: Effects of ginkgolic acid (31) on mPGES-1. 
(A) Concentration-response analysis. Microsomal preparations of IL-1β-stimulated 
A549 cells were pre-incubated for 15 min at 4 °C and PGE2 formation was induced by 
addition of variable PGH2 concentrations (1, 5, 20 and 50 µM). The amount of PGE2 
was quantified for 1 and 5 µM PGH2 by the use of a PGE2 High Sensitivity EIA Kit 
according to the manufacturer's protocol and PGE2 formation of samples with or w/o 
10% FCS stimulated with 20 and 50 µM PGH2 was analyzed by RP-HPLC. Data are 
given as mean + S.E., n = 3, *p < 0.05, **p < 0.01 ***p < 0.001 vs. vehicle (DMSO) 
control, ANOVA + Tukey HSD post-hoc tests (B) Reversibility of mPGES-1 inhibition. 
Microsomal preparations were pre-incubated for 15 min with 1 µM ginkgolic acid or 
vehicle (DMSO), and an aliquot was diluted 10-fold to obtain an inhibitor 
concentration of 0.1 µM. Then, 20 µM PGH2 was added and all samples were incubated 
for 1 min on ice, and PGE2 formation was analyzed as described by RP-HPLC. Data 
are given as mean + S.E., n=3, **p < 0.01 1 µM vs. vehicle (DMSO), ANOVA + Tukey 
HSD post-hoc tests. 
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3.4.4.2 Ginkgolic acid (31) inhibits prostanoid formation in vitro 
 
As COX enzymes are known to act upstream of mPGES-1, ginkgolic acid 
(31) was analyzed for its ability to interfere with COX-1 and -2. The 
formation of the COX-1 metabolites 12-HHT and TXB2 was analyzed in 
human platelets, pre-incubated with ginkgolic acid (31) and stimulated with 
AA (3 µM) as substrate of COX-1 (Fig. 3.43A). Ginkgolic acid (31) 
concentration-dependently blocked 12-HHT and TXB2 formation with 
similar IC50 values of 2.1 and 2.2 µM, respectively. To check whether this 
effect is due to a direct interference with COX, isolated ovine COX-1 and 
human recombinant COX-2 were pre-incubated with ginkgolic acid (31) 
and stimulated with AA for 5 min. Indomethacin, which was used as 
inhibitor in COX-1 test systems and celecoxib, as selective COX-2 
inhibitor, completely blocked COX formation as expected (not shown). 
Ginkgolic acid (31) moderately inhibited 12-HHT formation of COX-1, but 
not COX-2, with IC50 = 8.1 µM (Fig. 3.43B). As TXB2 formation in intact 
human platelets was affected with higher potency, the effects of ginkgolic 
acid (31) on TXAS in platelet homogenates stimulated with PGH2 as 
substrate were analyzed. The TXAS inhibitor CV4151 was used as control 
and completely blocked TXB2 formation as expected. Ginkgolic acid (31) 
could be identified as a moderate TXAS inhibitor (IC50 = 5.2 µM) (Fig. 
3.43B). 
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Fig. 3.43: Effects of ginkgolic acid (31) on human platelets, cell-free COX and TXAS 
(A) Platelets (108/ml PBS containing 1 mM CaCl2) were pre-incubated for 5 min prior 
to stimulation with AA (5 µM). After another 5 min at 37 °C, the formation of 12-HHT 
was determined by RP-HPLC as described and formation of TXB2 was determined 
using a TXB2 High Sensitivity EIA Kit according to the manufacturer's protocol. Data 
are given as mean + S.E., n = 3, *p < 0.05, ***p < 0.001 vs. vehicle (DMSO) control, 
ANOVA + Tukey HSD post-hoc tests. (B) Purified ovine COX-1 (50 units) or human 
recombinant COX-2 (20 units) were pre-incubated 5 min prior stimulation with AA (5 
µM or 2 µM, respectively). 12-HHT in the samples was analyzed using RP-HPLC. 
Thromboxane A2 synthase (TXAS) activity was determined in platelet homogenates 
(108/ml PBS containing 1 mM CaCl2, sonified 3 x 15 sec) pre-incubated for 15 min on 
ice and stimulated with 20 µM PGH2 for 1 min. TXB2 levels were detected in the 
supernatant using a TXB2 High Sensitivity EIA Kit according to the manufacturer's 
protocol. Data are given as mean + S.E., n = 3-4, **p < 0.01, ***p < 0.001 vs. vehicle 
(DMSO) control, ANOVA + Tukey HSD post-hoc tests. 
 
In addition, studies of COX-2 expression in intact human monocytes 
primed with LPS were performed. Dexamethason, used as control, 
completely blocked COX-2 expression compared to the unstimulated 
sample (Fig. 3.44). However, ginkgolic acid (31) only moderately blocked 
3 RESULTS 115 
the expression of COX-2, suggesting a slight synergistic effect on mPGES-
1 activity and COX-2 expression to suppress PGE2 formation. 
 
Fig. 3.44: Effects of ginkgolic 
acid (31) on intact human 
monocytes primed with LPS. 
Intact human monocytes (5 x 
106/exp. in RPMI 1640 medium 
containing 0.5 % FCS, P/S and 2 
mM glutamine) were stimulated 
with 1 µg/ml LPS and gingkolic 
acid (10 µM), dexathemason (1 µM) or vehicle (DMSO) was added for 24 h at 37 °C. 
After 24 h cells were detached and lysed (2 x SDS-b.). Samples were subjected to SDS-
PAGE and WB using a specific antibody against COX-2. ßactin was used as loading 
control. Results are representative of 2-4 independent experiments. 
 
To exclude interference of ginkgolic acid (31) at the level of AA supply, 
the effect on the enzymatic activity of human recombinant cPLA2 was 
studied. Whereas the pyrrolidine inhibitor (1 µM) effectively blocked AA 
release from phospholipids, ginkgolic acid (31) did not affect cPLA2 
activity (Fig. 3.45A). Moreover, ginkgolic acid (31) showed only minimal 
cytotoxic effects after 24 h (80% cell viability) that could not be detected 
after 48h, implying that no unspecific cellular effects adulterate results for 
cell-based assays (Fig. 3.45B). 
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Fig. 3.45: effects of ginkgolic acid (31) on cPLA2 activity and cytotoxic effects on A549 
cells. 
(A) Freshly prepared large unilamelar vesicles were incubated with cPLA2 enzyme, 1 
mM Ca2+ and the indicated compounds for 1 h at 37 °C. Reaction was stopped using 
methanol. Following derivatisation with p-anisidinium chloride, the resulting derivate 
was analyzed by RP-HPLC. Data are given as mean + S.E., n=3, ***p < 0.001 vs. 
vehicle (DMSO) control, ANOVA + Tukey HSD post-hoc tests. Performed by Marius 
Melzer in the lab of Prof. Dr. O. Werz (University of Jena, Germany). (B) Cytotoxicity 
in A549 cells. Cells (3 x 105) were incubated for 24 h and 48 h at 37 °C with Ginkgolic 
acid or vehicle (DMSO). After 24 h or 48 h, MTT was added and samples were 
incubated for 4 h at 37 °C. Reaction was stopped and the absorption was measured at 
570 nm. Results are reported as percentage of viable cells as compared to vehicle 
control. Data are given as mean + S.E. n=3. 
 
Studies using human whole blood could not confirm the potency of 
ginkgolic acid (31) demonstrated in the cell-free and cell-based 
experiments. Ginkgolic acid (31) did not interfere with prostanoid synthesis 
in vivo (Fig. 3.46). This might be due to plasma protein binding as has been 
demonstrated for mPGES-1 supplemented with 10% FCS (see Fig. 3.42). 
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Fig. 3.46: Effects ginkgolic 
acid (31) in whole blood 
experiments 
6-ketoPGF1a detection in 
human whole blood. 
Heparinized human whole 
blood was incubated with LPS 
(10 µg/ml) and ginkgolic acid 
or vehicle (DMSO) for 24 h at 
37 °C. After 24 h the reaction 
was stopped on ice and the 
formation of 6-ketoPGF1a was 
detected in the supernatant 
using a 6-ketoPGF1a High Sensitivity EIA Kit according to the manufacturer's protocol. 
TXB2 detection in human whole blood. Citrated human whole blood was pre-incubated 
with ginkgolic acid, indomethacin (50 µM) or vehicle (DMSO) for 15 min at 37 °C and 
the reaction was initiated with thrombin 2 U/ml. After 10 min the reaction was stopped 
on ice and TXB2 levels were detected in the supernatant using a TXB2 High Sensitivity 
EIA Kit according to the manufacturer's protocol. Data are given as mean + S.E. n=3. 
 
In summary, ginkgolic acid (31) is a potent inhibitor of mPGES-1 with a 
substrate independent and reversible mode of action. Ginkgolic acid (31) 
did not affect COX-2 activity and moderately inhibited COX-2 expression 
in monocytes. In addition, COX-1 and TXAS could be identified as 
molecular targets. 
 
3.4.4.3 Ginkgolic acid (31) interferes with the 5-LO pathway 
Inhibition of semi-purified 5-LO turned out to be concentration dependent 
with IC50 = 0.2 µM (Fig. 3.47A). However, when ginkgolic acid (31) was 
tested in a cell-free 5-LO activity assay based on crude neutrophil 
homogenates under the same experimental conditions, the potency clearly 
decreased (IC50 > 10 µM), indicating that cellular components present in 
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the homogenates may hamper 5-LO inhibition. Washout experiments 
demonstrate that inhibition of 5-LO by ginkgolic acid (31) is fully 
reversible, as a 10-fold dilution of a potent concentration of 1 µM could 
counteract the inhibition (Fig. 3.47B). BWA4C was used as reference 
inhibitor and suppressed 5-LO product formation as expected (not shown). 
A                                        B 
 
Fig. 3.47: effects of ginkgolic acid (31) on isolated 5-LO 
(A) Inhibition of isolated 5-LO. Semi purified, human recombinant 5-LO or PMNL 
homogenates (5 x 106 cells/exp.) were pre-incubated with ginkgolic acid, BWA4C (0.3 
µM) or vehicle (DMSO) in the presence of 1 mM ATP for 10 min. 5-LO product 
formation was initiated by addition of 2 mM Ca2+ and 20 µM AA for 10 min at 37 °C. 
Reaction was stopped with methanol on ice and 5-LO products were analyzed by RP-
HPLC. Data are given as mean + S.E., n = 3, *p < 0.05 and ***p < 0.001 vs. vehicle 
(DMSO) control, ANOVA + Tukey HSD post-hoc tests. (B) Reversibility of 5-LO 
inhibition. Semi purified, human recombinant 5-LO was pre-incubated in the presence 
of 1 mM Ca2+ and 1 mM ATP for 10 min and an aliquot was diluted 10-fold to obtain an 
inhibitor concentration of 1 µM.  5-LO product formation was initiated by addition of 
20 µM AA for 10 min at 37 °C. Reaction was stopped with methanol on ice and 5-LO 
products were analyzed by RP-HPLC. Data are given as mean + S.E., n = 3-4, ***p < 
0.001; 1 µM vs. diluted sample, ANOVA + Tukey HSD post-hoc tests. 
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Further investigation on 5-LO inhibition were performed in a cell-based 
assay using intact human neutrophils, stimulated with A23187 in the 
presence and absence of exogenous AA as substrate for 5-LO. As can be 
seen in Fig. 3.48, ginkgolic acid (31) blocked 5-LO product formation 
independent of the substrate supply comparably well (IC50 = 3.8 and 2.9 
µM, respectively), but was less potent in intact neutrophils primed with 
LPS and stimulated with fMLP (IC50 = 7.2 µM). BWA4C, used as 
reference inhibitor, suppressed 5-LO product formation in neutrophils as 
expected (not shown). 
Fig. 3.48: Effects of ginkgolic acid (31) 
on 5-LO in intact PMNL.  
Isolated PMNL (5 x 106/ml) were pre-
incubated with ginkgolic acid or 
vehicle (DMSO) for 10 min at 37 °C 
and stimulated with 2.5 µM A23187 or 
2.5 µM A23187 plus 20 µM AA. 5-LO 
products were determined by RP-
HPLC. Alternatively, cells were primed 
with LPS (1 µg/ml) for 30 min and 
formation of 5-LO products was 
initiated by addition of 1 µM fMLP. 
LTB4 levels were detected using a 
LTB4 High Sensitivity EIA Kit according to the manufacturer's protocol. Data are given 
as mean + S.E. n=3-5, ***p < 0.001 vs. vehicle (DMSO) control, ANOVA + Tukey 
HSD post-hoc tests 
 
As 5-LO activity is strongly regulated in the cell, i.e. phosphorylation by 
ERK-1/2 or MAPK pathway, experiments with ginkgolic acid (31) on the 
phosphorylation status of ERK-1/2 and p38 MAPK in human neutrophils 
stimulated with fMLP were performed and revealed that phosphorylation is 
not affected by ginkgolic acid (31) (Fig. 3.49A). U0126 that was used as 
reference inhibitor of ERK-1/2 phosphorylation inhibited ERK-1/2 as 
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expected. Several 5-LO inhibitors act by uncoupling the catalytic cycle of 
5-LO due to redox properties. Antioxidant properties can be excluded, 
since ginkgolic acid (31) failed to reduce the stable DPPH radical up to 100 
µM, whereas the positive controls ascorbic acid and cysteine reduced 
DPPH as expected (Fig. 3.49B). 
A                                            B 
 
 
 
 
 
 
Fig. 3.49: Influence on MAPK signalling and radical scavenger properties of ginkgolic 
acid (31) 
(A) Neutrophils (107) were pre-warmed for 3 min at 37 °C and pre-incubated with 
ginkgolic acid or vehicle (DMSO) at 37 °C for 15 min. The reaction was started by the 
addition of 0.1 µM fMLP, stopped after 1.5 min with SDS-b. and heated for 6 min at 95 
°C. Total cell lysates were analyzed for ERK1/2, phosphorylated ERK1/2 (Thr-202/Tyr-
204), phosphorylated p38 MAPK (Thr-180/Tyr-182), by SDS/PAGE and western 
blotting. Results are representative of 2-3 independent experiments (B) Radical 
scavenger capability. Ginkgolic acid, vehicle and controls were mixed with DPPH 
solution and incubated for 30 min in the dark. The absorbance was measured at 520 
nm. Data are given as mean + S.E. n=3. 
 
As has been demonstrated for prostanoid biosynthesis, ginkgolic acid (31) 
lost its inhibitory potential on 5-LO activity in human whole blood. 
BWA4C, which was used as standard inhibitor, reduced 5-LO product 
formation in human whole blood as expected. 
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Fig. 3.50: Effects of ginkgolic acid 
(31) on 5-LO inhibition in human 
whole blood. 
Heparinized whole blood was pre-
incubated with ginkgolic acid or 
vehicle (DMSO) for 15 min at 37 
°C and stimulated with A23187 (30 
µM) for 10 min. Reaction was 
stopped on ice and 5-LO product 
formation was detected using RP-
HPLC. Data are given as mean + 
S.E. n=2-3. 
 
Together, ginkgolic acid (31) potently inhibited 5-LO product formation in 
cell-free and cell-based experiments. The mechanism of action was fully 
reversible and non redox active. Investigations in crude neutrophil 
homogenates and human whole blood indicate a high affinity to proteins 
present in the sample. 
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4 DISCUSSION 
 
There is accumulating evidence that mPGES-1 might represent a druggable 
target in the therapy of inflammation and pain. mPGES-1 gene deletion 
studies and pharmacological approaches with selected mPGES-1 inhibitors 
support a role for mPGES-1 in inflammatory reactions, fever, pain, 
neurological disorders and cancer [20, 78, 194, 195]. In view of the 
considerable gastrointestinal, renal and cardiovascular side effects of COX 
inhibitors, the class of drugs widely used to treat inflammation, fever and 
pain, mPGES-1 inhibition might be a promising alternative strategy to 
NSAIDs. Accordingly, extensive efforts are underway to develop mPGES-
1 inhibitors. However, only a few agents show sufficient efficacy in 
preclinical models of inflammation and pain so far and thus could 
potentially enter clinical trials [20, 78, 194]. 
Dual inhibition of 5-LO and mPGES-1 seems to be preferable since 
inhibition of COX and 5-LO was suggested to be superior over single 
NSAID administration related to an improved anti-inflammatory 
effectiveness associated with a lower risk of gastrointestinal and 
cardiovascular side effects [101, 196]. As PGE2 is held the mainly 
responsible eicosanoid for inflammatory events, a dual inhibition of 
mPGES-1 and 5-LO is a promising strategy to avoid ordinary side effects 
of NSAIDs or coxibs and improve the safety of anti-inflammatory drugs 
[93]. 
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4.1 The acylphloroglucinol arzanol from Helichrysum 
italicum is seemingly a responsible constituent for the anti-
inflammatory potential of the plant 
 
Arzanol was discovered as a bioactive ingredient from the Mediterranean 
curry plant (Helichrysum italicum). With 0.05% of the dried plant weight, 
arzanol is one of its major active compounds. Extracts of the curry plant 
have been traditionally used in folk medicine to treat inflammatory 
disorders [197], but there are only few studies addressing the molecular 
targets. Interference at the level of pro-inflammatory cytokine and PGE2 
release from LPS stimulated human monocytes (IC50= 5-22 µM), which is 
attributed to an impaired activation of the NFκB pathway (IC50= 5 µM) 
[118, 129] could be monitored by the group of Appendino et al. in 2007. 
During my diploma thesis, mPGES-1 and 5-LO could be identified as 
molecular targets of arzanol [175, 198]. 
 
In this study the overall pharmacological profile within the eicosanoid 
biosynthesis was investigated and mechanistic studies were performed to 
identify the mode of action. Arzanol potently inhibits mPGES-1¶ (IC50= 0.3 
µM), 5-LO¶ (IC50= 3.4 µM) and TXAS (IC50= 2.7 µM) under cell-free 
conditions. A direct interference with the upstream signalling enzymes 
cPLA2, COX-1¶ and COX-2¶ can be excluded, since arzanol failed to block 
AA release and 12-HHT product formation, which is non-enzymatically 
formed from PGH2 [199], under cell-free conditions. Mechanistic studies 
reveal a reversible and competitive mode of action for mPGES-1 inhibition. 
Since arzanol was identified to protect linoleic acid against free radical 
attack in assays of autoxidation and EDTA-mediated oxidation, and 
inhibited TBH-induced oxidative stress in VERO cells [129], radical 
scavenger properties were assessed by DPPH assay. Thus, arzanol could be 
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identified as a redox-type inhibitor of 5-LO with a reversible mode of 
action.  
The inhibitory potential of arzanol was also evident in vitro using cell-
based test systems. As direct COX-2 inhibition can be excluded, PGE2 
suppression in human monocytes can be ascribed to an interference with 
mPGES-1 [200]. In addition, concomitant analysis of COX-2 and mPGES-
1 protein in human monocytes revealed that arzanol does not interfere with 
their expression levels. 5-LO inhibition in intact neutrophils was selective 
and comparable to the results under cell-free conditions. 
Many NSAIDs represent lipophilic acidic substances and hence suffer from 
high plasma protein binding in line with a loss of efficiency [201]. As 
arzanol is a lipophilic and weak vinylogue acid, plasma protein binding 
effects might play a role, but notably PGE2 biosynthesis was efficiently 
blocked by arzanol in LPS-stimulated human whole blood, whereas the 
formation of other prostanoids such as 6-keto-PGF1a and TXB2 was hardly 
affected. 
 
Extracts of Helichrysum italicum have already been shown to suppress 2-
Otetradecanoylphorbol 13-acetate (TPA)-induced mouse ear edema 
formation in preclinical studies [117]. Thus, in a model of carrageenan-
induced pleurisy in rats, arzanol was almost as effective as the NSAID 
indomethacin. Since PGE2 is the primarily responsible mediator in the early 
phase of carrageenan-induced pleurisy [202], mPGES-1 inhibition might 
contribute to the anti-inflammatory efficacy of arzanol. Because 5-LO-
derived metabolites cooperate with PGE2 in the induction of pleurisy [203], 
synergistic anti-inflammatory effects of dual mPGES-1/5-LO have been 
observed [17, 93] that also might be responsible for an improved efficiency 
profile with less severe side effects.  
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In addition, other constituents from the genus Helichrysum have also been 
reported as anti-inflammatory agents [117, 126, 204]. Since their amount in 
curry plant extracts was found to be rather low, it is likely that they are not 
liable for the anti-inflammatory effects of the plant.  
In summary, arzanol is a potent inhibitor of the key enzymes mPGES-1¶, 5-
LO¶ and TXAS of the AA cascade. In vivo studies in human whole blood 
and carrageenan-induced pleurisy in rats could confirm the anti-
inflammatory potential of arzanol and might explain the anti-inflammatory 
potential of Helichrysum italicum. As a dual mPGES-1/5-LO inhibitor of 
plant origin, arzanol might represent an innovative drug in the therapy of 
inflammation and cancer.  
 
Current SAR studies demonstrate that the pharmacophore of arzanol can be 
improved towards its anti-inflammatory potential of mPGES-1 and 5-LO 
inhibition. As arzanol is a mixture of tautomers and atropoisomers [205], it 
is tempting to speculate that different forms of the compounds may target 
distinct biological end-points. Thus, it is known that heterodimeric 
phloroglucinyl pyrones co-occur with symmetric homodimeric 
alkyliden(bis) pyrones in many plants [205]. To these purposes, SAR 
studies were performed on the alkylidene linker and/or the pyrone moiety 
of homodimeric and heterodimeric analogues. Introduction of lipophilic 
elements to the alkylidene linker of (heterodimeric) acylphloroglucinols or 
(homodimeric) phloroacetophenon-derivatives yield potent inhibitors of 
mPGES-1 and semi-purified 5-LO with IC50 values in the submicromolar 
range. Most potent mPGES-1/5-LO inhibitor was achieved by introduction 
of an n-hexyl residue to the alkylidene linker of the heterodimeric scaffold 
(1e) [206]. 
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In the present study 1e was identified as a potent dual mPGES-1/5-LO 
inhibitor with an interesting pharmacological profile. In fact, detailed 
investigations on eicosanoid biosynthesis address mPGES-1 (IC50= 0.2 
µM), 5-LO (IC50= 1.2 µM), COX-2 (IC50 > 10 µM) and TXAS (IC50= 2.5 
µM) as molecular targets of 1e, whereas COX-1 and cPLA2 activity were 
not affected. Importantly, COX-2 is only moderately inhibited by 1e with 
an at least 100-fold higher selectivity for mPGES-1. Studies on the 
mechanistic properties of mPGES-1 and 5-LO inhibition identified 1e as a 
direct and reversible inhibitor with redox-active and non-cytotoxic 
qualities. A loss of efficacy was observed in studies with human whole 
blood determined 5-LO product formations as well as TXB2 and 6-
ketoPGF1a formation. However, further investigations addressing in vivo 
effects and the bioavailability of 1e will be necessary to assess the 
relevance as a potential anti-inflammatory drug. 
 
4.2 Non-cannabinoids are involved in the anti-
inflammatory actions of cannabis sativa 
 
Cannabis sativa is one of the first plants that was used as herbal medicine. 
Up to date, several different phytocannabinoids and non-cannabinoids have 
been described, but only a few constituents were characterized for their 
biological activities. Pharmacological investigations on single 
cannabinoids, mostly THC, CBN and CBD, were first carried out in the 
early 1940s [207, 208]. Inhibition of PGE1 biosynthesis in bull seminal 
vesicles (IC50= 70 – 300 µM) by several cannabinoids was observed by 
Burstein et al. [209]. However, by now only few molecular targets of 
cannabis constituents involved in inflammation are known [141-143]. 
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This thesis demonstrates that phytocannabinoids and non-cannabinoids 
inhibit mPGES-1 and 5-LO in cell-free conditions. CBG was the only one 
among the tested phytocannabinoids that could be identified as potent 
mPGES-1 inhibitor (IC50= 0.9 µM). Notable, CBG is also present in 
Helichrysum species [134], implying that CBG might also contribute to the 
anti-inflammatory potential of Helichrysum italicum. Hence, further studies 
are necessary to verify the presence of CBG in Helichrysum italicum. 
Interestingly, THC inhibited mPGES-1 with a rather high IC50 value of 70 
µM, suggesting that it is not the mainly responsible constituent of Cannabis 
sativa involved in anti-inflammatory events related to PGE2. Among the 
non-cannabinoids, prenylated flavonoids (19, 20) and the prenylated 
dihydrostilbene canniprene (22) could be identified as potent dual mPGES-
1/5-LO inhibitors. Because 5-LO and mPGES-1 are key enzymes in the 
biosynthesis of lipid mediators involved in inflammation [25, 210] and 
CFA in line was already shown to inhibit TPA-induced PGE2 release from 
cultured synovial cells [140], the overall pharmacological profile within the 
AA cascade was further investigated. 
 
Studies on the prostanoid formation in vitro in human platelets and 
monocytes revealed a potent suppression of TXB2 formation that could be 
identified as TXAS inhibition (IC50= 6.8 µM). Notable, 12-HHT formation 
in vitro and in isolated COX-1 and -2 assays was hardly affected with IC50 
values > 10 µM. CFA (10 µM) blocked PGE2 formation in intact human 
monocytes comparable to the glucocorticoid dexamethasone. Since 
interference of CFA at the level of AA supply can be excluded, the 
observed effect might be due to synergistic (I) mPGES-1 inhibition and (II) 
blockage of COX-2 expression. Mechanistic investigations demonstrate a 
reversible mode of action that is independent of the substrate supply. 
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Also 5-LO could be identified as molecular target of CFA with a 
comparable potency of cell-free (IC50= 0.9 µM) compared to cell-based 
(IC50= 1.6 – 2.4 µM) assay. Indeed, studies in crude neutrophil 
homogenates resulted in a decreased potency (IC50= 5.4 µM). A similar 
observation was made in microsomal preparations of A549 cells 
supplemented with 10% FCS, indicating that CFA suffers from plasma 
protein binding. This could also be shown in vivo, where CFA failed to 
inhibit 5-LO product formation in human whole blood. Mechanistic studies 
reveal that 5-LO inhibition is only partially reversible and not related to the 
substrate supply of AA. CFA was identified as a nonredox active inhibitor 
of 5-LO that does not interfere with the MAPK signaling pathway which is 
known to regulate 5-LO activity. 
 
Plant cannabis extracts contain a complex mixture of phytocannabinoids 
and other non-cannabinoid compounds. In the 1970´s Sofia et al. [211-213] 
demonstrated potent anti-inflammatory effects of a crude marijuana extract 
and some single constituents (THC, CBD and CBN) in the carrageenan 
induced paw edema model of acute inflammation. Also CBCr was reported 
to possess anti-inflammatory potential in a carrageenan paw edema assay 
[214, 215]. More recently, CBD was shown to reduce joint inflammation in 
a murine model of collagen-induced arthritis [216]. Of interest, whole plant 
extracts of cannabis sativa seem to be superior over single administration 
of phytocannabinoids [217]. Hence, several animal models are reported on 
pytocannabinoids and only little is known about the effectiveness of non-
cannabinoids in animal models of inflammation.  
Taken together, CFA was identified as a potent dual mPGES-1/5-LO 
inhibitor in cell-free and cell-based test systems. In addition, TXAS could 
be identified as molecular target. Studies in human whole blood indicate 
high plasma protein binding due to its lipophilic character. Hence, further 
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in vivo studies are necessary to define the role of CFA in the treatment of 
inflammation. 
 
4.3 Benzofurane derivatives are potential anti-
inflammatory constituents of Krameria lappacea 
 
The roots of Krameria lappacea (syn. rhatany) are used in the treatment of 
inflammation predominantly of the mouth and throat [187, 188]. Vegetable 
tannins, having astringent and antimicrobial properties, were considered as 
the active anti-inflammatory components [218], but previous studies 
indicate that lignan derivatives may act as potent anti-inflammatory agents 
[189, 190]. 
A topical anti-inflammatory potential of a CH2Cl2 rhatany extract and 11 
isolated lignan derivatives could be revealed from animal studies, detected 
as antiedema activity in mice [176]. (Leukocyte infiltration and histological 
analysis were additionally performed). Attempts to clarify the mode of 
action were performed on the NFκB pathway and AA cascade that are 
involved in inflammation. Thus, interference with TNFa-induced NFκB 
signaling, COX-1 and -2, 5-LO and antioxidant properties could be 
demonstrated for several lignan derivatives, which may explain the 
promising anti-inflammatory activity of the CH2Cl2-soluble extract of 
Krameria lappacea roots on multiple targets in vivo and in vitro [176]. In 
this line mPGES-1 inhibition was suggested as a probable target for the 
anti-inflammatory effects. 
 
This study addresses mPGES-1 as a direct target of several lignan 
derivatives in a cell-free assay (IC50 values 5.3 – 42 µM). In particular, 
substituted propenylbenzofurans (9a – 9e) were most potent mPGES-1 
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inhibitors with IC50 values of 5.3 – 13.5 µM whereas 7,70-epoxy lignans 
showed no marked inhibition of mPGES-1 up to 50 µM. Taken together, 
these findings provide a strong evidence for the anti-inflammatory potential 
of rhatany by lignan derivatives, consistent with the anti-inflammatory 
targets that could already be addressed for several lignan derivatives.  
 
4.4 Depsides and depsidones from lichen spec. dispose of a 
promising anti-inflammatory potential 
 
Lichens are symbiotic associations between fungi (mycobionts) and algae 
and/or cyanobacteria (photobionts) [219]. Various extracts of lichen species 
have been used as remedies in folk medicine for the treatment of 
inflammatory disorders. By now, approximately 1,050 secondary 
metabolites from lichens have been identified [144]. Numerious 
pharmacological properties are reported for secondary metabolites, such as 
antibiotic, antimycobacterial, antifungal, antiviral, anticancer, 
antiproliferative, antioxidant, anti-inflammatory, analgesic, and antipyretic 
and cytotoxic effects [144, 148, 149, 220-225].  
For the development of novel mPGES-1 inhibitors as promising anti-
inflammatory agents, a pharmacophore model was generated by the group 
of Stuppner et al. (Innsbruck). In silico screening of the Chinese herbal 
medicine (CHM) database using this pharmacophore model revealed the 
group of depsides and depsidones as potential candidates [177]. To this 
purpose five depsides and five depsidones were investigated for their anti-
inflammatory potential. 
 
Among the selected depsides methylbetaorcinol carboxylate, evernic acid, 
perlatolic acid, olivetoric acid and atranorin only perlatolic acid (IC50 = 0.4 
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µM for mPGES-1 and 5-LO) and olivetoric acid (IC50 = 1.15 µM for 
mPGES-1 and 2.4 µM for 5-LO) could be identified as potent dual 
mPGES-1/5-LO inhibitors. Investigations on the selected depsidones 
fumarprotocetraric acid, physodic acid, salazinic acid, variolaric acid and 
scensidin revealed physodic acid as potent dual inhibitor of mPGES-1 and 
5-LO (IC50= 0.43 and 2.4 µM, respectively). In line with recent findings 
[82], lipophilic residues and abdication of the carboxylic group retained 
potent mPGES-1 inhibitors.  
 
For the class of depsides and depsidones in vitro studies revealed antiviral 
[226, 227], antibacterial [228-231], antimicrobial [220, 232, 233], 
antifungal [230], anticancer [220, 234, 235] and antioxidant properties 
[220, 232, 233, 236-238] as well as inhibition of MAO-B [239], 
acetylcholinesterase [240, 241] and p12-LO [222]. Interference with PG 
biosynthesis in rabbit renal microsomes [146] as well as on the 5-LO 
signaling pathway in porcine leukocytes [242, 243] and inhibition of 
malondialdehyde (MDA) formation in rat and monkey liver microsomes 
[244] is known for both classes and might contribute to the anti-
inflammatory potential of lichens. Hence, further studies adressing the 
molecular targets involved in inflammation are necessary.  
 
This thesis demonstrates that the depside perlatolic acid and the depsidone 
physodic acid are potent inhibitors of mPGES-1 (IC50= 0.4 and 0.43 µM, 
respectively), 5-LO (IC50= 0.4 and 2.4 µM, respectively) and TXAS (IC50= 
1.1 and 0.7 µM, respectively) under cell-free conditions. Inhibition of 
NFkB (IC50= 7.0 µM) [245] and COX-1 (IC50> 10 µM) for perlatolic acid 
is also evident but to a lesser extent. Because mPGES-1 and 5-LO are key 
enzymes involved in inflammatory events [25, 210], their inhibition by 
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perlatolic acid and physodic acid might contribute to the anti-inflammatory 
potential of lichens. 
Mechanistic studies on mPGES-1 and 5-LO inhibition reveal a 
concentration-dependent and reversible mode of action, which is largely 
independent of the substrate supply. Since radical scavenger properties can 
be excluded and no iron-chelating qualities are apparent for both, perlatolic 
acid and physodic acid can be structurally classed into non redox-type 
inhibitors of 5-LO. 
Inhibitory effects were also evident in terms of cell-based assay systems. 
Interference at the level of AA supply can be excluded, as both failed to 
inhibit isolated cPLA2 enzyme. PGE2 biosynthesis is suppressed by 
synergistic effects in vitro. Perlatolic acid completely and physodic acid 
moderately blocked COX-2 expression in LPS stimulated human 
monocytes, which in turn with downstream mPGES-1 inhibition is 
responsible for suppression of pro-inflammatory PGE2. Notable, inhibition 
of COX-2 activity could not be detected, what may contribute to an 
improved safety profile. 12-HHT and TXB2 were potently blocked by 
perlatolic acid in human platelets, indicating synergistic effects of COX-1 
and TXAS for blockade of TXB2. Surprisingly, physodic acid potently 
blocked cell-free TXAS activity (IC50= 0.7 µM), but the inhibitory 
potential decreased about 10 fold in intact human platelets, where the 
formation of 12-HHT and TXB2 (IC50= 8.8 and 5.2 µM, respectively) was 
detected.  
5-LO inhibition in neutrophils was evident with similar efficacy, as both 
compounds have comparable IC50 values with exogenous supplemented 
AA (A23187 + 20 µM AA) and AA provided from endogenous sources 
(A23187). Of interest, stimulation with physiological occurring 
inflammatory mediators (LPS, fMLP) decreased the potency of perlatolic 
acid (IC50= 8.0 µM in contrast to 1.8 µM with A23187 ± AA) in intact 
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human neutrophils, whereas the potency of physodic acid was increased 
(IC50= 1.3 µM in contrast to 5.0 and 6.4 µM A23187 ± AA). 5-LO product 
formation is modulated by cPLA2 (AA liberation) and regulation of 5-LO 
activity. 
Recently p38 MAPK and ERK1/2 were identified to up-regulate 5-LO 
activity via phosphorylation [246]. However, regulation of 5-LO activity by 
phosphorylation could be identified as a further target of physodic acid. 
Phosphorylation of ERK1/2 was completely blocked in a concentration 
dependent manner, which is responsible for the increased potency of 
physodic acid in LPS/fMLP stimulated human neutrophils compared to the 
stimulation with A23187 ± AA. 
 
Extracts of Teloschistes flavicans [247], Cladonia clathrata [248], 
Cladonia rangiformis [249] and  Peltigera rufescens [250] have shown to 
suppress acute (carrageenan or formaldehyde induced) and/or chronic 
(cotton pellet granule) inflammation in mouse models of inflammation as 
well as acetic acid-induced abdominal writhes, but studies on isolated 
secondary metabolites are rare. Thus, perlatolic acid, which is a major 
ingredient of lichens [245], was shown to inhibit the inflammatory 
recruitment of leukocytes in a peritonitis mouse model in vivo [245] and 
blocked PGE2 formation in a model of carrageenan-induced pleurisy in 
rats. Since PGE2 is the primarily responsible mediator in the early phase of 
carrageenan-induced pleurisy [202], mPGES-1 inhibition might contribute 
to the anti-inflammatory potential of perlatolic acid.  
 
In summary, perlatolic acid and physodic acid potently inhibit the 
biosynthesis of the pro-inflammatory mediators PGE2, TXB2 and LTB4, 
implying synergistic anti-inflammatory effects [20, 103, 251] and therefore 
an improved pharmacological safety profile compared to NSAIDs and 
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coxibs. Thus, (pro-inflammatory) PGE2 biosynthesis is selectively and 
reversibly blocked by the synergistic effect of (I) downstream mPGES-1 
inhibition and (II) blockade of inducible COX-2 expression. Importantly, 
suppression of PGE2 formation for perlatolic acid was also evident in vivo 
(physodic acid is not yet investigated). These findings offer broader 
perspectives and possibilities for the application of depsides and 
depsidones from lichens. 
 
4.5 Ginkgolic acid contributes to the anti-inflammatory 
properties of ginkgo biloba 
 
Ginkgo biloba is among the most widely used medicinal plants of the 
world. Its medicinal use goes back several centuries where it was first 
documented in the Chinese Materia Medica interalia for the treatment of 
cardiovascular and bronchial diseases, skin wounds and freckles [158, 
159]. By now, ginkgo preparations, which have been mostly standardized 
for their amount of terpene trilactones and flavonol glycosides, are 
available by several manufacturers. Terpene trilactones and flavonol 
glycosides are deemed to be the pharmacological active constituents of 
ginkgo biloba [170]. The proposed anti-inflammatory potential of Ginkgo 
biloba is due to anti-PAF activity by terpene trilactones [252, 253], 
inhibition of COX and LO by flavonoids [166] and radical scavenger 
activities [254, 255]. However, since not all effects are clearly attributed to 
these constituents, effects of other components present in the extract can 
not be excluded [170].  
To this purpose, the present study focused on ginkgolic acid, which is 
among the alkylphenols (ginkgolic acids) that are found in the fruit pods 
and in the leaves of ginkgo biloba [256]. Besides their antitumor, 
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antimicrobial and antiviral activities, allergenic effects are ascribed to 
alkylphenols [172, 256-258]. Ginkgolic acids are limited at 5 mg/g in 
commercial phytopreparations in the monograph of the Commission E of 
the former German Health Authority (Bundesgesundheitsamt, BGA) [259]. 
However, their allergenic potential has not been clearly verified, which in 
turn is why they were not yet in the main focus of inflammation research 
[173, 174, 260]. 
 
This thesis identified key enzymes involved in prostanoid and leukotriene 
biosynthesis as functional molecular targets of ginkgolic acid. Particularly, 
mPGES-1 (IC50= 0.7 µM), 5-LO (IC50= 0.3 µM), COX-1 (IC50= 8.1 µM) 
and TXAS (IC50= 5.2 µM) were affected by ginkgolic acid. Notable, 
inhibition of mPGES-1 and 5-LO is about 10 fold selective compared to 
COX-1 and TXAS. Studies on the mechanistic properties of mPGES-1 and 
5-LO inhibition reveal a direct and reversible mode of action which is 
independent of the substrate supply. Interference at upstream signaling 
events such as AA release can be excluded since ginkgolic acid failed to 
block cPLA2 activity. A moderate inhibition of COX-2 expression could be 
observed in human monocytes after 24 h, whereas COX-2 activity in cell-
free conditions was not affected. 
Efficiency of ginkgolic acid was also evident in cell-based assays of human 
platelets and neutrophils. 12-HHT and TXB2 were concentration-
dependently blocked by ginkgolic acid in human platelets equally well 
(IC50 values of 2.1 and 2.2. µM, respectively) indicating synergistic effects 
of COX-1 (IC50= 8.1 µM) and TXAS (IC50= 5.2 µM) inhibition. 
Investigations in human neutrophils reveal that 5-LO product formation is 
comparably blocked by ginkgolic acid where either substrate was provided 
from endogenous sources (stimulation with A23187 or LPS/fMLP) or 
supplemented exogenously (20 µM AA). Interference in 5-LO regulation 
4 DISCUSSION 136 
by phosphorylation can be excluded. Cytotoxic effects of alkylphenols 
(ginkgolic acids) are described in several human and animal cell-lines [261, 
262]. Interestingly, in a recent study ginkgolic acid was demonstrated to 
show less cytotoxicity in 96 h cultured primary rat hepatocytes than in 20 h 
cultured primary rat hepatocytes and HepG2 cells [171]. These results 
could be confirmed by MTT assay using A549 cells, where ginkgolic acid 
showed minimal cytotoxic effects after 24 h (80% cell viability) that were 
not detectable after 48 h.  
As ginkgolic acid is a lipophilic acidic agent, it suffers from high plasma 
protein binding. This could be demonstrated (I) in crude neutrophil 
homogenates, where ginkgolic acid lost its potency of 5-LO inhibition and 
(II) in microsomal preparations of A549 cells, where the potency of 
ginkgolic acid was impaired after addition of 10% FCS. Hence, in vivo 
studies in human whole blood resulted in a complete loss of efficacy.  
 
Investigations with Ginkgo biloba extract (GBE) on endotoxin induced 
uveitis (EIU) in rats indicate that suppression of inflammation is due to 
blockade of iNOS expression and inhibition of PGE2, TNFα and NO 
production [263]. Moreover, EGb 761 was shown to be beneficial in the 
prevention and treatment of mouse colitis by suppression of macrophage 
activation combined with a downregulation of several inflammatory 
markers (iNOS, COX-2 and TNFα) [264]. Since several GBEs are 
available standardized on different constituents with different amounts, the 
anti-inflammatory effects can not be explicit inferred. Notable, no adverse 
effects of Ginkgo homeopathic mother tinctures have been reported so far 
[170], although they contain 2.2% of ginkgolic acids which is about 22,000 
ppm [265]. However, no studies in animal models of inflammation were 
performed for ginkgolic acid so far and nothing is known about its 
bioavailability.  
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Taken together, ginkgolic acid could be identified as potent dual inhibitor 
of mPGES-1 and 5-LO with weaker anti-COX-1 activity. High plasma 
protein binding probably due to its lipophilic character, lead to a loss of 
efficacy in human whole blood. However, in vivo studies of ginkgolic acid 
will be necessary to define its anti-inflammatory and allergenic potential 
and composition of ginkgo biloba extracts may need to be reconsidered 
then. 
 
4.6 Synthetic-derivatives of acid-modified NSAIDs as 
mPGES-1 inhibitors 
 
NSAID administration is considered as the “medication of choice” in the 
treatment of inflammatory diseases. In view of severe side effects 
particularly on long-term application, there is still a need for the 
development of “saver drugs” [266]. 
Structural modification of NSAIDs, like replacement of the carboxylic acid 
functionality by substituted sulphonamide moieties, has turned out to be a 
useful approach in the development of dual mPGES-1/5-LO inhibitors with 
impaired COX activity [82]. This has already been demonstrated by the 
example of the advanced dual 5-LO/COX inhibitor licofelone [82].  
 
SAR studies with several NSAIDs (ibuprofen, ketoprofen, naproxen, 
indomethacin and lonazolac) yielded derivatives of lonazolac and 
indomethacin as new leads for dual mPGES-1/5-LO inhibitors with 
reduced COX-1 activity. The classical NSAIDs did not show any inhibition 
of mPGES-1 or 5-LO up to 10 µM. Introduction of lipophilic residues 
enhanced the inhibitory potential towards mPGES-1/5-LO inhibition. Most 
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potent inhibitor of mPGES-1/5-LO in this series was the 
chlorphenylsulfonamid and substituted phenylacetylene derivative 36g 
(IC50 values of 0.16 µM and 3.7 µM, respectively). The phenylacetylene 
substituted indomethacin derivative 35f was most efficient with respect to 
5-LO inhibition (IC50 = 0.9 µM). Additionally, impaired COX activity 
could be demonstrated for all potent candidates.  
Taken together, structural modifications of acidic NSAIDs by substituted 
sulphonamide residues have proved to yield (I) advanced mPGES-1 and 5-
LO inhibitors with IC50 values in the nanomolar to submicromolar range 
and (II) a reduced COX activity, which is attributed to an improved severe 
side effect profile [178]. 
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5  SUMMARY 
 
Prostaglandin (PG)E2 is a bioactive lipid mediator derived from the 
cyclooxygenase (COX) pathway and exerts various physiological and 
pathological actions depending on the amount of PGE2 and the subtype of 
receptor (EP1-4) available within the respective tissue. PGE2 is deemed to 
play a key role in inflammatory events. Three terminal synthases that 
catalyze PGE2 formation from COX-derived PGH2 are known. The 
inducible microsomal PGE2 synthase-1 (mPGES-1) is considered as the 
predominant isoform that is involved in pathophysiological PGE2 
formation. By now, multiple diverse structures of mPGES-1 inhibitors are 
described in literature, but no selective mPGES-1 inhibitor is available for 
clinical use. 
 
Leukotrienes (LTs) are derived from arachidonic acid (AA) by the 
conversion of 5-Lipoxygenase (5-LO) and act through their corresponding 
receptors. LTs are known to be involved in several pathologies, including 
allergic and inflammatory diseases. Inhibition of 5-LO product biosynthesis 
can be achieved by direct inhibition of 5-LO or antagonism of FLAP and 
cPLA2. By now, zileuton is the only 5-LO inhibitor that has entered the 
market. 
 
Current research outcomes propose a dual inhibition of mPGES-1 and 5-
LO as a promising strategy in the therapy of inflammation to avoid 
ordinary side effects of classical NSAIDs or coxibs and therefore improve 
the safety profile of anti-inflammatory drugs. 
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This study identified a number of natural compounds and synthetic 
derivatives that were identified as potent mPGES-1 and 5-LO inhibitors. 
Promising candidates were additionally characterized within the AA 
cascade. 
 
Arzanol is a major bioactive constituent of the mediterranean curry plant 
(Helichrysum italicum), which possesses anti-inflammatory properties. 
Arzanol was reported to inhibit the release of PGE2 from LPS stimulated 
human monocytes, but the underlying molecular mechanism have not been 
fully clarified. Inhibition of mPGES-1¶ (IC50= 0.3 µM) and 5-LO¶ (IC50= 
3.4 µM) was identified in 2009 as a part of my diploma thesis. Here, the 
interference within the AA cascade was investigated additionally yielding 
TXAS (IC50= 2.7 µM) as molecular target of arzanol. Inhibition of PGE2, 
TXB2 and LT biosynthesis was also evident in vitro and partially in vivo. In 
studies using LPS stimulated human whole blood, PGE2¶ was 
concentration-dependently inhibited by arzanol, whereas the formation of 
TXB2, 6-ketoPGF1a and LTs were not affected. In a model of carrageenan-
induced pleurisy in rats intraperitoneal application of arzanol was almost as 
effective as the NSAID indomethacin. Thus, arzanol highly contributes to 
the anti-inflammatory potential of Helichrysum italicum and represents a 
promising candidate in the therapy of inflammation and cancer. 
Structure activity relationship (SAR) studies were performed to improve 
the anti-inflammatory potency of arzanol. Introduction of a lipophilic n-
hexyl residue to the alkylidene linker resulted in the derivative 1e that 
inhibited mPGES-1 (IC50= 0.2 µM), 5-LO (IC50= 1.2 µM) and TXAS 
(IC50= 2.5 µM) with higher potency. Additionally 1e moderately affected 
isolated COX-2 activity (IC50 > 10 µM). The inhibitory potential of 1e was 
also evident in vitro, but 1e failed to suppress PG and LT formation in vivo 
using human whole blood. 
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Cannabis sativa possesses well known anti-inflammatory properties, which 
can not yet be clearly verified to its constituents. In this study, investigation 
of several phytocannabinoid and non-cannabinoid constituents identified 
CBG, CFA and CFB to block the conversion of PGH2 to PGE2 mediated by 
mPGES-1 (IC50= 0.9, 1.8 and 3.7 µM, respectively). CFA was additionally 
investigated as potent inhibitor of semi-purified 5-LO (IC50= 0.95 µM) and 
cell-free TXAS (IC50= 6.8 µM), whereas 12-HHT formation in intact 
human platelets and isolated COX-1 and -2 was hardly affected (IC50 >10 
µM). The effectiveness of CFA was also evident in vitro. In intact human 
monocytes TXB2 and PGE2 formation was suppressed after LPS 
stimulation by synergistic effects of mPGES-1 and TXAS inhibition and 
blockage of COX-2 expression. Inhibition of 5-LO product formation in 
intact neutrophils (IC50= 1.6 – 2.4 µM) resulted in a slight decrease 
compared to the effects observed from semi-purified 5-LO. But no 
efficiency was observed on PG and LT formation in vivo using human 
whole blood probably due to the lipophilic properties of CFA. Together, 
CFA has a promising anti-inflammatory profile that requires further in vivo 
investigation. 
 
Depsides and depsidones exclusively occur in lichen species that have been 
traditionally used for the treatment of inflammatory disorders. In this 
thesis, a dual inhibition of mPGES-1 derived PGE2 formation and 5-LO 
product formation could be identified for the depsides perlatolic acid (IC50= 
0.4 µM, equal potency) and olivetoric acid (IC50= 1.15 and 2.4 µM, 
respectively) as well as the depsidone physodic acid (IC50= 0.43 and 2.4 
µM, respectively). Further investigations revealed TXAS as molecular 
target of perlatolic and physodic acid (IC50= 1.1 and 0.7 µM, respectively), 
whereas cell-free COX-1 and -2 and cPLA2 activity was hardly (IC50 > 10 
µM) or not affected. The mode of action is reversible and largely 
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independent of the substrate supply. In addition, effects on the expression 
of COX-2 could be identified to suppress pathophysiological PGE2. 
Interference with leukotriene formation is mediated by (I) a direct 
inhibition of 5-LO (observed for perlatolic and physodic acid) and/or (II) a 
downregulation of 5-LO activity (observed for physodic acid via blockage 
of phosphorylation). A selective suppression of PGE2 formation in a model 
of carrageenan induced pleurisy in rats is evident for perlatolic acid, 
whereby no inhibitory effects on LTB4, TXB2 and 6-ketoPGF1a synthesis 
could be observed in in vivo studies with human whole blood. Thus, 
depsides and depsidones provide a rational basis for the anti-inflammatory 
effects of lichen species. 
 
Ginkgo biloba is among the most widely used medicinal plants of the world 
and extracts are mostly standardized on terpene trilactones and flavonol 
glycosides that are deemed as the active constituents of the plant. Because 
the allergenic potential of alkylphenols is still disputed, ginkgolic acid was 
not yet investigated if it contributes to the anti-inflammatory potential of 
the plant. Notable, no adverse effects of Ginkgo homeopathic mother 
tinctures have been reported so far, although they contain 2.2% of 
ginkgolic acids which is about 22,000 ppm. This study identified mPGES-1 
(IC50= 0.7 µM), 5-LO (IC50= 0.3 µM), COX-1 (IC50= 8.1 µM) and TXAS 
(IC50= 5.2 µM) as molecular targets of ginkgolic acid, whereby inhibition 
of mPGES-1 and 5-LO is about 10 fold selective compared to COX-1 and 
TXAS. Gingkolic acid suppressed the formation of PGE2 and 5-LO 
products in a direct and reversible mode of action under cell-free 
conditions. Inhibition of PGE2 synthesis in LPS stimulated intact 
monocytes could be demonstrated by synergistic inhibitory effects on 
mPGES-1 activity and COX-2 expression. Ginkgolic acid concentration-
dependently blocked 12-HHT and TXB2 formation equally well in intact 
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platelets due to its inhibitory effects on TXAS and COX-1 activity and 
investigations in intact human neutrophils reveal that 5-LO product 
formation is comparably blocked independent of the substrate supply. 
Minimal cytotoxic effects were observed after 24 h but not 48 h, which 
confirmed current findings described in literature. Likely because of its 
lipophilic character no inhibitory effects on PG and LT biosynthesis in vivo 
in human whole blood were observed for gingkolic acid. Therefore, further 
in vivo studies of ginkgolic acid will be necessary to define its anti-
inflammatory role and allergenic potential. 
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6 ZUSAMMENFASSUNG 
 
Prostaglandin (PG) E2 ist ein biologisch aktiver, lipophiler Botenstoff der 
Cyclooxygenase (COX) Signalkaskade. Er ist an verschiedenen 
physiologischen und patho-physiologischen Vorgängen im Körper 
beteiligt. Die Wirkweise ist jeweils abhängig von der gebildeten PGE2 
Menge und dem Rezeptorsubtyp (EP1-4) am Gewebe. PGE2 wird eine 
Schlüsselrolle im entzündlichen Geschehen zugesprochen. Drei terminale 
PGE2 Synthasen sind bekannt, die PGE2 aus dem COX Produkt PGH2 
katalysieren können. Dabei wird der induzierbaren mikrosomalen PGE2 
synthase-1 (mPGES-1) Isoform eine dominante Rolle im 
Entzündungsgeschehen zugesprochen. Mittlerweile sind diverse mPGES-1 
Inhibitoren unterschiedlichster Strukturen in der Literatur beschrieben, 
allerdings steht noch kein selektiver mPGES-1 Hemmer für den klinischen 
Einsatz zur Verfügung. 
 
Leukotriene (LTs) werden aus Arachidonsäure (AA) unter anderem durch 
die katalytische Aktivität der 5-Lipoxigenase (5-LO) gebildet und entfalten 
ihre Wirkung durch ihre entsprechenden Rezeptoren. LTs sind an 
verschiedenen pathogenen Vorgängen im Körper beteiligt, wie z.B. 
allergische und entzündliche Erkrankungen. Die Hemmung der 5-LO 
Produktbildung kann durch eine direkte Inhibition des Enzymes 5-LO oder 
durch einen Antagonismus an den Enzymen FLAP oder cPLA2 erreicht 
werden. Bisher konnte nur der Wirkstoff Zileuton als direkter Hemmer der 
5-LO auf den Markt gebracht werden. 
 
Aktuellen Forschungsergebnissen zufolge handelt es sich bei der dualen 
Hemmung der Enzyme mPGES-1 und 5-LO um eine erfolgversprechende 
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Strategie in der antientzündlichen Therapie, da übliche Nebenwirkungen, 
die unter der Therapie mit klassischen NSAIDs oder Coxiben auftreten, 
hier vermieden werden können.   
 
In dieser Doktorarbeit konnten mehrere Naturstoffe und/oder deren 
synthetische Derivate als potente mPGES-1/5-LO Inhibitoren identifiziert 
werden. Das Profil vielversprechender Kandidaten wurde zudem innerhalb 
der AA Kaskade umfassend charakterisiert.  
 
Arzanol ist einer der Hauptinhaltsstoffe der mediterranen Curry Pflanze 
(Helichrysum italicum), die für ihre antientzündlichen Eigenschaften 
bekannt ist. In der Literatur ist bereits ein Einfluss auf die PGE2 
Freisetzung in LPS stimulierten Monozyten beschrieben, jedoch konnte der 
zugrunde liegende Mechanismus nicht abschließend geklärt werden. Eine 
direkte Hemmung der Enzyme mPGES-1¶ (IC50= 0.3 µM) und 5-LO¶ 
(IC50= 3.4 µM) konnte bereits 2009 als Teil meiner Diplomarbeit gezeigt 
werden. In dieser Arbeit wurde der Eingriff in die AA Kaskade näher 
untersucht, bei der zusätzlich TXAS (IC50= 2.7 µM) als molekulares Target 
identifizieren konnte. Mechanistische Studien ergaben, dass es sich bei 
Arzanol um einen reversiblen Inhibitor der Enzyme mPGES-1 und 5-LO 
handelt, der zudem unabhängig von der Substratkonzentration ist. Die 
Hemmung der Biosynthese von PGE2, TXB2 und LTs konnte in vitro und 
teilweise in vivo bestätigt werden. Arzanol inhibierte die mPGES-1 
vermittelte PGE2 Bildung in intakten Monozyten und A549 Zellen¶ sowie 
in LPS stimuliertem humanem Vollblut¶. Zudem konnte auch eine 
Hemmung der TXB2 Bildung in intakten Thrombozyten (IC50= 2.9 µM) 
und eine Hemmung der 5-LO Produktbildung in intakten neutrophilen 
Granulozyten (IC50= 2.4 - 2.9 µM) nachgewiesen werden. Studien mit LPS 
stimuliertem humanem Vollblut zeigten eine konzentrationsabhängige 
6 ZUSAMMENFASSUNG 146 
Hemmung der PGE2 Bildung durch Arzanol, wohingegen die TXB2, 6-
ketoPGF1a und LT Bildung nicht beeinflusst wurde. Die intraperitoneale 
Applikation von Arzanol erwies sich im Tiermodell der Carrageen 
induzierten Brustfellentzündung in Ratten als nahezu ebenbürtig zu 
Indomethacin. Somit gilt Arzanol als vielversprechender Kandidat in der 
Entzündungs- und Krebstherapie. 
Struktur-Wirkungs-Beziehungen wurden durchgeführt, um die 
Wirksamkeit von Arzanol noch zu steigern. Die Einführung einer n-hexyl-
Seitenkette an der Alkylidenverbindung (Verbindung 1e) zeigte ein 
deutlich verbessertes inhibtorisches Potential auf mPGES-1 (IC50= 0.2 
µM), 5-LO (IC50= 1.2 µM) und TXAS (IC50= 2.5 µM). Zusätzlich wurde 
für 1e eine moderate Hemmung der isolierten COX-2 (IC50 > 10 µM) 
nachgewiesen. 1e erwies sich auch in vitro als wirksame Substanz, jedoch 
konnte in in vivo Untersuchungen mit humanem Vollblut keine Wirkung 
mehr auf die PG und LT Bildung nachgewiesen werden. 
 
Cannabis sativa verfügt über bekannte antientzündliche Eigenschaften, die 
jedoch nicht eindeutig ihren Inhaltsstoffen zugeordnet werden können. In 
dieser Arbeit wurden verschiedene pflanzliche cannabinoide und nicht-
cannabinoide Bestandteile auf ihre antientzündlichen Eigenschaften hin 
untersucht. Für CBG, CFA und CFB konnte eine Hemmung der mPGES-1 
vermittelten PGE2 Synthese in mikrosomalen Präparationen aus IL-1ß 
stimulierten A49 Zellen nachgewiesen werden mit entsprechenden IC50 
Werten von 0.9, 1.8 und 3.7 µM. Eine direkte Hemmung der aufgereinigten 
5-LO (IC50= 0.95 µM) und der zellfreien TXAS (IC50= 6.8 µM) konnte 
zusätzlich für CFA gezeigt werden, wobei eine die Bildung von 12-HHT, 
als Marker der COX-1 und -2 Aktivität, in intakten Thrombozyten und am 
isolierten Enzym kaum beeinflusst wurde (IC50 > 10 µM). Deutlich konnte 
die Wirksamkeit von CFA auch in vitro nachgewiesen werden. In intakten, 
6 ZUSAMMENFASSUNG 147 
humanen Monozyten konnte die Hemmung der TXB2 und PGE2 
Biosynthese nach pro-inflammatorischer Stimulation mit LPS durch 
synergistische Einflüsse auf die mPGES-1 und TXAS Aktivität sowie die 
COX-2 Expression nachgewiesen werden. In intakten neutrophilen 
Granulozyten wurde die Hemmung der 5-LO Produktsynthese durch CFA 
mit einem geringen Wirkverlust (IC50= 1.6 – 2.4 µM) nachgewiesen 
verglichen mit den Effekten am isolierten Enzym. Allerdings konnte kein 
Effekt mehr auf die PG und LT Synthese in vivo in humanem Vollblut 
nachgewiesen werden. Wahrscheinlich gilt hierfür der lipophile 
Säurecharakter von CFA, der für eine ausgeprägte Plasmaproteinbindung 
verantwortlich sein kann. Zusammen genommen verfügt CFA über ein 
vielversprechendes antientzündliches Profil, welches jedoch noch weiterer 
in vivo Untersuchungen bedarf. 
 
Depside und Depsidone kommen ausschließlich in Flechtenarten vor. Diese 
wurden bereits volksmedizinisch zur Behandlung entzündlicher 
Erkrankungen verwendet. In der vorliegenden Arbeit konnte eine duale 
Hemmung der mPGES-1 vermittelten PGE2 Synthese und der 5-LO 
vermittelten Produktbildung für die Depside Perlatolsäure (IC50= 0.4 µM, 
für beide Enzyme) und Olivetolsäure (IC50= 1.15 bzw. 2.4 µM), sowie für 
das Depsidon Physodsäure (IC50= 0.43 bzw. 2.4 µM) nachgewiesen 
werden. In weiteren Untersuchungen konnte TXAS als molekulare 
Zielstruktur von Perlatol- und Physodsäure (IC50= 1.1 bzw. 0.7 µM) 
aufgeklärt werden. Ein direkter Einfluss auf die COX-1 oder -2 Aktivität 
sowie die cPLA2 Aktivität konnte dagegen nicht oder nur kaum (IC50 > 10 
µM) nachgewiesen werden. Die Wirkungsweise von Perlatol- und 
Physodsäure auf die Enzyme mPGES-1 und 5-LO ist reversibel 
weitestgehend unabhängig dem Substratangebot. Zudem konnte ein 
Einfluss auf die Expression der COX-2 nachgewiesen werden. Die 
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Hemmung der LT Bildung in vitro wird durch einen direkten Angriff am 
Enzym 5-LO (konnte für Perlatol- und Physodsäure beobachtet werden) 
und eine Herunterregulierung der 5-LO Aktivität (beobachtet für 
Physodsäure durch Eingriff in die Phosphorylierungskaskade) 
hervorgerufen. In vivo konnte eine selektive Hemmung der PGE2 
Biosynthese im Tiermodell der Carrageen-induzierten Brustfellentzündung 
in Ratten für Perlatolsäure nachgewiesen werden. Effekte auf die LTB4, 
TXB2 und 6-ketoPGF1a Synthese konnten dagegen in humanem Vollblut 
nicht beobachtet werden. Somit lässt sich zusammenfassend sagen, dass 
Depside und Depsidone, vorallem Perlatol- und Physodsäure, sehr 
wahrscheinlich an der antientzündlichen Wirkung diverser Flechtenarten 
beteiligt sind. 
 
Ginkgo biloba zählt zu den weltweit am häufigsten verwendeten 
Arzneipflanzen. Extrakte dieser Pflanze werden meist auf die für die 
Wirkung verantwortlich geltenden terpentrilaktonischen und 
flavonolglykosidischen Bestandteile standardisiert. Da ein allergenes 
Potential für Alklphenole noch immer umstritten ist, wurde Ginkgolsäure 
noch nicht auf mögliche antientzündliche Eigenschaften hin untersucht. 
Interessanterweise wurden für die homöopathische Ginkgo Urtinktur, 
welche große Mengen an Ginkgolsäuren enthält, bisher keine 
Nebenwirkungen gemeldet. In der vorliegenden Doktorarbeit konnten die 
Enzyme mPGES-1 (IC50= 0.7 µM), 5-LO (IC50= 0.3 µM), COX-1 (IC50= 
8.1 µM) und TXAS (IC50= 5.2 µM) als molekulare Zielstrukturen der 
Ginkgolsäure identifiziert werden, wobei die duale mPGES-1/5-LO 
Inhibition etwa 10-fach potenter als die COX-1 und TXAS Hemmung 
auftrat. Ginkgolsäure ist ein direkter und reversibler Hemmer der PGE2 und 
5-LO Produktbildung. In LPS stimulierten Monozyten inhibierte 
Ginkgolsäure die PGE2 Bildung durch synergistische Effekte auf die 
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mPGES-1 Aktivität und COX-2 Expression. Eine konzentrationsabhängige 
Unterdrückung der 12-HHT und TXB2 Bildung in intakten Thrombozyten 
infolge der direkten COX-1 und TXAS Hemmung konnte beobachtet 
werden. Untersuchungen in intakten neutrophilen Granulozyten zeigen eine 
vergleichbare Hemmung der 5-LO Produktbildung unabhängig von der 
verfügbaren Substratkonzentration. Minimale zytotoxische Effekte auf die 
Zellvitalität nach 24 Stunden konnten beobachtet werden die jedoch nach 
48 Stunden nicht mehr nachweisbar waren. Dieser Effekt wurde bereits in 
der Literatur beschrieben. Wahrscheinlich auf Grund der lipophilen 
Eigenschaften der Ginkgolsäure, konnten die beobachteten Effekte auf die 
PG und LT Biosynthese in vivo in humanem Vollblut nicht bestätigt 
werden. Somit sind weitere in vivo Untersuchungen notwendig, um das 
allergene Potential und eine mögliche antientzündliche Rolle im genau zu 
bestimmen. 
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